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Over the past few years, natural products have already become increasingly important in anti-
infectious drug research. This is especially the case as innovations in omics’ technologies, 
chemical biology and genetics have facilitated the discovery of new drugs and their targets. 
Natural products have a privileged role in the drug discovery due to their intrinsic cell 
permeability, structural diversity, rich functionality and stereochemistry. They also provide 
unique scaffolds for further drug optimization towards increased potency and selectivity. China 
has been using herbs in medicine for centuries and these are now attracting global interest. In 
response to the challenge of increased anti-microbial resistance our group established a China-
UK collaborative team to explore the potential of Traditional Chinese Medicines (TCM) to 
reveal new drug leads. 
 
This project focuses on 19 traditional Chinese herbs which were screened for a bioactives using 
a well-established analysis pipeline. All the plants were provided from China and underwent 
authentication using DNA barcoding and bioactivity screening of the extracts, mainly focusing 
on anti-microbial activities. Based on rbcl  based DNA barcoding data some samples were mis-
identified in China whilst some samples of the same species exhibited differences in minimum 
inhibitory concentrations (MIC).  
 
The initial focus was on an assay-based evaluation of isolated compounds from Artemisia 
annua against mycobacteria. Artemisia annua is native to temperate Asia, known have 
antimalarial, anti-inflammatory, antitumor and allelopathic activities. Natural products with 
relatively weak anti-mycobacterial activity with MIC of 250 µg/mL from Artemisia annua 
were found with. Several fractions, isolated using different chromatography techniques, 
showed very significant anti-tubercular activity against M. smegmatis. Purification, isolation 
and identification of two compounds (artemisinic acid and deoxyartemisinin) using various 
chromatography techniques and identification using high-resolution mass spectrometry and 
nuclear magnetic resonance (NMR) with the best activity have been performed along with 
toxicity assays and Schistosoma mansoni assays. The mode of action using computer-
predicting docking with other known targets of M. tuberculosis. Based on the MIC pattern and 




Next the antimicrobial properties of herbs, Dryopteris crassirhizoma Nakai were identified as 
potential drug lead against Methicillin-resistant Staphylococcus aureus (MRSA). Bioactive 
phloroglucinols from D. crassirhizoma were isolated, purified, and identified using a range of 
bioactivity screens coupled with chromatographic and metabolomics approaches. The 
antimicrobial properties of the extracts and fractions yielded MIC ranging from 3.25-50 
µg/mL. The potential compounds responsible for MIC were tentatively identified through 
metabolite fingerprinting using flow infusion electrospray high-resolution mass spectrometry 
(FIE-HRMS). Additionally, the mode of action of the selected fractions was suggested using 
non-targeted metabolomics analysis with other known antibiotics and docking with known 
targets. Metabolomics data shows that the anti-MRSA activity was linked to the altered 
carbohydrate metabolism that could reflect the inhibition of growth of the cells.  
 
This study requires further validation for the compounds from D. crassirhizoma using 
genomics, proteomic, and lipidomic analyses and in silico studies. Overall, our study can help 
find different naturally available compound and help in the identification of targets to fight 
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This thesis focuses on revisiting traditional medicine and investigate their chemical entity in 
the search of a new drug and new mechanisms of action against tuberculosis and MRSA. 
Chapter 1 briefly reviews the causes of antimicrobial resistance, the importance of natural 
products and known natural products, as source of alternative, drugs; Traditional Chinese 
medicine in comparison with the western medicine and how it represents an important corpus 
of “folk-medicine” are presented. Finally, the aims and objectives of this thesis are described 
in this chapter. Chapter 2 introduces the material and methods commonly utilised throughout 
the thesis. With the increase in consumer demand Chapter 3 introduces different methods used 
to authenticating traditional Chinese medicine and derives an analysis pipeline which is used 
throughout the thesis. Chapter 4 focuses on Artemisia annnua and screens for 
antimycobacterial activity. Here bioassays- guided the purification of chemical with in vitro 
anti-microbial activity. In this chapter, computational molecular docking is used to predict the 
interaction sites. Chapter 5 introduces to Dryopteris crassirhizoma and focuses on its anti-
MRSA activity. It also employs a similar bioassay guided purification as used in chapter 4. 
Also, in this chapter metabolomics technology is applied to rapidly elucidate potential 
bioactives in a complex biochemical mix. In Chapter 6 metabolomics is used to target likely 
bioactives with anti-MRSA functions in a fraction from D. crassirhizoma. Chapter 7 integrates 
and discusses all the results obtained in the previous chapters, providing a critical global 
overview and future perspectives on drug and target discovery of natural products. Chapter 8 
presents the publications, posters and oral communications related to this thesis. A subchapter 
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1.1. ANTIMICROBIAL RESISTANCE (AMR)  
Introduction 
The continual battle between human and infection causing microorganisms turned in favour of 
humans in the middle of 20th century when penicillin became available to use. Equally, the 
anti-microbial importance of sulphonamides need to he acknowledged. As early, as 1935 
(penicillin was not widely used until the 1940s), the first sulphonamide, prontosil was 
synthesized against Streptococcus infections by Gerhard Domagk (Cohen & Swerdlik, 2009). 
However, this success was short lived as with time the pathogens countered back with various 
forms of resistance. The struggle to gain the upper hand against infection is still on. Scientists 
working on new antimicrobial agents are struggling as organisms are evolving cleaver 
mechanisms of resistance (Tenover, 2006). The period after 1980 is defined as an “antibiotic 
discovery void” as no successful antibiotic discoveries are made also no new class of antibiotics 
has been discovered to treat Gram-negative bacteria since 1962 (Silver, 2011) (Figure 1.1)  
 Figure 1.1 Discovery of new classes of antibacterial drugs has stalled (1930s to 2000s). 
 Source: World Health 
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Teixobactin, a new antibiotic after nearly 30 years have been discovered to be active against a 
broad range of organisms like Streptococcus pneumoniae, Staphyloccocus aureus (MRSA) and 
Mycobacterium tuberculosis without any noticeable resistance (Ling et al., 2015). 
Alexander Fleming’s Nobel Prize acceptance speech stated, “it is not difficult to make 
microbes resistant to penicillin in the laboratory by exposing them to concentrations not 
sufficient to kill the and the same thing has occasionally happened in the body. There is the 
danger that the ignorant man may easily under-dose himself and, by exposing his microbes to 
non-lethal quantities of the drug, make them resistant” (Fleming, 1945). Currently, almost all 
strains in UK and USA are resistant to penicillin and more than 50% are resistance to 
methicillin (Huttner et al., 2013). Antimicrobial resistance (AMR) is recognized as one of the 
greatest threats to human health worldwide by organizations such as the US Centers for Disease 
Control and Prevention (CDC), the European Centre for Disease Prevention and Control 
(ECDC) and the World Health Organization (WHO). The period between 2014 to 2016 has 
observed an estimation of ~1 million deaths and suspects ~300 million deaths by the year 2050 
due to AMR (O’neill, 2016) (Figure 1.2) Resistance among gram-positive organisms is very 
Figure 1.2: The impact of antimicrobial resistance in 2050.  
(Bassetti et al., 2017) 
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common while in contrast the resistance in gram-negatives is relatively rarer but in both groups 
of bacterial it is an urgent concern. 
 
Cause of resistance 
The main reason of AMR is generally associated to the selective pressure caused by the 
improper use, overuse, or misuse of antimicrobials in humans and animals (Who_Food_2011, 
2011). Individually a microbe is limited in its ability to cope with diverse environmental 
factors, but when in communities these microbes are extremely adaptable. The main reason for 
this adaptability is the rapid generation time, which help them, have a new evolved species 
without losing the adaptive genes. Antimicrobials are used to block the growth of 
microorganisms, so under this treatment microbes that can overcome this selective pressure 
and survive to become predominant in an evolved microbial community. Persistent use of 
antimicrobials will drive the selection pressure causing them to evolve faster.  
Figure 1.3: An infographic to show the considered potential contribution of each factor as a 
driver for antimicrobial resistance. 
(Holmes et al., 2016) 
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Three major factors determine that cause resistance: (1) the increasing frequency of AMR 
phenotypes among microbes due to the widespread use of antimicrobials; (2) the large and 
globally connected human population allowing bacterial spread and (3) the extensive and often 
unnecessary use of antimicrobials by humanity providing a strong selective pressure (Michael, 
Dominey-Howes, & Labbate, 2014) (Figure 1.3). 
Antimicrobial resistant bacteria is naturally present in environment including Antarctica as 
they coexists with non-resistant species for stability (Martinez, 2009). Further, bacterial species 
that would normally be considered as gut microflora are found in the environment, drinking 
water, soil, food, and food products (Rubin, Ekanayake, & Fernando, 2014) (Walsh, Weeks, 
Livermore, & Toleman, 2011). This represents a continuum for environmental AMR to enter 
humans. However, it is selective pressure exerted within human use of antibiotics that is the 
Figure 1. 4: Mutation selection resistance. 
The population of bacteria, before exposure to an antibiotic, is composed of genetically variable 
bacteria. Upon repeated short exposure to antibiotic, natural selection takes place with survival of 
resistant bacteria. (Lagasse, 2008) 
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main driver for AMR. It is suggested that 50 % antimicrobials prescribed to patients are 
unnecessary, so that their excessive use of is selecting for resistant organisms in patients 
(Frieden, 2013). As the human body is a complex system, several factor influence the 
derivation of resistant strains including pathogen-drug interactions, pathogen-host interactions, 
mutation rates of the pathogen, emergence of successful antimicrobial-resistant clones, the 
transmission rates of pathogens between human beings, animals, and the environment, cross-
resistance, and selection of co-resistance to unrelated drugs (Figure 1. 4) (Holmes et al., 2016). 
However, several other external factors lead to resistance such as the use of antibiotics in food 
products, sanitization. Other social factors such as population densities and the efficacy of the 
health care system are also important (Turnidge & Christiansen, 2005).  
 
Handling antimicrobial resistance 
Due to the urgency to deal with this antimicrobial crisis healthcare bodies such as CDC 
(Frieden, 2013) and the WHO (World Health Organisation, 2015) have provided a series of 
recommendations to manage the crisis. To decrease the rise and spread of MDR, cooperative 
efforts are required to control the factors responsible for resistance in particular, the use of 
antimicrobials and reducing spread of resistant microorganisms. Several antimicrobial 
conservation (AC) programs (traditionally known as antibiotic stewardship programs) have 
been suggested to optimize antibiotic prescription practices, however the program has had 
limited reach worldwide. Among several AC initiatives, the reduced prescription of 
floroquinone and cephalosporin resulted to have resulted in a 70 % reduction in AMR 
Clostridium difficile infections (CDI) in UK over the past five years (Huttner et al., 2013).  
Besides direct human consumption, the largest volumes of antimicrobials is used in livestock 
production which become a source of AMR. To support antimicrobial stewardship, the WHO 
has promoted an integrated surveillance of consumption and resistance in both the human and 
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animal sectors (WHO, 2017) and have listed the “critically important” antimicrobials to be 
used use in development and implementation of risk management strategies in livestock 
production (Figure 1.5). Withdrawing the use of a third-generation cephalosporin (ceftiofur) in 
Canada with a resulting reduction in resistance rates in Salmonella enterica serovar Heidelberg 
is an example of the success of such a strategy (Dutil et al., 2010; Willemsen et al., 2015).  
 
 
1.2. NATURAL PRODUCTS 
Natural environment is frequently identified as a rich source of unique chemical diversity for 
pharmaceutical lead-compound discovery. According to an estimate, about 50 % of the 
medications validated from 1981-2010 have natural origins. (Mushtaq, Abbasi, Uzair, & 
Abbasi, 2018) 
Figure 1.5: Different ways to handle antimicrobial 
resistance. 
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 The investigation of natural products as source of novel human therapeutics reached its peak 
in the Western pharmaceutical industry in the period 1970–1980, which resulted in a 
pharmaceutical landscape heavily influenced by non-synthetic molecules. Despite this success, 
pharmaceutical research into natural products has experienced a slow decline. However, the 
emergence of multidrug-resistant microbes has increased the urge to search for new therapeutic 
lead compounds. Major advantages of a natural product in comparison to synthetic entity are 
that they exhibit tremendous chemical and structural. Also, they are more prone to evolutionary 
pressure compared to a synthetic molecule. Natural products can be obtained from four main 
sources i.e., plants, animals, marine organisms and microorganisms 
 
Microorganisms as a source of natural products 
The discovery of penicillin from the filamentous fungus, Penicillium notatum in 1929 started 
the Golden Age of antibiotics with intensive research on nature as source of novel bioactives 
(Swann, 1992).There are about 25,000 species of basidiomycetes, of which about 500 are 
members of the Aphyllophorales. Approximately 75% of tested polypore fungi have shown 
strong antimicrobial antiviral, cytotoxic, antineoplastic, cardiovascular, anti-inflammatory, 
immune-stimulating and anticancer activities (Stamets, 2002; Zjawiony, 2004). 
Figure 1.6 shows some examples of microbe isolated natural product such as vancomycin (1) 
that was isolated from Amycolatopsis orientalis in 1953 and has been proven to be active 
against a broad range of organisms and was approved by FDA (Federal Drug Agency, USA) 
in 1958. Erythromycin (2), originated from Saccharopolyspora erythraea and is also a broad 
spectrum antibiotic against gram positive bacterial species (Butler, 2004; Dewick, 2002). 
Ganoderic acid β (3) was isolated from the fruiting bodies and spores of Ganoderma lucidum, 
and displayed significant anti-HIV-1 protease activity with an IC50 value of 20 µM (Min, 
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Nakamura, Miyashiro, Bae, & Hattori, 1998). Doxorubicin (4) (Adriamycin®), isolated from 
Streptomyces peucetius is used to treat acute leukaemia, soft tissue and bone sarcomas, lung 
Figure 1.6: Some examples of microbe-derived natural products. 
1: vancomycin; 2: erythromycin; 3: ganoderic acid β; 4: doxorubicin; 5: cephalosporins; 6: 
cyclosporine; 7: rapamycin; 8: mevastatin; 9: lovastatin; 10: ivermectins. 
9 | P a g e  
cancer, thyroid cancer and both Hodgkin’s and non-Hodgkin’s lymphomas (Butler, 2004; 
Dewick, 2002). Amongst a plethora of possible other example it is possible to include 
antibacterial agents such as cephalosporins (5) from Cephalosporium cryptosporium; 
aminoglycosides, tetracyclines , and other polyketides of many structural types from the 
Actinomycetales sp.; immunosuppressive agents like cyclosporine (6), and rapamycin (7) from 
Streptomyces species; cholesterol-lowering agents such as mevastatin (8) and lovastatin (9) 
from Penicillium species and anthelmintics, antiparasitic drugs, such as the ivermectins (10) 
from Streptomyces species (Goodman & Ro, 1995).  
 
Plants as a source of natural products 
The earliest records of the uses of a natural products is from 2600 B.C which describes the use 
of oils from Cupressus sempervirens (Cypress) and Commiphora species (myrrh) Glycyrrhiza 
glabra (licorice), Commiphora species (myrrh), and Papaver somniferum (poppy juice) to treat 
cough, colds, parasitic infections and inflammations (Cragg & Newman, 2005). An Egyptian 
pharmaceutical record of 2900 B.C documents the use of 700 plant-based drugs. Likewise, the 
Chinese Materia Medica from1100 B.C and the Indian Ayurveda system dates from about 1000 
B.C provide extensive examples of the use of natural products in medicine. A similar 
comprehensive medical compendium is not seen in the western world until the work of 
Theophrastus (~300 B.C.) a Greek philosopher and natural scientist who described the 
medicinal qualities of herbs in the History of Plants. 
Plants have been an important source of medicines for thousands of years. World Health 
Organization (WHO) states that 80% of people rely on plant-based medicine for their primary 
health care needs (Fabricant & Farnsworth, 2001). Beyond this, further investigation of 
medicinal plants has resulted in the isolation of many natural products which have been 
developed as front-line drugs. For example, paclitaxel (Taxol®) (11) widely used breast cancer 
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drug, was isolated from Taxus brevifolia (Pacific Yew) by the United States Department of 
Agriculture (USDA) in 1962 (Cragg, 1998) and obtained FDA approval for its clinical use in 
1992 (Kaufman, Cseke, Warber, Brielmann, & Duke, 2010). As Taxol® (11) is present only at 
low quantities in its natural source, its large scale use required it chemical synthesis to be 
established (Nicolaou et al., 1995).  
Figure 1.7 shows a wide range of plant derived examples such as Ingenol 3-O-angelate (12), a 
derivative of the polyhydroxy diterpenoid ingenol was isolated from the sap of Euphorbia 
peplus (known as “petty spurge” in England or “radium weed” in Australia), and is currently 
under clinical development by Peplin Biotech as a potential anti-tumour compound (Kedei et 
al., 2004) although more recently the European Medicines Agency (EMA) has highlighted an 
increased risk of skin cancer with this drug (Schmutz, 2020). 14-succinyl triptolide sodium salt 
(13) is a semisynthetic analogue of triptolide isolated from Tripterygium wilfordii used for 
autoimmune and inflammatory diseases in China (Fidler et al., 2003; Kiviharju, Lecane, 
Sellers, & Peehl, 2002). Combretastatin A-4 phosphate (14) a stilbene derivative from 
Combretum caffrum, an anti-angiogenic agent, is currently in Phase II clinical trials (Holwell 
et al., 2002; Newman & Cragg, 2005). Artemisinin (15), arteether (16) and its derivatives were 
isolated from Artemisia annua are known to have antimalarial properties. Artemisinin (15) as 
artemisin and arteether (16) as Artemotil are approved as antimalarial drugs while other 
derivatives are in various stages of clinical development (Cragg & Newman, 2005; Dewick, 
2002). Potential analgesic agents Grandisines A (17) and B (18) were isolated from the leaves 
of the Australian rainforest tree, Elaeocarpus grandis (Carroll et al., 2005). Galantamine 
hydrobromide (19) an Amaryllidaceae alkaloid from the plant Galanthus nivalis is used for the 
treatment of Alzheimer’s disease (Heinrich & Teoh, 2004; Howes, Perry, & Houghton, 2003). 
Apomorphine hydrochloride (20), a potent dopamine receptor agonist used to treat Parkinson’s 
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disease, a derivative of morphine isolated from Papaver somniferum (Deleu, Hanssens, & 
Northway, 2004). 
 
Marine organisms as a source of natural products 
Our earth is covered by 70% of oceanic water, hence has enormous resources that are still being 
explored. Since the techniques to explore, the seabed is very recent, no historical evidence of 
traditional applications from marine sources have been found. In early 1950’s C-nucleosides, 
spongouridine, and spongothymidine, was isolated from the Caribbean sponge, Cryptotheca 
crypta. These antiviral compounds were eventually used to synthesize cytosine arabinoside 
(Ara-C) clinically useful anticancer agent (McConnell, Longley, & Koehn, 1994). With this 
Figure 1.7: Some examples of Plant-driven natural products. 
11: Taxol®; 12:ingenol 3-O-angelate; 13:14-succinyl triptolide sodium salt; 14:combretastatin A-
4 phosphate; 15:artemisinin; 16:arteether; 17:grandisines A; 18: grandisines B; 19:galantamine 
hydrobromide; 20:apomorphine hydrochloride. 
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discovery, there was an increased interest in exploring bioactive in marine environment. From 
past 40 years several studies proved that marine environment is a great source of bioactive but 
no compound has pass through clinical trials. 
Most notable example is bryostatin 1 (21) anti-cancer agent, isolated from the bryozoan, 
Bugula neritina though has completed both phase I and phase II levels but only in combination 
with other cytotoxic drugs (Mayer et al., 2010). Dolastatin 10 (22), a linear depsipeptide 
another anticancer drug from Dolabella auricularia did manage to overcome Phase I clinical 
trials but failed in phase II trials due to lack of significant activity (Newman & Cragg, 2005). 
Plitidepsin (23) (Aplidin®, PharmaMa), a depsipeptide anti-cancer agent isolated from the 
Mediterranean tunicate Aplidium albicans, currently in phase II clinical trials (Mayer et al., 
2010) (Urdiales, Morata, De Castro, & Sánchez-Jiménez, 1996). Ecteinascidin 743 (ET743; 
Figure 1.8: Some examples of Marine-driven natural products. 
21: bryostatin 1; 22: dolastatin 10; 23: plitidepsin; 24:Yondelis™. 
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Yondelis™) (24), became the first marine anticancer drug to be approved in the European 
Union in 2007 (Figure 1.8) 
 
Importance and limitations of plant natural products as antimicrobials 
The plant kingdom includes a high number of species, producing highly diverse bioactive 
compounds. According to some estimates, only 6% of plant species have been systematically 
investigated for their pharmacological properties. This represents a missed opportunity as to 
date of 122 plant derived compounds in clinical use of which 80% have ethno-medical origins. 
Papaverine from Papaver somniferum (Figure 1. 9) is probably the best example of ethno 
medical information guiding drug discovery and development along with the antimalarial 
drugs, quinine and artemisinin (15) (Cragg & Newman, 2013). Although the isolation of 
quinine from the bark of Cinchona species was reported in 1820 (Buss, Cox, & Waigh, 2003) 
it was target as a result of its traditionally use by tribes in the Amazon region in treating fever. 
With the emergence of resistance to synthetically derived quinine drugs, Artemisia annua 
(Quinhaosu), long known in TCM, has gained prominence as a frontline drug for malaria 
(Miller & Su, 2011). 
As plants used for medicinal purposes obtained from natural habitat, it is of extreme importance 
that the plants identified genetically, chemically besides morphological and anatomical 
identification. However, with climate change, there is a great risk of endangering the sources 
Figure 1. 9: Chemical structure of Papaverine. 
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of potential drugs from nature. This is not only through species loss, continuous environmental 
changes leads to biochemical changes in plants which could include the loss of key bioactives 
(Bucar, Wube, & Schmid, 2013; David, Wolfender, & Dias, 2015). It is vital to consider the 
collection of protected species in the right season and habitat. The United Nation's Convention 
on Biological Diversity (CBD) (CDB, 1992) by the international community in Rio de Janeiro, 
Brazil, aims at: (1) conserving the biodiversity; (2) sustainably using its genetic resources; and 
(3) sharing the benefits from their use in a fair and equitable manner. Although the CBD 
provided a framework for countries to regulate and define bioprospecting, the treaty left many 
open questions, particularly in the issue of access and benefit sharing, resulting in reduction of 
access to the plant material and thus decreased interest of pharmaceutical companies for plant 
based drug discoveries (Cragg & Newman, 2013; Kingston, 2011). To overcome this, the 
Nagoya Protocol (CDB, 2010) on access to genetic resources and the fair and equitable sharing 
of benefits arising from their utilization to the convention on biological diversity has been 
published in 2011 and has come into force in October 2014. 
Besides the accessibility of the plant material, also its quality is of great importance. The 
chemical composition of a plant depends on various factors like species identity and harvest 
time, but also on soil composition, altitude, actual climate, processing, and storage conditions. 
Another aspect determining the chemical composition of the starting plant material is presence 
and absence of endophytic organisms, inhabiting the plant as the metabolites might alter due 
to the interaction of organisms (David et al., 2015).  
Another important barrier are accessibility of the starting material and the low yield of 
bioactives. Larger quantity of bioactives required to characterise a potential pharmacological 
lead and is a frustrating drawback especially when initial investigations are promising. This 
low yield is especially problematic as the investigation of plant extracts using involves high-
through put screening (HTS), then this is followed by the identification of bioactive 
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constituents. In general, HTS requires high reproducibility, accuracy, robustness, and reliable 
liquid handling systems. Test compounds should not decompose or precipitate, should not 
interfere with assay reagents nor show non-specific effects and natural products often fail to 
fulfil these requirements. Plant extracts are usually complex, viscous, tends to precipitate and 
sometime contains components like inorganic components, fluorescent components, organic 
components that non-specifically bind proteins, or have toxic constituents might interfere with 
assays (Coan, Ottl, & Klumpp, 2011; Henrich & Beutler, 2013; Johnson et al., 2011; Maes et 
al., 2012; Schmid, Sattler, Grabley, & Thiericke, 1999; Ying Tu et al., 2010). The technical 
demands linked to natural products characterisation leads to development costs that are much 
higher than the costs for small molecule drugs. As a result interest in natural product-based 
drug discovery has been declining (Beutler, 2009; David et al., 2015; Ortholand & Ganesan, 
2004). 
 
1.3. TRADITIONAL CHINESE MEDICINE 
China is the second largest country based on area and this results in wide differences in 
topography, climate and soil types. As a result, it is considered to be the third most bio-diverse 
country in the world. China has over 32,000 species of vascular plants and 10,000 recorded 
species of Fungi. Out of such biodiversity, over 7000 species have medicinal uses. China has 
been using herbs for centuries as traditional Chinese medicine (TCM) and these are now 
attracting global interest as a source of natural products. However, the information regarding 
their use is often inaccessible to the wider scientific community. With the increased export of 
Chinese Medicines, global access to TCM has never been easier but there remain difficulties 
in targeting the most appropriate sources, and product quality assessments. 
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Western medicine was introduced into China in the sixteenth century, but it did not obtain any 
wide acceptance in that country until the nineteenth century. This was due to its competition 
with traditional Chinese medicine (TCM), widely used by the Chinese for centuries. Shen Nong 
is regarded as the father of Medicine (K. C. Wong & Wu, 1936). and founder of Chinese 
medicine. The “Classic of Shen Nong’s Materia Medica” is the first book summarizing the 
properties and functions of over 300 herbs (P. Chen, Lu, & Lin, 1997). The Yellow Emperor’s 
Inner Canon is the oldest work of Chinese medical theory (dated around the first century BC), 
and explains the relationship between humans and their environment as it impacts on the body, 
vitality, and pathology. Methods of diagnosis and therapeutic approaches ideas were developed 
based on this ancient philosophy (Boltz & Loewe, 1993; Harper, 2013; G.-D. Lu & Needham, 
2012). The concept of Yin, Yang and Five Phases (Ellis & Wiseman, 1995; Ergil & Ergil, 
2009; Kaptchuk, 2000; Mayor, 2007) have had a great influence on the TCM approach (Figure 
1. 10). The TCM view of a human body model is not only restricted to anatomical structures 
but also focuses its dynamic functions (Barrett, 2011; Matuk, Sc, & Sc, 2006; Ross, 1985). 
Figure 1. 10: Yin, Yang and Five Phases 
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TCM encompasses a combination of energy theories, acupuncture, and herbal prescriptions. 
Thus, TCM is similar to the European humoral Theory of the Medieval and Renaissance 
periods (Novella, 2012). 
TCM is still considered as a pseudoscience as no scientific evidence have been found to support 
its basic concepts. As such, the use of TCM is a subject of controversy (Qiu, 2007). An article 
in 2006 by Prof. Zhang “Farewell to Traditional Chinese Medicine?” argued that TCM should 
be removed from public healthcare and academia. Stephen Barrett of Quackwatch (2011) wrote 
that “TCM theory and practice are not based upon the body of knowledge related to health, 
disease, and health care that has been widely accepted by the scientific community. TCM 
practitioners disagree among themselves about how to diagnose patients and which treatments 
should go with which diagnoses. Even if they could agree, the TCM theories are so nebulous 
that no amount of scientific study will enable TCM to offer rational care" (Barrett, 2011). 
However, the Chinese Government is still interested in TCM and encourages research into its 
underlying science, as well as its export and development. 
 
The Modern Concept of Medicine in China 
By the 19th Century, Western medicine had developed rapidly and was available to common 
people so that TCM began to lose its prominence in China. By the 20th century, people realized 
that Western and TCM were in opposition to each other in their basic philosophies. Although 
it was believed that TCM could cure diseases, there was logical imperative to prove it. In 
Western medicinal approaches, scientific proof is paramount. As indicated above, this has 
proven difficult for TCM.  
Nevertheless, TCM does represent an important corpus of “folk-medicine” than could be seen 
as the product of centuries of “trial-and-error” approaches used by doctors. TCM is therefore 
attracting considerable interest throughout the world. With the increased export of Chinese 
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Medicines, it has been easier to apply the modern research ways to detect the molecules, define 
their mode of action and pharmacokinetic and pharmacodynamics properties. As a result, the 
Chinese have gained new knowledge of the use of these herbs and also their most effective 
utilization following clinical and toxicity trials. With increase consumer demand, effective 
tools have been developed to allow the study of compounds derived from a single plant species. 
This has led to the establishment of "measures for examining and approving new drugs".  
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1.4. AIMS AND OBJECTIVES 
Natural products have become one of the most important resources for developing new lead 
compounds and scaffolds. Traditional Chinese medicines are one of the most comprehensive, 
well-documented traditional and folk medicines in human history. Since the breakthrough in 
the discovery of Artemisinin from Artemisia annua, scientists have conducted comprehensive 
research into TCM pharmaceutical chemistry and chemical biology. The discovery of 
artemisinin illustrates how TCM constitutes a great store of knowledge about natural products 
holds considerable promise. However, the exploitation of natural products represents 
considerable challenge. These include, for example, adulteration of material due to high 
demand in the western pharmacology industry, existence of synergistic effects of compounds 
resulting in activity, and the modes and mechanisms of action are seldom very clear. 
The central aim of this thesis is to investigate examples of TCM as sources for new anti-
microbials. The specific objectives of this thesis can be summarised as follows: 
• Authentication the received TCM samples via DNA barcoding. 
• In vitro anti-microbial screening of the received TCMs, against a range of clinically 
relevant pathogens, to ascertain the best candidate TCM for future characterisation.  
• Bioassay guided purification and isolation of the natural product from the selected TCM’s. 
and to determine the toxicity of the isolated compounds in vitro; 
• Establish a rapid metabolomics methodology approach and computational modelling to determine 



























General materials and methods 
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2.1. MATERIAL  
Plant materials 
The plants and fungi were selected by Prof. Jianying Shen from Institute of Chinese Materia 
Medica, Beijing, Prof Fuzhong Li from Shanxi Agricultural University, Shaanxi based on 
interrogation of Chinese TCM databases. The 16 samples were screened based on the 
ethnopharmacological use confirmed based on internationally available literature (Table I). 
Information gathered includes Chinese name, common name, traditional benefits, parts and 
preparation used in TCM.  
 
Microbial strains 
Two Gram-negative species (Escherichia coli ATCC 25922, Pseudomonas aeruginosa, ATCC 
27853), two Gram-positive strains (Staphylococcus aureus ATCC 29213, methicillin-resistant 
Staphylococcus aureus USA300 (MRSA)), Mycobacterium smegmatis mc2155, and one fungal 




Total genomic DNA of was extracted using a DNeasy Plant Mini kit (Qiagen, UK) in 
accordance with the manufacturer’s instructions. For plants, the rbcL sequences where 
amplified with rbcLa-F: 5′-ATGTCACCACAAACAGAGACTAAAGC-3′ and rbcLa-R: 5′-
GTAAAATCAAGTCCACCRCG-3′ primers (CBOL 2009). PCR used a total volume of 20 
µL with 10 µL BioMix (BioLine, UK) 1 µl forward primer (10 µM), 1 µL reverse primer (10 
µM), and 1 µL of the DNA template (50 ng/µL) and 7 µL HPLC water. PCR involved 1 cycle 
(94 °C for 3 min), 35 cycles (94 °C for 1 min, 55 °C for 1 min, and 72 °C for 1 min), and 1 
cycle 72 °C for 7 min.  
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For fungi, ITS sequences were amplified with ITS8-F: 5’-
AGTCGTAACAAGGTTTCCGTAGGTG-3’ and ITS4-R 5’- 
TCCTCCGCTTATTGATATGC- 3’ primers. PCR used a total volume of 20 µL with 11.11 
µL BioMix (BioLine, UK) 0.89 µl forward primer (10 µM), 0.89 µL reverse primer (10 µM), 
and 1 µL of the DNA template (50 ng/µL) and 7.11 µL HPLC water. PCR involved 1 cycle 
(95 °C for 2 min), 35 cycles (95 °C for 30 sec, 55 °C for 30 sec, and 72 °C for 1 min), and 1 
cycle 72 °C for 10 min (Dentinger, Margaritescu, & Moncalvo, 2010). The resulting 600 bp 
band was sequenced in both directions on an ABI3730X, using the same primers as used for 
PCR.  
The derived sequence was submitted to BLAST to confirm 100 % identity to rbcL and ITS 
sequences. The rbcL and ITS sequences has been submitted to GenBank (Table II).  
 
Crude sample preparation  
Dried plant material (aerial parts, roots, leaves, twigs, fruits, rhizome or whole plants) was 
ground into a powder using a mortar and pestle with liquid nitrogen. Totals of 20 g powder for 
each TCM were sequentially extracted in 2Í500mL of n-hexane, dichloromethane (DCM), 
ethyl acetate (EtOAc) and methanol (MeOH) at room temperature with continuous stirring for 
24 h, in each solvent. The extracts were filtered, concentrated and stored at 4 oC until use. 
 
Anti-microbial assay 
The plant material was dissolved in 50 % methanol - 50 % water to a final concentration of 5 
mg/mL. The antimicrobial activity of all the extracts and isolated compounds was evaluated in 
96-well plates by micro-dilution technique. Concentration of the extracts was ranged from 500 
µg/mL to 3.125 µg/mL. Serial two-fold dilutions was performed in nutrient broth (E. coli, P. 
aeruginosa, S. aureus, MRSA), yeast mould broth (C. albicans) and nutrient broth 
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supplemented with 0.05 % tween 80 and 0.2 % glycerol (M. smegmatis). Overnight cultures of 
the bacterial and Candida strains were prepared and ~105 cells were incubated in the diluted 
extracts and compounds. The assays were performed in triplicate and incubated at 37 oC for 24 
h for E. coli, P. aeruginosa, S. aureus, MRSA and C. albicans and 72 h for M. smegmatis. 
Rifampicin and gentamycin sulphate were used as reference drugs. The absorbance was read 
in microplates (Hidex Sense) at 630 nm evaluated the bacterial growth. Mycobacterium and 
Candida growth was assessed by adding 20 µL 3-( 4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) stain.  
  
Column Chromatography 
Column chromatography (CC) was performed using Material Harvest Ltd silica gel 60 (20-230 
mesh). Thin layer chromatography (TLC) was performed on Sigma-Aldrich silica gel 60 F254 
gel plates and visualized under UV light and by spraying sulphuric acid-MeOH (1:1) followed 
by heating.  
 
Flash column chromatography 
Purification of compounds by flash chromatography was performed using a Biotage Flash+ 
chromatography system with SNAP C18 silica cartridges (30g. 40-63 µm, 60 Å) and fraction 
collection controlled by photo-diode array (PDA) at 250nm. 
 
Semi-preparative high-performance liquid chromatography (Semi-preparative HPLC) 
Chromatographic separation was performed on a reverse phase (RP) ACE 10 C18 250x21.2mm 
using water with 0.1% formic acid as a mobile phase solvent A and methanol with 0.1% formic 
acid as a mobile phase solvent B. Each sample was injected using a flow rate of 10 ml/min. 
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Column oven temperature was set to 40°C. Data was acquired with a photo-diode array (PDA) 
at 250nm (Dionex). 
 
Ultra-high-performance liquid chromatography-high resolution mass spectrometry 
(UHPLC-MS) 
Fractions were analysed on an Exactive Orbitrap (Thermo Fisher Scientific) mass 
spectrometer, which was coupled to an Accela Ultra High-Performance Liquid 
Chromatography (UHPLC) system (Thermo Fisher Scientific). Chromatographic separation 
was performed on a reverse phase (RP) Hypersil Gold C18 1.9 µm, 2.1 × 150 mm column 
(Thermo Scientific) using H2O using 0.1 % formic acid (v/v, pH 2.74) as the mobile phase 
solvent A and ACN: isopropanol (10:90) with 10 mM ammonium acetate as mobile phase 
solvent B. Each sample (20 µL) was analysed using 0-20 % gradient of B from 0.5 to 1.5 min 
and then to 100 % in 10.5 min. After 3 min isocratic at 100 % B the column was re-equilibrating 
with 100 % A for 7 min. 
A flow rate of 340 µL/min was used for running the samples. Column oven temperature was 
set to 60 °C and the data were acquired in both positive and negative ESI, using a heated 
electrospray ionisation source (HESI). Mass spectra were acquired from 70 to 1400 mass-to-
charge ratio (m/z) using a mass resolution of 100,000. The spray voltage was 4 kV for both 
ionization modes. The temperature of the ion transfer capillary was 370 °C and sheath and 
auxiliary gas was 30 and 15 arbitrary units, respectively.  
The data were recorded using the Xcalibur 2.0.0 software package (Thermo Fisher Scientific). 
Mass calibration was performed for both ESI polarities before the analysis using a mixture of 
caffeine, MRFA (L-methionyl-arginyl-phenylalanyl-alanine), Ultramark 1621, sodium 
dodecyl sulfate (SDS), and sodium taurocholate dissolved in acetonitrile-methanol-water 
solution with 1 % acetic acid. 
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Flow injection electrospray high-resolution mass spectrometry (FIE-HRMS): 
FIE-HRMS was performed using an Exactive HCD mass analyzer equipped with an Accela 
UHPLC system (Thermo-Scientific) which generated metabolite fingerprints in both, positive 
and negative ionization mode, in a single run. Samples (20-µL volume) were injected into a 
flow of 100-µl.min−1 methanol: water (70:30, v/v). Ion intensities were acquired between m/z 
50 and 1000 for 3.5 min at a resolution setting of 100,000 (at m/z 200) resulting in 3 (± 1) ppm 
mass accuracy. ESI source parameters were set according to the manufacturer’s 
recommendations. Raw files were exported to CDF-files, mass aligned and centroided in 
MATLAB (V8.2.0, The MathWorks) maintaining highest mass accuracy. Mass spectra around 
the apex of the infusion peak were combined in a single intensity matrix (runs x m/z) for each 




UV-visible spectra were determined using the Unicam UV-500. NMR spectra were obtained 
using Bruker Ultra shield-500 NMR spectrophotometer (1H-NMR 500MHz, 13C-NMR 100 

























Antimicrobial screening of  
Traditional Chinese Medicine 
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Abstract 
 
In collaboration with Chinese institutions a series of traditional Chinese medicines (TCM) were 
tentatively linked with antimicrobial activity. This involved searches of the Chinese literature 
focusing on treatments for various types of infections. Eighteen TCM were targeted (sixteen 
plant and two fungal TCM) and obtained from commercial sources in China. The identity of 
the TCM was confirmed through DNA barcoding based on rbcL for plant TCM and the Internal 
Transcribed Sequences (ITS) for fungal TCM followed by sequence comparison with vouchers 
samples in Genbank. DNA barcoding helped us confirming the species and indicated that some 
of them that were mislabeled. Extracts of different polarities for selected species were screened 
for their antimicrobial activity against a range of Gram-negative (Escherichia coli, 
Pseudomonas aeruginosa) and Gram-positive (Staphylococcus aureus, methicillin-resistant 
Staphylococcus aureus (MRSA)) Mycobacterium smegmatis bacteria as well as Candida 
albicans using the 96-well plate micro-dilution method. Anti-microbial activity was observed 
in some TCM extracts against S. aureus, MRSA, M. smegmatis and C. albicans. No anti-
microbial effect was observed against gram-negative bacteria. The highest activities were 
shown by n-hexane and dichloromethane extracts of Dryopteris crassirhizoma Nakai against 
S. aureus and MRSA (MIC= 6.25 µg/mL and 50 µg/mL respectively) and n-hexane fraction of 
Oldenlandia diffusa (Willd.) Roxb. was against S. aureus (MIC= 62.5 µg/mL). Our studies 
indicate the utility of exploring TCM’s for drug leads based on records of folk medicine. We 
also show how rigor is required in sample identification if obtained from commercial sources 
and confirmation of activities from different sample sources is required before robust 
conclusions of any intrinsic anti-microbial activities.   
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3.1. INTRODUCTION 
Ethnobotany 
With the known side effects of synthetic drugs, there is an increase interest in natural products 
as they have the advantage of their long-term use by humans. A vast majority of people 
especially from developing countries rely on traditional medicinal plants for their everyday 
healthcare. The use of plants by humans followed a trial and error method and the successful 
results were passed over generations; most often verbally. As a result, ethnobotany plays an 
important role in recording the traditional medicinal knowledge before it gets lost with the 
increased “sophistication” of modern societies (Figure 3.1). The successes of ethnobotanical 
approaches to yield drug leads are well-known. The isolation of anti-malarial drugs quinine 
from the bark of Cinchona species in 1820 by Caventou and Pelletier attracted  
scientist to re-evaluate the therapeutically knowledge of all the traditional medicines. Now, 
most of the 122 plant-derived drugs from 94 plant species currently used in modern science 
were discovered through ethnobotanical analysis (Gao & Watanabe, 2011; Plengsuriyakarn et 
al., 2012). 
 
2 3 1 
Figure 3.1: Chinese Materia medica.  
1: Chrysanthemum; 2: Ginseng; 3: Plantago. Image credit: wellcomeimages.org 
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 Ethnobotanical data can represent a substitute to high throughput screening of bioactives 
(Rout, Choudary, Kar, Das, & Jain, 2009). Ayurveda (Traditional Indian Medicine) and TCM 
are considered as two of the most ancient systems in the application of medicinal plants for 
therapeutic treatments each with histories stretching over several millennia. However, 
traditional medicines do not represent “off-the-shelf” solutions to current medical need and 
require validation and quality assurance. Thus, exploitation of traditional medicine requires 
rigorous scientific assessment of any bioactivities coupled with a consideration of the variation 
in the bioactives in each sample of the traditional medicine.  
 
Q-Markers in TCM  
Chinese medicine quality marker (Q-marker) is a chemical constituent and can be defined, 
according to the following four basic conditions: (1) quality marker exists in herbs, pieces, 
extracts, unilateral or compound formulations; (2) quality marker should be analysed through 
either qualitative and quantitative approach; (3) based on principle of multiple-flavour 
prescription TCM (such as the King (Jun), minister (Chen), assistant (zuo) and guide (Shi), as 
Figure 3.2: A general flowchart for Q-marker-based establishment of holistic quality control 
system of TCM. 
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well as the compatibility of TCM and modern pharmacological study, the drug effect (such as 
effectiveness and safety) should be demonstrated to be associated with the identified quality 
marker, (4) the quality marker is a chemical substance that are transferable and traceable in the 
process of production and preparation (Figure 3.2). 
The relevance of Q-markers for TCM quality control is exemplified by ginseng. Ginseng is 
ranked among the most popular natural products worldwide (Qi, Wang, & Yuan, 2011). Three 
Panax species, P. ginseng (Asian ginseng), P. quinquefolius (American ginseng), and P. 
notoginseng (Sanchi ginseng), are largely consumed as the healthcare products, dietary 
supplements, and herbal medicines (Yang, Hu, Wu, Ye, & Guo, 2014). Establishment of the 
Q-markers that ensure the authenticity of Ginseng Radix et Rhizoma (Panax ginseng; Ren-
Shen) is difficult, since the chemical difference among the congeneric species (such as Panax 
quinquefolius and Panax notoginseng) and different parts (the root/rhizome, stem/leaf, flower, 
berry, and seed) needs to be clarified. Given the bioactivity and specificity ginsenosides, 
saponins and flavonoid (Park, Rhee, & Lee, 2005; Yang et al., 2014), were mainly used to 
establish the quality markers or the exact identification among the root/rhizome, stem/leaf, 
flower, and berry of P. ginseng.  
 
Challenges with the quality standards 
Many factors, such as the species, cultivation/production area conditions (geo-herbalism), 
harvesting, processing, transportation/storage conditions, extraction/purification, ADME 
(absorption, distribution, metabolism, and excretion), and interaction of diverse components 
(Liu et al., 2016), can affect the quality of TCM. The chemical composition and content of 
markers in TCM medicinal materials, extractives, products, and formulae, are measured by 
Ultraviolet-visible spectroscopy (UV), thin layer chromatography (TLC), High Performance 
Liquid Chromatography (HPLC) (or Ultra-High-Performance Liquid Chromatography 
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(UHPLC)), Gas chromatography (GC), Liquid chromatography-mass spectrometry (LC-MS), 
or Gas chromatography-mass spectrometry (GC-MS), for authenticity identification and 
quality evaluation. The difficulties of quality assessment of TCM products can be listed as 
following: (1) it is associated with Good Agricultural Practice, Good Collection Practice 
(GACP), and Good Supplement Practice (GSP); (2) specific eco- geographic regions (EGRs) 
of botanical raw materials is of particular importance; (3) how to reduce the variability from 
the plant raw materials to production process; and (4) based on well-known mechanism of 
action (MOA) and TCM theory, potency evaluation of bioactive response become flexible for 
control of the manufacturing process. Based on the above, it is suggested that: (i) TCM products 
are complex with multiple chemical components (known and unknown active components) and 
natural variations; (ii) generally TCM product is the mixture of the active pharmaceutical 
ingredients (API) and inactive ones from raw materials of herbs; (iii) TCM products are very 
difficult to satisfy the identical requirement of quality, safety and efficacy as that of chemical 
drugs; and (iv) the principle of multiple-flavour prescription in TCM is also far different from 
the strategy used in Western medicine. The intrinsic “multicomponent and multi-target” feature 
of TCM necessitates the establishment of a unique quality and bioactivity evaluation system, 
which is different from that of the Western medicine (Yang et al., 2017). 
This chapter will aim to use the expertise of our Chinese collaborators to identify potentially 
anti-microbial TCM and establish an analysis pipeline (Figure 3.3) which would include the 
confirmation of their identities to screening for bioactivities.  
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3.2. RESULTS 
In order to screen followed by isolation of bioactive from of the selected TCMs, we 
have instigated a pipeline where interrogation of Chinese sources can indicate usage of 
particular TCM in diseases where anti-microbial activities could be prominent can 
indeed, yield the hypothesised (Figure 3.3). It involves the following steps: 
• Initial screening of the crude extract  
• Sequence of bioassay guided purification 
• Structure elucidation of isolated compounds by spectroscopic techniques namely 
High-Performance Liquid Chromatography (HPLC) and 2D Nuclear Magnetic 
Resonance (NMR) 
• Assessment of biological activities of purified compounds in vitro 
• Mode of action studies using different omics technologies 
• Preclinical studies to understand pharmacokinetics and mechanism of action of the 
selected bioactive compound 
The 16 different genera used in TCM were selected based on literature research. There common 
name, traditional ways of consumption, physiological portions used as medicine and already 
studied biological activities are listed in  
Table I and Table II 
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Figure 3.3: Pipeline for TCM bioactive discoveries. 
(A): Collaborators with expertise in TCM are identified and an agreement in line with the Nagoya protocols are established. (B) SCOUTING:  The folk medicinal 
literature is consulted to identify TCM which may have relevant bioactivities; (e.g. countering infections as a source of anti-microbials). (C) EXTRACTION: The 
TCM are sourced and chemicals are extracted using various solvents. (D) BIOASSAYS: The extracted are screened for activities against clinically relevant bacterial 
based on establishing the minimum inhibitory concentration (MIC) using a 96 -well plate dilution methods. Anti-parasite activities are based on screens against 
Schistosoma mansoni. (E) PURIFICATION: involved sequential bioactivity guided fractionation to eventually yield a pure product. (F) IDENTIFICATION: was 
based on high resolution mass spectroscopy and nuclear magnetic resonance (NMR). (G): Further derivatization of the product is based on ‘OMIC 
DETERMINATION OF MODE OF ACTION (MoA). The ultimate aim of the pipeline is to define a possible DRUG LEAD(H). 
A 
B 
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Table I: Ethnobotanical data of the plants studied.  
N.A: no literature on bioactivity found. 




proved properties References 







(Ho, Peh, Chan, & Wong, 2014a; J.-B. 
Jiang, Guo, Li, Kong, & Arnold, 1982; 
Kuhn & Wang, 2008) 













(H.-J. Kim, 2019; C. Lu, Zhang, Ji, & 
Wang, 2012; She et al., 2011) 
Fritillaria cirrhosa  















(Wang et al., 2014; Wang et al., 2014; 
Wang, Yang, Du, Li, & Wang, 2016; 
Wang et al., 2011) 
Fritillaria thunbergii  
Miq. 
 












(Li, Xu, Zhang, Liu, & Tan, 2005; Shin, 
Yong-Kyu; Jang, Han-Su; Kim, Jee-In; 
Sohn, 2009) 
35 | P a g e  
Pseudostellaria 
heterophylla  (Miq.) Pax 
  





Decoction Antitumor  
(Wang & Ng, 2006; Wong, Leung, Fung, 
Fung, & Choy, 1994) 
Paeonia lactiflora Pall. 






Herbal teas or 







(He & Dai, 2011; Ngan, Moon, Kim, 
Shibamoto, & Ahn, 2012; Ngan, Moon, 





Rěn dōng téng 





















(Rumalla, Avula, Zhao, Smillie, & Khan, 
2011) 
Forsythia suspense  
(Thunb.) Vahl 
 

















(Guo, Lin, & Wang, 2015; Kuo, Chen, 
Yang, Lin, & Peng, 2014; Ozaki, Rui, & 
Tang, 2000; H. Qu, Zhang, Wang, Li, & 
Sun, 2008; X. yan Qu et al., 2016; Wen, 
Huifu, & Hao, 2010; Zhang, Song, Ren, & 
Xu, 2002; Zhang, Miao, Yan, Sheng, & Ji, 
2018) 
Oldenlandia diffusa or 
Herba Hedyotidis 
Diffusae 






















(Lin et al., 2010, 2011; Niu & Meng, 2013; 
Ye, Liu, Zhang, & He, 2015) 
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Astragalus 
membranaceus Fisch. ex 
Bunge 













(Agyemang et al., 2013; Jin, Zhao, Huang, 
& Shang, 2014) 

















(Jung et al., 2009; J. M. Kim, Jung, Choi, 
& Lee, 2010; Kong et al., 2009; Tsai, 
Chen, & Lo, 2008) 








Powder Antidiabetic (Zheng et al., 2017) 

















(Geng, Yang, Chou, & Wang, 2010; Q. 
Zhou et al., 2013) 
Menispermum dauricum 
DC. 
















(M. Lin et al., 2013; Qian, 2002) 
Chrysanthemum lucidum 




Cold and flu 
Headache and 
dizziness 
Decoction N.A N.A 
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Table II: Ethnobotanical data of the fungi studied. 
 
Dryopteris crassirhizoma 
Nakai Guan Zhong 
Wood Fern, 












(Kapadia et al., 1996; Kwon et al., 
2007;Lee, Kim, & Lee, 2009; Lee, 
Miyashiro, Nakamura, & Hattori, 2008; 
Magalhães et al., 2010; Yang et al., 2013; 
Zhao et al., 2014) 









proved properties References 
Polyporus 










(Xingqun Li & Xu, 2011; Xinqun Li, Xu, & 
Chen, 2010; Sun & Zhou, 2014; G. Zhang, 


























(Gao, Lan, Dai, Ye, & Zhou, 2004; Gao et al., 
2002; Suay et al., 2000; Wang, Xi, Li, Wang, 
& Yao, 2012; Wasser, 2005) 
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Figure 3.4: Phylogenetic relations between of the selected TCM plants and associated vouchers based on 
rbcL sequence variation 
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As the plants and fungi were collected from commercial sources, it was essential to authenticate 
the sample to avoid adulteration. DNA barcoding was used in this study to authenticate the 
plant species. The plant DNA barcode regions rbcL (ribulose-bisphosphate carboxylase) and 
fungal barcode region the internal transcribed spacer (ITS) were used. The barcode sequences 
were further submitted online to GenBank database using the Bankit tool (Figure 3.4 and Figure 
3.5). Their accession numbers are shown in Table III. 
 
The extracts were prepared by sequentially extracting with solvents based on polarity resulted 
in 64 extracts. The MIC values of the extracts in context to the respective bacteria are 
summarized in Table III. The antimicrobial activity assessments were undertaken in triplicate 
and no variation in results was observed. The type of extracts in rank of their activity are n-
hexane, DCM, EtOAc and MeOH. Extracts showed activity against S. aureus, MRSA, M. 
smegmatis and C. albicans, while were not active against E. coli and P. aeruginosa. The n-
hexane and ethyl acetate extract of Dryopteris crassirhizoma and n-hexane extract of 
Oldenlandia diffusa were particularly effective against S. aureus and MRSA with very low 
Figure 3.5: Phylogenetic relation of the selected fungi TCM  and associated vouchers based 
on ITS sequence variation  
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MICs.  Extracts showed no activity against Gram-negative bacteria even if displaying some 
activity against Gram-positive, fungi and M. smegmatis. The poor results obtained for Gram-
negative bacteria could reflect the hydrophobic outer membrane creating a permeability barrier 
for different antibiotics mainly hydrophilic compounds (Poole, 2002) (Nikaido, 1994).  
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Table III: Antimicrobial screening of authenticated TCMs (MIC µg mL-1) 
Plant species Accession numbers Part Solvents E. coli P. aeruginosa S. aureus MRSA M. smegmatis C. albicans 
Artemisia annua MH051919 Aerial parts 
n-Hexane >500 >500 500 500 500 500 
DCM >500 >500 >500 >500 >500 500 
EtOAc >500 >500 >500 >500 >500 500 
MeOH >500 >500 >500 >500 >500 500 
Polygala tenuifolia MN431187 Root 
n-Hexane >500 >500 >500 >500 >500 >500 
DCM >500 >500 >500 >500 >500 >500 
EtOAc >500 >500 >500 >500 >500 >500 
MeOH >500 >500 >500 >500 >500 >500 
Fritillaria cirrhosa MT354770 Bulbs 
n-Hexane >500 >500 >500 >500 250 >500 
DCM >500 >500 >500 >500 >500 >500 
EtOAc >500 >500 >500 >500 >500 >500 




n-Hexane >500 >500 >500 >500 500 >500 
DCM >500 >500 >500 >500 >500 >500 
EtOAc >500 >500 >500 >500 >500 >500 
MeOH >500 >500 >500 >500 >500 >500 
MN431200 Roots n-Hexane >500 >500 >500 >500 >500 >500 




DCM >500 >500 >500 >500 >500 >500 
EtOAc >500 >500 >500 >500 >500 >500 




n-Hexane >500 >500 >500 >500 >500 >500 
DCM >500 >500 >500 >500 >500 >500 
EtOAc >500 >500 >500 >500 >500 >500 
MeOH >500 >500 >500 >500 >500 500 
Ganoderma lucidum MN431189 Whole 
n-Hexane >500 >500 >500 >500 >500 >500 
DCM >500 >500 250 >500 >500 >500 
EtOAc >500 >500 >500 >500 >500 >500 
MeOH >500 >500 >500 >500 >500 >500 
Lonicera japonica 
 
MN431192 Dried flowers 
n-Hexane >500 >500 500 >500 500 >500 
DCM >500 >500 500 >500 >500 >500 
EtOAc >500 >500 250 250 >500 >500 
MeOH >500 >500 >500 >500 >500 >500 
Forsythia suspensa 
 
No accession number 
obtained 
Fruit shell 
n-Hexane >500 >500 >500 >500 >500 >500 
DCM >500 >500 500 500 >500 >500 
EtOAc >500 >500 500 500 >500 >500 
MeOH >500 >500 >500 >500 >500 >500 
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Oldenlandia diffusa or 
Herba Hedyotidis 
Diffusae 
MN431193 Whole plant 
n-Hexane >500 >500 62.5 125 500 >500 
DCM >500 >500 >500 500 >500 >500 
EtOAc >500 >500 250 >500 >500 >500 
MeOH >500 >500 >500 >500 >500 >500 
Astragalus membranaceus 
(Fisch.) Bunge (AM) 
MN309697 Root 
n-Hexane >500 >500 >500 250 500 >500 
DCM >500 >500 >500 500 >500 >500 
EtOAc >500 >500 >500 >500 >500 >500 
MeOH >500 >500 >500 >500 500 >500 
Coptis chinensis MN431186 Rhizome 
n-Hexane >500 >500 >500 >500 250 >500 
DCM >500 >500 250 500 >500 >500 
EtOAc >500 >500 >500 >500 >500 >500 
MeOH >500 >500 125 500 >500 250 
Corydalis edulis Maxim. MN431194 Rhizome 
n-Hexane >500 >500 >500 >500 >500 >500 
DCM >500 >500 500 500 >500 >500 
EtOAc >500 >500 >500 >500 >500 >500 
MeOH >500 >500 >500 >500 >500 >500 
Plantago asiatica MN431195 Seed 
n-Hexane >500 >500 >500 >500 500 >500 
DCM >500 >500 500 >500 500 >500 
EtOAc >500 >500 >500 >500 >500 >500 
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MeOH >500 >500 >500 >500 >500 >500 
Menispermum dauricum MN431199 Root 
n-Hexane >500 >500 250 250 250 >500 
DCM >500 >500 500 250 250 >500 
EtOAc >500 >500 500 >500 >500 >500 
MeOH >500 >500 >500 >500 >500 >500 
Chrysanthemum lucidum MN431196 flower 
n-Hexane >500 >500 >500 >500 500 >500 
DCM >500 >500 500 >500 500 >500 
EtOAc >500 >500 500 >500 500 >500 
MeOH >500 >500 >500 >500 >500 >500 
Dryopteris crassirhizoma MN431197 Rhizome 
n-Hexane >500 >500 3.125 3.125 500 >500 
DCM >500 >500 25 50 500 >500 
EtOAc >500 >500 >500 >500 >500 >500 
MeOH >500 >500 >500 >500 >500 >500 
Rifampicin  - -   - - 1.14 - 
Gentamycin Sulphate  - - 1.6 3.13 3.13 3.13 - - 
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3.3. DISCUSSION 
TCM are available to be used by consumers in a variety of forms such as capsules, extracts, 
teas, tinctures and traditional formulations. Several agencies have provided guidance prior to 
its use for research purposes. Specific journals and their editors have provided specifications 
on the characteristics of the targeted natural products before publication is permitted (Kellogg 
et al. 2019). These are that: (1) the identities of major metabolites, especially those that may be 
biologically active needs to be defined; (2) the in vitro or in vivo targets and activities require 
accurate definition; (3) the results need to fill a current knowledge gaps; and that (4) prior 
consumer usage of the TCM was study (Kellogg et al. 2019). It is suggested that the product 
selected must collected from the same commercial products used by the target population. 
Products can be either collected from (1) the regional or national herbaria , who have historical 
records of the specimen, (2) research groups who can prepare or grow the respective specimen, 
(3) from a commercial supplier or (4) collected from the wild condition. 
Once samples are collected, the first and the most important step is their authentication. 
Samples can be authenticated by multiple means, including examination of the morphological 
and microscopic characteristics, DNA barcoding, chemotaxonomy, chemical fingerprints and 
untargeted metabolomics (Kellogg et al. 2019). In our experiments, we authenticated the 
commercially obtained samples using DNA barcoding by sequencing specified PCR 
fragments. The plant DNA barcode regions rbcL is the most characterized plastid coding 
sequence in GeneBank with wide representation from all major groups. In polymerase chain 
reaction (PCR), rbcL gene had shown higher amplification efficiency and sequencing success 
rate compared to other selected plant characterization genes (Parveen, Singh, Raghuvanshi, 
Pradhan, & Babbar, 2012; Pawlowski et al., 2012). Due to this unique property of rbcL gene, 
it is ideal for studying the genetic 
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variations of the plants species (Hamdan, Abd Samad, Hidayat, & Mohd Salleh, 2013). White 
et al., 1990 suggested that fungal ITS are remarkably robust, works with the vast majority of 
fungi The ITS varies in length considerably among major taxonomic groups and gives superior 
resolution in those groups with longer amplicons. Fungal ITS is indel rich, which makes it 
useful for the development of molecular diagnostics involving taxon specific 
oligonucleotides(Seifert, 2009). Here conserved DNA sequences (used as primer binding site) 
straddle a hypervariable region where variation may be associated with specific genera or 
species. DNA barcoding is an effective tool for fresh, dried, or powdered material, where intact 
DNA is still present. However, it fails in case of a processed products where either the DNA is 
absent or degraded in the process. However, in our hands the value of a DNA barcoding 
validation step was demonstrated. For example, we were provided one of the plant sample 
stating it to be Forsythia suspense, but once the sample was barcoded the sequence resembled 
Syringa yunnanensis (Figure 3.8: Received material tagged as Forsythia suspensa); for which 





Figure 3.7: Two sets of Dryopteris crassirhizoma supplied to us from different provinces of 
China. 
DNA barcoding confirmed as (A) Dryopteris crassirhizoma, (B) Plantago lanceolata 
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Polygala rehmannii. Additionally, when we received a second set of Dryopteris crassirhizoma 
this was barcoded to be Plantago lanceolate ( Figure 3.7).  
 
 
Once the samples are authenticated, the next step in our analysis pipeline (Figure 3.3) was to 
prepare extracts from the samples. In our experiment, samples were extracted using gradient 
of solvent resulting in a range of chemical products with difference in polarity. The solvents 
were later evaporated from the extracted products for long-term storage of the samples. 
These extracts were then screened for their antimicrobial potential. The susceptibility of 
pathogen against an antibiotic can be determined using MIC. The MIC represents the lowest 
concentration of antimicrobials needed to inhibit the bacterial growth. Considering different 
criteria and the reference drugs, extracts with ≤250µg/mL were considered as active for this 
study. We selected a panel of hospital derived bacterial species including Gram-positive, 
Gram-negative bacteria, fungi and multi-drug-resistant strains. Several extracts showed no 
activity against Gram-negative bacteria than those found for Gram-positive, fungi and M. 
smegmatis. The poor results obtained for Gram-negative bacteria can be justified by their 
Figure 3.8: Received material tagged as Forsythia suspensa 
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hydrophobic outer membrane that creates a permeability barrier for different antibiotics mainly 
hydrophilic compounds (Baptista, Bhowmick, et al. 2018).  
The bioactivity screens suggested further variation in the levels of active compounds. Thus, we 
were donated A. annua from two different Chinese groups (Figure 3.9). DNA barcoding 
confirmed that both are Artemisia species, but on testing antimicrobial activity, we discovered 
that plant 2 in Figure 3.4, was completely inactive. We concluded that the difference in the 
activity could be because of the constituents of the material. As from the Figure 3.9, we can 
see that plant 1 contains more of leaves and aerial part of the plant while plant 2 have more of 
twigs and old leaves. There is a long history of use of the aerial parts and leaves of A. annua 
for medicinal purposes in certain Asian countries (Fallis, 2013) but our data suggested this 
could have a lower content of anti-mycobacterial compounds.  
Other positive anti-microbial activities were also observed. Fritillaria chirriosa is known to 
hydrate lungs and treat phlegm. Fritillaria bulbs are frequently used in a blend formulation for 
acute bronchitis and tuberculosis, such as San She Dan Chuan Bei Mu Ye and Chuan Bei Pi 
Pa Lu. Beyond such traditional uses pharmacological studies stated anti-inflammatory, 
Figure 3.9: Two different types of Artemisia annua. 
1: From China Academy of Chinese Medical Sciences, Beijing, 2: From local TCM shops from China 
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antitumor, antitussive and antibacterial activity (D. D. Wang et al. 2014). Our results confirmed 
such activities and showed an MIC of 250 µg/mL of the n-hexane extract against M. smegmatis, 
suggesting that our approach was appropriate.  
Oldenlandia diffusa is used in a TCM to treat hepatitis, tonsillitis, sore throat, appendicitis, 
urethral infection and malignant tumours of the liver, lung and stomach. The herbs have been 
reputed to have antitumor, immunomodulatory, anti-mutagenic, anti-inflammatory, 
hepatoprotective, anti-oxidative and neuroprotective properties (Liang et al. 2008). Our studies 
provided a new description of antimicrobial activity in the herb (Table III). 
Coptis chinensis a used the treatment of diarrhea, fever and eczema. Phytochemical studies 
indicate antibacterial, antiviral, anti-inflammatory and antitumor activities. In this case, activity 
seem to be based on berberine which has a reported MIC in the range of 32 to 128 µg/mL 
against MRSA (Zuo et al. 2012). Our results show a MIC of 250 µg/mL of the n-hexane extract 
showed against M. smegmatis, DCM extract against S. aureus and methanol extract against C. 
albicans respectively and a MIC of 125 µg/mL against MRSA.  
Menispermum dauricum rhizome are well known traditional medicine in China used to treat 
sore throat, jaundice, lung-heat cough, dysentery, detoxify and rheumatism. Phytochemical 
studies have reported its anticancer properties (Zhou et al. 2019) and antimicrobial properties 
(Kang et al. 2013). Our results show a MIC of 250 µg/mL of n-hexane extract against M. 
smegmatis, S. aureus, MRSA and the DCM extract against MRSA and M. smegmatis. 
The literature has reported antimicrobial activity of different extracts of Ganoderma lucidum. 
This species is one of the most famous traditional medicinal mushrooms, being used as 
functional food and in traditional medicines (Heleno et al. 2013). Our work indicated activities 
similar to those previously reported with an MIC of 250 µg/mL against S. aureus, which was 
considered to be quite poor activity. 
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Dryopteris crassirhizoma is commonly used as an anti-viral in TCM. It also has anticancer, 
antioxidant, antibacterial, anti-inflammatory, antimalarial and antitumor activities (Na et al. 
2003). Our data shows that the n-hexane extract active against S. aureus (MIC of 6.25 µg/mL) 
and against MRSA (MIC of 6.25 µg/mL), DCM extract against S. aureus (MIC of 25 µg/mL) 
and against MRSA (MIC of 50 µg/mL). The plant has been previously reported to active 
against different MRSA isolates (Kwon et al. 2007).  
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3.4. CONCLUSION 
The quality, precise identification and reliability in the plant species from where the natural 
product is obtained is very critical step for successful innovative drug discovery. The complex 
chemical composition of plants or TCM material and variation in source can lead to batch-to-
batch inconsistency. Genomic techniques such as DNA barcoding are established techniques 
that rely on sequence diversity in short, standard rbcL regions (400–800 bp) and internal 
transcribed spacer for species-level identification.(Ganie, Upadhyay, Das, & Prasad Sharma, 
2015) Thus, we have attempted to incorporate some quality assessments based on DNA 
barcoding and assessments of more than one batch as variation could be importance as 
bioactivities are likely not be uniformly present in every batch.  
Based on these studies, it is possible to suggest that TCM could yield new medicines against 
infectious diseases. The authentication and promising activity of some of the plant extracts will 
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Abstract 
 
The development of anti-parasitic artemisinin from Artemisia annua L. is an example of how 
traditional Chinese medicine (TCM) may be exploited to meet a recognized need. We 
systemically investigated A. annua for its antimicrobial activity, which has not previously 
reported. In this study, we assessed A. annua as a source of bioactive natural products for anti-
mycobacterial activity.  
Anti-mycobacterial activity-guided purification of the A. annua leaf on a silica gel column and 
structure elucidation using UHPLC-HRMS and NMR resulted in the identification of active 
compounds. Crude extracts, isolated compounds and artemisinin were assessed against 
Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, methicillin-resistant 
Staphylococcus aureus (MRSA), Mycolicibacterium smegmatis strains by serial micro dilution 
method (31.25-1000 µg/mL). Anthelmintic activity of isolated compounds and artemisinin 
against Schistosoma mansoni was analyzed by the Roboworm anthelmintic discovery platform. 
The isolated compounds were tested for synergistic effects against Mycobacterium. We also 
used a molecular docking approach to investigate the interactions between selected anti-
mycobacterial compounds and proteins involved in vital physiological functions in M. 
tuberculosis, namely MtPks13, MtPknB, MtPanK, MtKasA, MtInhA and MtDprE1. 
Identity of A. annua was confirmed by rbcL DNA barcoding, bioactive compounds were 
purified and identified as deoxyartemisinin and artemisinic acid. Artemisinic acid (MIC 250 
µg/mL) was more effective in comparison to deoxyartemisinin (MIC 500 µg/mL) and 
artemisinin (MIC 1000 µg/mL) against M. smegmatis. Deoxyartemisinin and artemisinic acid 
did not exhibit any anthelmintic activity against S. mansoni. The docking score for ligands 
towards each protein was calculated to estimate the binding free energy, with the best docking 
score (lowest energy value) evaluation and MtKasA was suggested as a target for artemisinic 
acid. 
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4.1. INTRODUCTION 
China is considered as one of the most botanically bio-diverse countries in the world. Out of 
such biodiversity, over 7000 plant species have medicinal uses and are utilised in Traditional 
Chinese Medicine (TCM). TCM represents an important corpus of “folk-medicine” than could 
be seen as the product of centuries of clinical practice approaches used by doctors (Kuhn & 
Wang, 2008; Xutian, 2012). Recently, modern research ways have been used to detect the 
molecules, define their mode of action and pharmacokinetic and pharmacodynamics properties. 
As a result, TCM is benefitting from new knowledge in the use of plant species as well as in 
the most effective applications of identified products following clinical and toxicity trials 
(Sucher, 2013).  
Artemisia annua L. is native to temperate Asia and is commonly called sweet wormwood. It 
belongs to the family of Asteraceae and the genus Artemisia has over 400 species (Figure 4.1). 
It is a well-established TCM exemplar, referred locally as qinghao, meaning green herb, and is 
commonly used to treat fever (Figure 4.2) (Youyou Tu, 2011). The plant is known to have anti-
malarial (J.-B. Jiang et al., 1982; Kuhn & Wang, 2008), anti-inflammatory, anti-tumour and 
allelopathic activities (Ho, Peh, Chan, & Wong, 2014b).   
Figure 4.1: Artemisia annua (left); Dried Artemisia annua (right). 
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The most potent anti-malarial natural product from A. annua is artemisinin; a sequiterpene 
trioxane lactone (Van Agtmael, Eggelte, & Van Boxtel, 1999) that recently was the subject of 
the 2015 Nobel Prize in medicine. Artemisinin and its semi-synthetic derivatives artesunate, 
artemether and arteether are now front line anti-malarial drugs (Ho et al., 2014b). Common 
features of all of these drugs are an endoperoxide bridge and conversion into the active 
metabolite, dihydroartemisinin in the human body (Ho et al., 2014b). The anti-malarial 
mechanisms of all of these artemisinin drugs remains to be firmly established but is accepted 
to be dependent on free-radical generation linked to the breaking of the distinctive 
endoperoxide bridge by a haem-mediated reaction (Jefford et al., 1996; Meshnick, Thomas, 
Ranz, Xu, & Pan, 1991). Within malaria causing Plasmodium species, the killing mechanisms 
may include haem and protein alkylation as well as disruption of a sarcoplasmic, endoplasmic 
reticulum PfATPase6 calcium pump (SERCA) (Ding, Beck, & Raso, 2011).  
 
Figure 4.2: Image credit: South China Morning Post. 
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Beyond Plasmodium, artemisinin (and its semi-synthetic derivatives) exhibits activity against 
other protozoan parasites including Trypanosoma (Mishina, Krishna, Haynes, & Meade, 2007) 
and Toxoplasma (Chen et al., 2007; Ou-Yang, Krug, Marr, & Berens, 1990) as well as 
metazoan parasites including blood fluke species of Schistosoma (Xiao, You, Yang, & Wang, 
1995). Where the mechanism of action has been defined, this is linked to oxidative events. For 
example, in Schistosoma mansoni, artemisinins have been linked to increase lipid peroxidation 
and reduced glutathione levels (El-Bassiouni et al., 2007; Zhai, Jiao, Mei, & Xiao, 2002). 
Increased oxidative effects have also been linked to artemisinin’s anti-viral activity (Efferth et 
al., 2008), anti-fungal activity and anti-cancer activity (Kaptein et al., 2006).  
Interestingly, the activity of artemisinin against bacteria remains poorly defined. In a mouse 
model, artesunate was shown to synergise with ampicillin to reduced sepsis linked to infection 
with Escherichia coli (Jun Wang et al., 2006). However, rather than any direct antimicrobial 
effects, the observed improved mortality rates appeared to be linked to reducing inflammatory 
effects (Shi, Li, Yang, & Hou, 2015; Jun Wang et al., 2006). Similarly, synergistic 
improvements are observed with artemisinins administered with other antibiotics to treat 
Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) infection in association 
with reduced inflammation (Jiang et al., 2011; Li et al., 2015). Furthermore, while artemisinin 
itself has minimal anti-tuberculosis activity, when attached to a Mycobacterium tuberculosis 
siderophore shows significant potency (Miller et al., 2011; Ratledge, 2004). Siderophores are 
bacterial metal chelators that play an important role in iron assimilation and virulence. 
Siderophore conjugation is likely to improve the anti-tubucular activity of artemisinin by 
increasing the availability of iron for endoperoxide bridge linked oxidative events and / or 
easing bacterial penetration by the drug (Miller et al., 2011) (Figure 4.3). Given the wide-
ranging activities of artemisinins (Ho et al., 2014b) and anti-mycobacterial properties of 
conjugated artemisinin, we sought to identify artemisinin-like molecules from A. annua that, 
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by themselves, contain potent anti-microbial activity. Thus, we isolated a small library of 
compounds with anti-mycobacterial action from Artemisia annua. These were identified as 
deoxyartemisinin and artemisinic acid which, whilst showing some structural similarity to 
artemisinin, lacked the endoperoxide bridge.  
  
Figure 4.3: Mycobacterium tuberculosis siderophore activity. 
H37Rv was treated with rifampicin (0.1 μg mL-1 and 1 μg mL-1) or mycobactin-artemisinin 
conjugate 3 (0.5 μg mL-1 and 5 μg mL-1) at 1 and 10 MIC. Following 3 h incubation, reactive 
oxygen species were measured with HPF (Miller et al., 2011). 
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4.2. METHODS 
Extraction and Isolation 
Dried leaf material (200 g) of Artemisia annua supplied from Chinese sources was extracted 
sequentially using n-hexane, dichloromethane, ethyl acetate and methanol (2Í3L) at room 
temperature with continuous stirring for 24 hours in each case. The fractions were dried and 
resuspended in 50 % aqueous methanol. These crude extracts were screened for antimicrobial 
activities and the MIC for each was determined.  
 
Purification 
The n-hexane extract (18.49 g) fractionated on a silica gel CC (4Í50 cm, 150 g of SiO2), eluted 
with n-hexane-EtOAc (1:0 to 0:1, at 5 % gradient, 300 ml of each eluent), and EtOAc- MeOH 
(1:0 to 8:1, 300 mL of each eluent) to yield 14 fractions (designated H for “n-hexane” and A 
through to N; thus HA through to HN). Fraction HF (2.86 g) was again subjected to silica CC 
(1.5Í50 cm, 60 g of SiO2) eluting with n-hexane-EtOAc (1:0 to 0:1, 5% gradient, 300 mL of 
each eluent) and EtOAc-MeOH (1:0 to 8:1, 300 mL of each eluent) to yield 6 crude fractions 
(A through F; thus HFA-HFF). The HFE fraction (824.7 mg) was then run again fractionated 
using reversed-phase flash chromatography, eluted with a methanol/water gradient resulting in 
7 fractions (HFE1 through HFE7). HFE3 was then subjected to further fractionation in a Semi-
preparative HPLC, to yielding 8 fractions (HFE3a through HFE3h). Fraction HFE3e was pure 
compounds compound 1 (6 mg) and HFE3f was compound 2 (4.5 mg) at > 95% purity. 
 
Synergy assay 
The compounds were further screened for their synergistic effect on each other. Compounds 
were dissolved in MeOH and diluted to a sub inhibitory concentration. The compounds were 
serially diluted for the MIC determination in triplicate. The fractional inhibitory concentration 
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index (FICI) expressed the effect of the combination of antibacterial agents (Eliopoulos et al., 
1996):  
FICI = FIC (A) + FIC (B) 
FIC (A) = MIC (A in presence of B)/MIC (A alone) 
FIC (B) = MIC (B in presence of A)/MIC (B alone) 
FICI≤ 0.5, Synergism; FICI> 4.0, Antagonism; FICI >0.5 to 4.0 no interaction. 
 
Anti-Schistosoma assay 
The anthelmintic activities of compounds were assessed against the schistosomula lifecycle 
stage of Schistosoma mansoni as previously described (Nur-E-Alam et al. 2017). Briefly, all 
compounds were solubilized in DMSO (Fisher Scientific, 10122140) and screened in 
concentrating range from 0.625 to 10 µM against ~120 schistosomula per well, within a 384 
well plate (Perkin Elmer, 6007460) in triplicate. Schistosomula were cultured in 80 µL of 
Basch media (Basch 1981) containing a final DMSO concentration of 0.625 %. To assess the 
effect of each compound on schistosomula following 72 hours of culture (37 °C, 5 % CO2, 
humidified environment), the motility and phenotype of schistosomula was assessed based on 
the image analysis model reported previously (Paveley et al. 2012). All results were tested for 
significance using one-way ANOVA with a Dunn’s post-test to measure significant differences 
(P <0.05) between DMSO control wells and individual treatments.  
 
In silico studies 
All chemical structures were retrieved from the PubChem compound database (NCBI) 
(http://www.pubchem.ncbi.nlm.nih.gov). The crystal structures and control ligand inhibitors 
(Table V) of MtDprE1 (PDB ID: 6HEZ), MtInhA (PDB ID: 1ENY), MtKasA (PDB ID: 
2WGE), MtPanK type 1 (PDB ID: 4BFT), MtPknB (PDB ID: 2FUM) and MtPks13 (PDB ID: 
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5V3X) were retrieved from the RCSB Protein Data Bank (PDB) database 
(https://www.rcsb.org).  
In silico prediction of physico-chemical and structural properties of the compounds was 
performed using PaDEL-Descriptor (Yap 2011) including the descriptors: nHBAcc_Lipinski 
(acceptor H-bonds), nHBDon_Lipinski (donor H-bonds), nRotB (number of rotation bonds), 
TopoPSA (topological polar surface area), MW (molecular weight) and XLogP (prediction of 
logP based on the atom-type method).  
An extended PDB format, termed a PDBQT file, was used for coordinate files, which includes 
atomic partial charges (Umamaheswari et al. 2012). All file conversions were performed using 
the open source chemical toolbox Open Babel 2.3.2 (O’Boyle et al. 2011). The ligand and 
protein structures were optimised using AutoDock Tools software (AutoDock 1.5.6) which 
involved adding all hydrogen atoms to the macromolecule, which is a step necessary for correct 
calculation of partial atomic charges. Gasteiger charges are calculated for each atom of the 
macromolecule in AutoDock 1.5.6 (Umamaheswari et al. 2012). 
All the compounds were docked against target proteins along with the controls. Molecular 
docking calculations for all compounds with each of the proteins were performed using 
AutoDock Vina 1.1.2. Docking calculation was generated with the software free energy 
binding own scoring function. The binding affinity of the ligand was observed as a negative 
score with units expressed as kcal.mol-1. Nine different poses were calculated for each protein 
with the parameters num_modes = 9 and exhaustiveness = 16. The lowest energy conformation 
was chosen for binding model analysis. Molecular interactions between ligand and protein were 
generated and analysed by LigPlot+ and depicted by PyMOL. PyMOL Molecular Graphics 
System, Version 2.0 Schrödinger (http://www.pymol.org) was used to prepare figures (Ali et 
al. 2018). To provide enough space for free movements of the ligands, the grid box was 
constructed to cover the active sites and was defined using AutoDock 1.5.6. 
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All the compounds were docked against known anti-Mycobacterium targets, MtDprE1, 
MtInhA, MtKasA, MtPanK, MtPknB,and MtPks13 along with their respective control 
inhibitors for each drug target. 
To validate the accuracy of the docking and to allow a comparison between docking scores, all 
co-crystallised inhibitory ligands were re-docked into the corresponding protein structures. The 
grid points for MtDprE1, the grid points were set to 20 × 20 × 20, at a grid center of (x,y,z) 
14.99, -20.507, 37.226 with spacing of 1 Å. For MtInhA, the grid points were set to 26 × 24 × 
22, at a grid center of (x,y,z) -5.111, 33.222, 13.410 with spacing of 1 Å. For MtKasA, the grid 
points were set to 20 × 20 × 20, at a grid center of (x,y,z) 38.342, -7.033, 13.410 with spacing 
of 1 Å. For MtPanK, the grid points were set to 20 × 20 × 20, at a grid center of (x,y,z) -18.742, 
13.919, 11.679 with spacing of 1 Å. For MtPknB, the grid points were set to 21 × 20 × 20, at a 
grid center of (x,y,z) 61.518, 2.429, -25.588 with spacing of 1 Å. For MtPks13 the grid points 
were set to 16 × 18 × 14, at a grid center of (x,y,z) 3.954, 27.324, 8.499 with spacing of 1 Å. 
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4.3. RESULTS 
Wide-ranging anti-microbial activity was observed in the hexane extract against 
Mycobacterium smegmatis albeit at high MICs (Figure 4.4). M. smegmatis is a well-established 
model species for M. tuberculosis, and given the known activity of the artemisinin-siderophore 
conjugate (Miller et al., 2011; Ratledge, 2004). Bioactivity-linked fractionations of the hexane 
extract were based on the ability to suppress the growth of M. smegmatis. 
The n-hexane fraction was assayed against M. smegmatis and HF displayed the highest anti-
mycobacterial activity (Figure 4.4). HF was further purified and screened suggesting that 
fraction HFE had the highest activity (Figure 4.4). Fractions HFE3 (92.68 mg) and HFE7 
(30.55 mg) had the highest anti-mycobacterial activity (Figure 4.4). Fraction HFE3 and HFE7 
were run through UHPLC-MS and processed with Xcalibur (Figure 4.5), to detect their 
differences of mass ion spectra. However, fraction HFE7 was not further studied as there was 
many peaks in the ion spectra and very low quantities. 
 
Figure 4.4: Bio-assay guided purification of A. annua based on MIC against M. smegmatis. 





Figure 4.5: Total ion count (TIC) chromatograms of. HFE3(red) and HFE7(black) obtained by UHPLC-MS. 
 A: Positive Ionisation B: Negative ionisation 
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HFE3 was then further fractionated and the fractions were again run through UHPLC-MS 
(Figure 4.6 and Figure 4.7) to determine the ion mass and semi-preparative HPLC confirming 
RT: 0.00 - 22.04
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Figure 4.6: Total ion count (TIC) chromatograms of HFE3e.  
A: Positive Ionisation B: Negative ionisation 
RT: 0.00 - 22.03
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Figure 4.7: Total ion count (TIC) chromatograms of HFE3f. 
A: Positive Ionisation B: Negative ionisation 
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the purity. The identities of the purified compounds 1 and 2 were determined by NMR yielding 
the following data:  
1: 1H-NMR (500MHz, CDCl3) δ 0.93 (3H, s, H-14), 0.99 (2H, m, H-8), 1.11 (1H, m, H-9), 
1.19 (3H, d, J=7.2 Hz, H-13), 1.23 (1H, m, H-2), 1.25 (1H, m, H-10), 1.27 (3H, m, H-1), 1.51 
(3H, s, H-15), 1.61 (1H, m, H-3), 1.79 (2H, m, H-3’ and H-9’), 1.90 (2H, m, H-2’ and H-8’), 
1.99 (1H, m, H-7), 3.17 (1H, m, H-11), 5.69 (1H, s, H-5) ppm; 13C-NMR (100 MHz, CDCl3) 
δ 12.74 (C-13), 18.69 (C-14), 22.20 (C-2), 23.68 (C-8), 24.09 (C-15), 32.92 (C-11), 33.66 (C-
9), 34.17 (C-3), 35.53 (C-10), 42.64 (C-7), 44.85 (C-1), 82.58 (C-6), 99.80 (C-5), 109.32 (C-
4), 171.88 (C-12) ppm. 
2: 1H-NMR (500 MHz, MeOD) δ 0.92 (3H, d, J = 6.3 Hz, H-14), 1.07 (1H, m, H-9), 1.30-1.45 
(2H, m, H-3), 1.40 (3H, m, H-1 and H-8), 1.55 (1H, m, H-10), 1.59 (3H, s, H-15), 1.70-1.83 
(2H, m, H-2), 1.90 (1H, m, H-9’), 1.98 (1H, m, H-6), 2.68 (2H, m, H-7), 5.02 (1H, s, H-5), 
5.45 (1H, s, H-13), 6.29 (1H, s, H-13’) ppm; 13C-NMR (100 MHz, MeOD) δ 20.2 (C-14), 23.8 
(C-15), 26.7 (C-2), 27.1 (C-8), 27.3 (C-3), 28.9 (C-10), 36.5 (C-9), 39.4 (C-6), 43.1 (C-1), 43.7 
(C-7), 121.5 (C-5), 124.6 (C-13), 135.9 (C-4), 145.3 (C-11), 170.7 (C-12) ppm. 
These results indicated that compound 1 was deoxyartemisinin and compound 2 was 
artemisinic acid. These are known compounds allowing their identification to be confirmed 
from NMR data in the literature (Bhandari, Gupta, Singh, & Kaul, 2005; Misra, Ahmad, 
Thakur, Lotter, & Wagner, 1993; Srivastava et al., 2009) and by comparison with commercially 
obtained standards. In both cases, anti-mycobacterial activity has not been demonstrated for 
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these natural products. Crucially, both display an artemisinin-like structure but neither 
possesses the key endoperoxide bridge, which is distinctive for artemisinins. (Figure 4.8) 
 
The antimicrobial properties of the compounds 1 and 2 were assessed against our full panel of 
bacterial strains (Table IV).  
Table IV: Antibacterial activity (MIC µg mL-1) of compounds.  
Deoxyartemisinin), artemisinic acid and artemisinin against Gram-positive and Gram-negative bacteria 
Organisms Deoxy-artemisinin Artemisinic acid Artemisinin Rifampicin Gentamycin Sulphate 
E. coli 500 ≥1000 ≥1000 ND 1.6 
P.aeruginosa 500 ≥1000 ≥1000 ND 3.13 
S. aureus 500 250 ≥1000 ND 3.13 
M. smegmatis 500 500 ≥1000 1.14 ND 
M. smegmatis 
mc2155 
500 250 500 1.41 ND 
MRSA 500 250 ≥1000 ND 3.13 
Figure 4.8: The chemical structures of the bioactive natural products isolated from A. annua. 
 B: Deoxyartemisinin, C: Artemisinic acid. A: Artemisinin was used as control to compare the 
structure and bioactivity 
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In isolation, each compound showed some activity against M. smegmatis, although less than 
exhibited by the parental extract (HFE3). Compounds 1 and 2 exhibited some antimicrobial 
activities, which were significantly better than that shown by artemisinin. We searched for 
artemisinin in each of fractions based on accurate mass compared to commercially sourced 
standards, but this was never detected.  
The discrepancies between the MICs obtained for the parental fraction (HFE3) against those 
obtained for the purified compounds could reflect a synergistic action between the two 
compounds. This was assessed using the checkerboard assay where the two compounds were 
combined in an anti-mycobacterial screen. We found a synergy effect between the two 
compounds with FICI=0.5. This demonstrated that the compounds are synergistic and in 
combination, the MIC for compounds 1 and 2 was reduced by a factor of 4 to 125 µg/mL. 
Deoxyartemisinin has been demonstrated to have dramatically reduced anti-malarial activity 
compared to artemisinin, suggesting that the killing mechanism was dependent on peroxidative 
activity (Kaiser et al., 2007). In the case of S. mansoni, artemisinin, artemisone, 
dihydroartemisinin and artemether have been shown to be particularly effective, again through 
the peroxidative activity (Gold et al., 2017). We re-assessed the anti-parasitic properties of 
deoxyartemisinin and also that of artemisinic acid, which has not been previously assessed. 
Using the Roboworm platform (Figure 4. 9) (Nur-E-Alam et al., 2017), the impact on the 
phenotype and motility of S. mansoni was measured against those of the front-line anti-
Schistosoma drug Praziquantel (PZQ) as well as the thioredoxin glutathione reductase (TGR) 
inhibitor Auranofin (AUR); both of which do not act through peroxidative events (Danso-
Appiah, Olliaro, Donegan, Sinclair, & Utzinger, 2013; Kuntz et al., 2007). Using the 
Roboworm platform, anthelminthic activity of deoxyartemisinin (C1) and arteminisic acid (C2) 
were compared to those of Auranofin (AUR, 10 µM), Praziquantel (PZQ, 10µM) and the 
negative control dimethylsulphoxide (DMSO). (A) Images of schistosomula at 72 h following 
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treatments. Schistosomula treated with AUR and PZQ exhibited obvious phenotypic changes 
compared to DMSO. Treatments (two-fold dilutions; 10 µM-0.625 µM) with C1 and C2 
showed no obvious effect. Viability for (B) C1 and (C) C2 treatments as well as assessments 
of motility for (D) C1 and (E) C2 were quantified. All results were tested for significance using 
one-way ANOVA with a Dunn’s post-test. Results falling within the “hit zone” were 
significantly (P <0.05) from negative DMSO treated controls. In no case were significant 
effects for C1 and C2 observed. Here, neither deoxyartemisinin or artemisinic acid negatively 
impacted parasite phenotype nor motility when compared to PZQ or AUR.  
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In an attempt to provide further insight into these natural products, their ability to dock to 
known anti-Mycobacterium targets were assessed. Thus, artemisinin, deoxyartemisinin and 
arteminisic acid were organized in phytochemical groups and their individual binding energies 
Figure 4. 9: Screening of bioactives isolated for anthelminthic activity against Schistosoma 
mansoni schistosomula.  
C1: Deoxyartemisinin, C2: artemisinic acid, AUR: Auranofin; PZQ: Praziquantel 
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were analysed by docking against MtDprE1, MtInhA, MtKasA, MtPanK, MtPknB and 
MtPks13 and compared with their respective control. AutoDock Vina was used to predict 
binding affinities. Known molecules, that had been reported previously in the literature as 
inhibitors of the target enzymes and for which the nature and role of the binding site residues 
were known from their available complexes with the proteins, were used as controls. 
Individual binding energy of artemisinin, artemisinic acid and deoxyartemisinin was analysed 
by docking against MtDprE1, MtInhA, MtKasA, MtPanK, MtPknB and MtPks13, and 
compared with the respective control inhibitor, retrieved from Protein Data Bank (PDB). 
AutoDock Vina was used to predict binding affinities (Table V). 
 
Table V: Binding energies (kcal.mol-1) of compounds and their respective controls 
Targets Artemisininc acid Artemisinin Deoxy-
Artemisinin 
Respective controls 




MtPknB -6.7 -8.4 -8 Mitoxantrone: -7.7 





MtKasA -8.3 -6.4 -6.9 Thiolactomycin: -6.57 
MtInhA -8 -8.9 -8.5 Isoniazid: -10.4 
MtDprE1 -7.2 -8.3 -8.3 Bedaquiline: -10.1 
 
 
Artemisinic acid shows lower binding energy against MtKasA in comparison to artemisinin 
and deoxyartemisinin and also the respective control thiolactomycin (Table V). To further 
investigate the key properties necessary for an optimal binding, the chemical space spanned by 
the compounds was studied for all the compounds. The physiochemical properties were studied 
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using PaDel-Descriptor including: molecular weight (MW), partition coefficient (xLogP), 
rotatable bonds (nRotB), H-bond donors (nHBDon_Lipinski), H-bond acceptors 
(nHBAcc_Lipinski) and topological polar surface area (TopoPSA) (Table VI). 
 
73 | P a g e  


























MW AMW XLogP 
Artemisinic 
acid 
2 2 2 2 1 1 2 
0.1111
11 
5 0.277778 0 37.3 234.162 6.004153 4.592 
Artemisinin 5 5 5 5 0 0 0 0 3 0.130435 0 53.99 282.1467 6.717779 3.039 
Deoxyartemisin
in 
4 4 4 4 0 0 0 0 3 0.136364 0 44.76 266.1518 6.491508 2.913 
Thiolactomycin 2 2 2 2 1 1 2 
0.1428
57 
6 0.428571 0 62.6 210.0715 7.502552 2.458 
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Figure 4. 11: Superposition of the best docking positions of deoxyartemisinin (Red), 
artemisinin(green), artemisinic acid (orange), Thiolactomycin (Blue) against KasA 
Figure 4. 10: Molecular interactions of the best docking position. 
 Thiolactomycin (blue: top left), artemisinic acid (Orange: top right) artemisinin (green: 
down left) and deoxyartemisinin (down right) against MtKasA. Hydrogen bonds are 
evidenced with magenta dashed lines. 
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After analysing the binding energies and physiochemical properties, a structural study was 
carried out based on their binding energy by docking the compounds onto MtKasA and their 
interaction were further investigated (Figure 4. 10, Figure 4. 11 and Figure 4.12). 
A closer look at the interactions between artemisinic acid and MtKasA reveals that the C-12 
carboxylic acid end of the molecule have a strong hydrogen bond with nitrogen (contact 
distance 3.0 Å) and oxygen (contact distance 2.77 Å) of Gly403 and oxygen (contact distance 
3.25 Å) Asn 408. While the 4,7-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl group 
binds to the hydrophobic pocket of Pro280, Phe 402 and His311. The active site, and amino 
acid are in close similarity to what has been previously described as the mode of binding of the 
TLM control (Luckner, Machutta, Tonge, & Kisker, 2009a). 
  
Figure 4.12: Ligplot illustration of Artemisinic acid and thiolactomycin with MtKasA.  
H-bonds in green dash. Carbons are in black, nitrogens in blue and oxygens in red. Red spheres 
are hydrophobic interactions 
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4.4. DISCUSSION 
Artemisinin is a sesquiterpene lactone that is representative of a diverse range of natural 
products that can be found in the Asteraceae family. Artemisinin has a low aqueous solubility 
of 63 mg/L at pH 7.2, a Log P of 2.94 (Haynes et al., 2006), and short half-life. The mean oral 
clearance was 417 L/h, and the terminal elimination half-life was 1.93 h (Birgersson et al., 
2016). The molecule releases reactive oxygen species when in contact with high iron 
concentrations (Gharib, Faezizadeh, Mesbah-Namin, & Saravani, 2014). To overcome these 
limits, several semi-synthetic and synthetic derivatives of artemisinin are currently being 
developed or are actively being used to treat malaria, primarily as part of drug combination 
therapies (Borstnik, Paik, Shapiro, & Posner, 2002; Nosten & Brasseur, 2002). The World 
Health Organization is now urging the adoption of ACT (Artemisinin Combination Therapy) 
in which artemisinin is combined with another drug like mefloquine, to reduce the development 
of artemisinin resistance against the malaria parasite, Plasmodium falciparum (Gu, Li, 
Melendez, & Weina, 2008; Krishna, Woodrow, Staines, Haynes, & Mercereau-Puijalon, 2006).  
While the precise mechanism of anti-malarial action by artemisinin remains unclear and 
controversial, the importance of an artemisinic endoperoxide bridge is irrefutable (Jefford et 
al., 1996; S. R. Meshnick et al., 2003; Steven  Meshnick, 2002; Olliaro, 2001; Posner et al., 
2001). Much evidence points to Fe (II)-catalyzed reductive cleavage of the endoperoxide 
bridge within the parasite, leading to an unstable carbon-centered radical capable of forming 
protein adducts (Steven Meshnick, 2002). An alternative mechanism suggests that heterolytic 
opening of the endoperoxide moiety of artemisinin yields a hydroperoxide, leading to a reactive 
carbonium ion intermediate as well as the formation of hydroxyl radicals (Krishna et al., 2006). 
This pathway would also promote alkylation of protein nucleophiles by structurally different 
intermediates based on carbon-centered free radical derivatives (Olliaro, 2001).  
77 | P a g e  
Along with malaria, TB is one of the most challenging global public health threats confronting 
humanity with nearly 1 million people currently suffering from infection with the causative 
agent, M. tuberculosis. The development and spread of multidrug resistant (MDR) and 
extensively drug resistant (XDR) strains of M. tuberculosis have stimulated global research 
efforts (Dorman & Chaisson, 2007). As a consequence, the pipeline of potential new drugs has 
expanded (Stover et al., 2000). In this context, the possible anti-mycobacterial activities of 
artemisinins are relevant but their wide-spread use as TB drugs would potentially accelerate 
the selection of drug-resistant P. falciparum strains due to the overlapping ranges of both 
infectious organisms. The antibacterial and antifungal activities of different Artemisia species 
have been reported (Ivanescu, Miron, & Corciova, 2015) but our research strategy here was to 
assess if Artemisia could contain novel antimicrobials. 
In a systematic assessment of extracts from dried Artemisia annua, only the crude hexane 
extract of the plant showed activity against gram positive bacterial species (Figure 4.4). 
Following activity-based purification, two main components (compound 1 - deoxyartemisinin; 
compound 2 - artemisinic acid) in this fraction of the extract were isolated, purified and 
identified (Figure 4.8). Neither proved to be artemisinin but both were artemisinin-like 
molecules. We note that under certain conditions artemisinins are liable for example in water 
they can to react with the ferrous ion and haem-Fe(II) or in solvents such as dimethyl sulfoxide 
(DMSO) and degrade very quickly (Haynes et al., 2007) Therefore, we were concerned that 
we were observing break down products from other artemisinin. However, our extraction 
conditions using hexane have been not linked to the decomposition of arteminsins. Further, our 
chemical standards proved to be stable under our chromatographic and biological assay 
conditions. Therefore, we suggest that the isolated arteminsins represent bone fide natural 
arteminsins from Artemisia annua.  
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The deoxyartemisinin that was isolated from A. annua L has an ether bridge instead of an 
endoperoxide bridge and is inactive against malarial parasites (Klayman, 1985). Previous 
antimicrobial studies on S. aureus with deoxyartemisinin and artemisinin showed a MIC of 1 
and 2 mg/ml, respectively (Srivastava et al., 2009). There have been no such anti-mycobacterial 
studies on deoxyartemisinin as it is often used as a negative control in experiment where 
artemisinins are assessed for anti-malarial activity. Artemisinic acid was also isolated from A. 
annua L, and the absolute configuration of the structure was deduced previously (Pang et al., 
1997). Artemisinic acid has been reported to be a less efficient antimalarial than artemisinin 
(Ji, Sun, Wang, Yang, & Tu, 2008), although some antibacterial activity on gram positive 
bacteria (Bhakuni, Jain, Sharma, & Kumar, 2001) but no antifungal activity (Galal, Ross, 
Jacob, & ElSohly, 2005) has been reported. However, the activity of A. annua against 
Mycobacterium has not been previously studied. Both deoxyartemisinin and artemisinic acid 
exhibited a minimum inhibitory concentration of 0.5 mg mL-1. We noted that these MICs were 
higher than those reported for these compounds against other bacterial species (Srivastava et 
al., 2009). This was case, even though the bacterial species that we used are well-established 
models for anti-microbial studies. Such results could reflect the strains that we used and/or our 
culture conditions. However, crucially, this MIC fell four-fold in assessments for synergistic 
effects. Given the common use of artemisinin and its derivatives as combination therapies for 
anti-malarial treatments, a similar strategy is suggested from this observation.  
One important observation was that the anti-mycobacterial activity of both Artemisia-derived 
natural products was not dependent on an endoperoxide bridge. Similarly, the activity of both 
molecules could not be linked to an α-methylene-γ-lactone group in natural products from the 
Artemisia genus which has been linked to a range of biological activities including 
antimicrobial (Ivanescu et al., 2015). Our data would therefore suggest a discrete mode of 
action for the Artemisia-isolated natural products reported herein. Given the structural 
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similarity of deoxyartemisinin to artemisinin, this previously unsuspected mode of anti-
mycobacterial action could also be exhibited by the wider artemisinin class of drugs.  
We sought to demonstrate that these two compounds were not active against co-endemic 
parasites, thereby offering the possibility of specific anti-mycobacterial activity. To begin to 
assess this, we noted that in addition to anti-malarial properties artemisinin derivatives also 
have anti-schistosomal properties. For example, artemether (Xiao, Booth, & Tanner, 2000) and 
artesunate (Batty, Ilett, Timothy, & Davis, 1996) have shown prominent anti-schistosomal 
activity. However, neither deoxyartemisinin nor artemisinic acid exhibited any effect on S. 
mansoni viability or mobility. Thus, we have no evidence that the anti-mycobacterial mode of 
action for these natural products is relevant to helminth parasites. Whether these compounds 
are active against P. falciparum is currently unknown. 
Furthermore, we investigated the anti TB potential of the compounds using a guided molecular 
docking approach to find a potential target. We selected some key enzymes required 
for M. tuberculosis to grow and survive within the eukaryotic host, that were involved in 
essential mycobacterial pathways and were absent from mammalian cells. Thus, predicted 
binding affinities of isolated A. annua compounds against seven M. tuberculosis enzymes - 
caseinolytic peptidase P (MtClpP1P2) (Schmitza, Carneyb, Sellob, & Sauera, 2014), 
decaprenylphosphoryl-β-D-ribose 2′-epimerase 1(MtDprE1) (Batt et al., 2012; Richter et al., 
2018), Enoyl-ACP Reductase (MtInhA) (Dessen, Quemard, Blanchard, Jacobs, & Sacchettini, 
1995; Rozwarski, Vilcheze, Sugantino, Bittman, & Sacchettini, 1999), β-ketoacyl acyl carrier 
protein synthase I(MtKasA) (Luckner, Machutta, Tonge, & Kisker, 2009b), pantothenate 
kinase (MtPanK) (Bjorkelid et al., 2013), protein kinase B(MtPknB) (Wehenkel et al., 2006) 
and polyketide synthase (MtPks13) (Aggarwal et al., 2017; Gavalda et al., 2014). Henceforth, 
we performed molecular docking and predicted interactions, using AutoDock Vina (Trott & 
Olson, 2010). Molecular docking is widely used to model interactions at the atomic level 
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between a small molecule (ligand) and a known macromolecule. Several studies have 
successfully used AutoDock Vina to investigate the interactions of natural products against 
specific protein targets, including mycobacterial enzymes (Meng, Zhang, Mezei, & Cui, 2012; 
Sundarrajan, Lulu, & Arumugam, 2015; Yadav et al., 2013).  
The purpose of molecular docking is to use scoring algorithms to estimate the likelihood of the 
compound to bind to the protein ligand. Based on our MIC results and binding energies, it is 
likely that the artemisinic acid displayed a strong predicted binding with the MtKasA enzyme 
in comparison to artemisinin, deoxyartemisinin and its control thiolactomycin. Figure 4. 11 and 
Figure 4. 10 indicates that all the compounds accept artemisinin enter the binding site of 
thiolactomycin and artemisinic acid forms stronger hydrogen bonding in comparison to 
deoxyartemisinin acid and thiolactomycin. The docking studies provided strong evidence that 
the molecular basis for this activity is probably due to KasA inhibition.  
Mycolic acids are unique to mycobacteria and play a crucial role in the architecture of the 
mycobacterial cell envelope. Fatty acid biosynthesis involves two synthases, namely, type I 
fatty acid synthase (FAS-I) and type II fatty acid synthase (FAS-II). KasA, the mycobacterial 
β-ketoacyl ACP synthase I is an essential enzyme in the mycobacterial fatty acid biosynthesis 
(FAS-II) pathway (Figure 4.13) (Kremer et al., 2002) (Lu, Zhang, & Rock, 2004). This enzyme 
Figure 4.13: Fatty acid biosynthesis with antibiotics and its known target points. 
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is hypothesized to be a potential target yet to be explored (Bhatt, Kremer, Dai, Sacchettini, & 
Jacobs, 2005). 
Molecular docking technology is the main method of computer-aided drug design (CADD). 
With the rapid rise in genomics, proteomics, metabolomics, and other omics technologies, as 
well as the mutual integration of various subject areas, this technology can help to explore the 
mechanisms of action for treating diseases and guidance the development of natural products 
to potential drug-leads. However, there are still some common problems in molecular docking 
which impact on its utility as an approach. There are still differences between the virtual data 
obtained by molecular docking and the experimental data in vivo, and it needs to be verified in 
combination with other experimental methods. This will also filter out any spurious interactions 
with non-biological relevance. Validation is also important as the existing evaluation methods 
for molecular docking technology are still immature, and molecules with higher scores may 
not be the best ligands.  Further, its success is dependent on existing protein structures held in 
databases so these need to be constantly updated. It is also the case, that existing molecular 
docking software programs are cumbersome and complex, and they need to be optimized  
(Chen, Seukep, & Guo, 2020). Therefore, this hypothesis needs to more carefully investigated 
and validated in vitro. This could involve cloning and expressing the putative target so that 
interaction can be directly assessed as well as the impact on protein function. This approach 
can be complemented by genomic approaches involving such as transcriptomics and 
metabolomics where the impact of the natural product on the presumed target can be described.  
 
4.5. CONCLUSION 
Our studies have demonstrated that, even in a species which is a well-characterised sources of 
natural products, novel bioactivities can be defined. Our definition of anti-mycobacterial 
activities in natural products from A. annua was particularly relevant to artemisinin research. 
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It indicated endoperoxide bridge-independent activity that was exhibited at least against 
Mycobacterium. A virtual screening of the compounds was performed, which indicated that 
KasA could be a potential target of artemisinic acid and is responsible of its MIC. The 
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Abstract 
 
Dryopteris crassirhizoma Nakai, is a perennial herbaceous fern, is listed in Chinese 
Pharmacopoeia as a treatment of viral diseases. It is also known to have anticancer, antioxidant, 
antibacterial, anti-inflammatory, antimalarial and antitumor activities.  
Work in this chapter aimed to explore different methods to isolate and purify bioactives from 
D. crassirhizoma including a range of screens focused on anti-microbial activities. Part I: 
comprises of bioassays coupled with a successive series of chromatographic separation to 
identify some key chemicals; Part II: Chemometric approaches to profile active and non-active 
fractions and identify bioactive metabolites, after a round of fractionation, using flow infusion 
electrospray – high resolution mass spectrometry (FIE-HRMS). Initially screens identified 
significant activity in D. crassirhizoma extracts against Methicillin resistant Staphylococcus 
aureus (MRSA). The minimum inhibitory concentrations (MIC) of different extract fractions 
ranged from 3-50 µg/mL.  
Bioassay guided of HB sub-fractions resulted in fractions HB5d/e3 and HB5d/e5 with MICs 
of 6.125 and 12.25 µg/mL respectively. The targeted key metabolites were identified and 
confirmed by UHPLC-MS and tandem mass spectroscopy (MS2/MS3) data as norflavaspidic 
acid AB and flavaspidic acid AB. While, chemometric approach on HL sub-fraction the second 
most active and comparison with the literature, three compounds, flavaspidic acid AB, filixic 
acid ABP and dryocrassin ABBA were predicted to have antimicrobial activity against S. 
aureus and MRSA. Further purification using preparative-HPLC and tests are required for full 
structural elucidation and bioctivity. 
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5.1. INTRODUCTION 
Dryopteris crassirhizoma Nakai, a perennial herbaceous fern (Figure 5.1), known as “the king 
of antivirals”, is widely distributed in Korea, China and Japan (Gao et al., 2008). The roots, 
known as “Gwanjung” in Korea; “Guan Zhong” in China and “Oshida” in Japan, are used in 
TCM to treat parasitic infestation, haemorrhage, epidemic flu, cold, and cancer (Committee, 
1999; Encycl. Ref. Tradit. Chinese Med., 2003; C. Lu et al., 2012; Shinozaki, Shibuya, Masuda, 
& Ebizuka, 2008). Powdered and dried rhizomes of various Dryopteris ferns have been used 
as remedies for helminthiasis caused by Diphyllobothrium latum (Murakami & Tanaka, 1988). 
Previously reported phytochemical constituents include triterpene, phloroglucinol, flavonoids 
and other phenolic compounds (Chang, Li, Koike, Wu, & Nikaido, 2006; Min, Tomiyama, Ma, 
Nakamura, & Hattori, 2001; Noro et al., 1973; Shiojima, Arai, & Ageta, 1990).  
Several triterpenes isolated from the dried and fresh leaflets of D. crassirhizoma, with hopane 
or migrated hopane skeletons (25) (Ageta, Shiojima, Arai, Kasama, & Kajii, 1975; Hiroyuki 
Ageta, Iwata, & Natori, 1963; Shiojima, Suzuki, Matsumura, & Ageta, 1994). Dryopteric acids 
A (26) and B (27) were isolated from D. crassirhizoma rhizome and showed potent inhibitory 
Figure 5.1: Dryopteris crassirhizoma Nakai.  
Image credit: Shaanxi Yongyuan Bio-Tech Co.Ltd. 
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activities against HIV-1 protease with IC50 values 26.5 and 44.5 µM respectively (Lee et al., 
2008) (Figure 5.2). 
Flavonoids consist of a large group of polyphenolic compounds having a benzo-γ-pyrone 
structure. They are ubiquitously present in plants and are synthesized through the 
phenylpropanoid pathway (Waterman, 1986) and occur as aglycones, glycosides, and 
methylated derivatives. A range of kaempferol glycosides which are inhibitors of human 
immunodeficiency virus-1 (HIV-1) reverse transcriptase have been isolated from the rhizome 
of D. crassirhizoma. These were designated crassirhizomosides A, B, C and sutchuenoside A 





Figure 5.2: Some known flavonoids isolated from D.crassirhizoma.  
28: Crassirhizomoside A; 29: Crassirhizomoside B; 30: Ccrassirhizomoside C; 31 Sutchuenoside A 
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Phloroglucinol derivatives are a major class of secondary metabolites of wide occurrence in 
the Myrtaceae family as well as in several other families such as Guttiferae, Euphorbiaceae, 
Aspidiaceae, Compositae, Rutaceae, Rosaceae, Clusiaceae, Lauraceae, Crassulaceae, 
Cannabinaceae and Fagaceae. These compounds have also been reported to occur in marine 
and microbial sources. Phloroglucinol is an organic compound used in the synthesis of 
pharmaceuticals and explosives. Phloroglucinol, and its benzenetriol isomers, are also defined 
as "phenols" according to the IUPAC official nomenclature rules of chemical compounds. Such 
chemicals are often termed "polyphenols" by the cosmetic and parapharmaceutical industries, 
but this not a scientifically accepted definition. D. crassirhizoma also contains the acyl 
phloroglucinol derivatives. They exhibit a wide range of bioactivity including antimalarial, 
antibacterial, antiviral, antidepressant, anti-allergic, anti-inflammatory, antifeedant, 
antidiabetic, algicidal potential. phloroglucinols have not been fully explored for their 
biological activity, and for many compounds, only the structures have been elucidated (Pal 
Singh & Bharate, 2006). Phloroglucinol derivatives albaspidin, aspidin, flavaspidic acids, 
dryocrassin ABBA, filixic acid (Hisada & Noro, 1961), flavaspidic Acid PB and AB (Lee, Na, 
Na, Min, & Lee, 2003) were isolated from this plant species. Polyphenols like protocatechuic 
33 
Figure 5.3: Some polyphenols isolated from D.crassirhizoma. 
32: Protocatechuic acid;33: Kaempferitrin 
32 
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acid and kaempferitrin were also isolated from the rhizome (Jiang, Chi, Fu, Zhang, & Wang, 
2013) (Figure 5.3). 
Several components from D. crassirhizoma have been reported to have antiviral activity. 
Crassirhizomosides A, B, C and sutchuenoside A are HIV-1 reverse transcriptase inhibitors 
(Min et al., 2001) inhibitory activity against HIV-1 protease (Lee et al., 2008). Dryocrassin 
ABBA may have the potential to be used against influenza virus H5N1 infection (Wang et al. 
2017). A series of acylphloroglucinols has been reported to have inhibit fatty acid synthase 
with IC50 values ranging from 23.1 ± 1.4 to 71.7 ± 3.9 µM (Na et al., 2006). D. 
crassirhizoma has also shown to have anti-cancer properties by inducing cell cycle arrest and 
apoptosis through the extrinsic and intrinsic pathway in PC3-MM2 cells (Chang et al., 2010). 
Two chemicals from D. crassirhizoma, flavaspidic Acid PB and flavaspidic Acid AB have also 
shown antioxidant activity (Lee, Na, Na, Min, & Lee, 2003). An acidic polysaccharide fraction 
(DCP-3) was obtained from D. crassirhizoma have also been reported to have a strong activity 
for scavenging DPPH radical (IC50: 2.04 mg/mL), hydroxyl radical (IC50: 1.70 mg/mL), and 
superoxide anions (IC50: 4.20 mg/mL) and also was capable of reducing ferric ions (Zhao et 
Figure 5.4: Dactylogyrus intermedius scanning electron micrographs. 
A:Untreated control helminth, showing smooth surface (scale bar = 40 μm); B: Distinct contraction of body 
surface (scale bar = 50 μm), C: view of ventral surface showing abnormal tegumental folds (scale bar = 10 μm), 
and D: clumps of dishevelled protuberances (scale bar = 10 μm). Image credits: Jiang et al. 2013 
89 | P a g e  
al., 2019). Sutchuenoside A and kaempferitrin were observed to be effective against D. 
intermedius with median effective concentration (EC50) of 3.01 and 2.71 mg L−1, respectively 
(Jiang et al. 2013) (Figure 5.5).  
D. crassirhizoma also known to be used for verminosis was investigated for anti-parasitic 
properties. Phloroglucinol compounds like aspidin, flavaspidic acid, methylene-bis-aspidinol 
and desaspidin were incubated with Schistosoma mansoni adult worms for 24 h. Aspidin and 
flavaspidic acid showed decrease motor activity with tegumental alterations while methylene-
bis-aspidinol and desaspidin showed decrease motor activity without tegumental alterations 
(Magalhães et al. 2010). The chloroform extract of D. crassirhizoma demonstrated 
ultrastructural changes in M. incognita after treatment at 1 mg·mL−1 for 24 h (Liu, Xie, Feng, 
& Cai, 2013) (Figure 5.6) 
Flavaspidic acid PB and AB showed antibacterial activity on a range of bacteria with MIC of 
12-20 µg mL−1 based on paper disc diffusion tests (Lee et al., 2009). The n-hexane fraction of 
D. crassirhizoma MeOH extract showed MIC of 15.6 µg/µL against S. aureus determined by 
Figure 5. 5: Scanning electron microscope of M. incognita.  
Image credits: Liu et al. 2013 
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broth dilution method (Kwon et al., 2007). The plant extract showed bactericidal and 
bacteriostatic activity against Streptococcus mutants with MIC and MBC of 62.5 and 250 
µg/mL, respectively) (Ban, Kim, Pandit, & Jeon, 2012). The MIC of D. crassirhizoma crude 
extract and hexane fraction was 0.008 mg/mL and 0.001 mg/mL, respectively against 
Propionibacterium acnes (Hisada & Noro, 1961) 
 
Development of the chemometric approach to bioactive detection:  
The standard purification approach is also a major challenge in the identification of the active 
components in TCM. TCM often acts in a combination of different components which are 
likely to be separated by extensive fractionation and sub-fractionation and therefore would 
not be detected in any bioassay-based identification strategy. In contrast, metabolomics 
simultaneously quantifies multiple small molecule types, such as amino acids, fatty acids, 
carbohydrates, or other products of cellular metabolic functions in a complex biological 
sample. Metabolite levels and relative ratios reflect metabolic function, and out of normal 
range perturbations are often indicative of disease. The progress in metabolomics has been 
largely driven by the development of mass spectrometry, and contemporary methods such as 
nuclear magnetic resonance (NMR), as well as various types of chromatography, 
spectrometry, and electrophoresis (Nagana Gowda and Djukovic, 2014). Combined analytical 
tools include gas chromatography coupled to mass spectrometry (GC-MS), liquid 
chromatography coupled to mass spectrometry (LC-MS), capillary electrophoresis coupled to 
mass spectrometry (CE-DM), ultra-high performance liquid chromatography coupled to mass 
spectrometry (UPLC-MS), high-performance liquid chromatography-electrospray ionization 
coupled to mass spectrometry (HPLC-ESI-MS), high-performance liquid chromatography-
diode array detection-electrospray ionization tandem mass spectrometry (HPLC/DAD/ESI-
MS), and others. 
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One method of identifying compounds in complex mixtures is based on the application of 
metabolomic approaches. This is a high-throughput analytical technique that offers a global 
analysis of the products of all cellular metabolic reactions, regardless of the reactions that lead 
to their production (Perić-Concha & Long, 2003). To more accurately detect the lower 
concentration components of an extract, chemometric techniques can be used to profile every 
chemical in a mixture using chromatographic analysis coupled with 
spectrometric/spectroscopic techniques, so that fewer rounds of purification of the original 
extract is needed. The large data created from metabolomics can then be analysed by 
techniques such as principal component analysis (PCA) and the data created can be integrated 
with chemical data sets to predict the active components of the complex mixture without all 
the steps of bioassay-guided fractionation. This technique is called biochemometrics 
(Kellogg, Paine, McCune, Oberlies, & Cech, 2019). This technique makes the preliminary 
screens for effective antimicrobials more efficient and cheaper making research into natural 
extracts a more viable option and opens up new possibilities in natural product research. 
This chapter focuses on the isolation and identification of the bioactive responsible for anti-
MRSA activity of D. crassirhizoma observed in Chapter 2.  The initial extractions of 
Dryopteris crassirhizoma (DC) were done following a bioassay guided purification and the 
most active fraction was further extracted. The fractions were simultaneously prepared for FIE-
HRMS and UHPLC-MS. The data obtained from FIE-HRMS was randomised and assessed 
using multi-variate statistical approaches. Metabolites present only in active fractions were 
identified and used to search the literature, based on these, tentative identifications of the 
bioactive compounds were possible.  
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5.2. METHODS: 
Part I: Traditional methods for isolation of bioactives 
Extraction and purification: 
Dried and powdered rhizome (800 g) of Dryopteris crassirhizoma was extracted sequentially 
(See Chapter 3). Approximately 93 g of n-hexane extract was fractionated using silica gel 
column chromatography (CC) (4Í50 cm, 150 g of SiO2,). The column was run four times and 
eluted with n-hexane-EtOAc (1:0 to 0:1, at 10 % gradient, 500Í4 mL of each eluent), and 
EtOAc-MeOH (1:0 to 1:2, 500 mLÍ3 of each eluent) to yield 16 fractions (designated H for 
“n-hexane” and A through to P; thus, HA through to HP). Fraction HB (59.11g) was again 
subjected to silica CC (4Í50 cm, 150 g of SiO2,) eluting with n-hexane-EtOAc (1:0 to 3:20, 
1% gradient, 500 mLÍ4 of each eluent) and EtOAc-MeOH (1:0 to 1:2, 5% gradient, 500 
mLÍ5 of each eluent) to yield 8 fractions (1 through 8; thus HB1-HB8). The HB5 fraction 
(10g) fractionated again using silica gel CC (4Í50 cm, 150 g of SiO2,) eluted with n-hexane-
EtOAc (1:0 to 1:10, 1% gradient, 500 mÍ4 of each eluent); n-hexane-EtOAc (1:10 to 0:1, 10% 
gradient, 500 mL Í4 of each eluent) and EtOAc-MeOH (1:0 to 1:2, 10% gradient, 500 mL Í2 
of each eluent). This resulted in 14 fractions, a through to n; thus HB5a-HB5n.  
B5d underwent a series of purification processes using silica CC (1.2Í34 cm, 15 g of SiO2). 
Eluting with n-hexane-DCM (1:0 to 0:1, 10% gradient, 15 mLÍ4 of each eluent) and DCM-
MeOH (1:0 to 1:2, 15 mLÍ4 of each eluent); Semi-preparative HPLC (see 4.2.6), 20mg was 
run through Sephadex LH20 CC (34 × 1.2 cm) was used to eluted with chloroform (CHCl3) 
and MeOH (1:1) sample collected every hour (Ren et al. 2016). Fractions B5d and B5e showed 
similarity in components detected by UHPLC-MS, B5e was further purified using silica CC 
same as B5d. 
As no pure compounds were obtained, B5d and B5e was combined (~1g) and further 
fractionated with silica CC (4Í33 cm, 150 g of SiO2). Eluting with n-hexane-DCM (1:0 to 0:1, 
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10% gradient, 500 mL×4 of each eluent) and DCM-MeOH (1:0 to 1:2, 500 mL×4 of each 
eluent) yielding four fractions HB5d/e1 - HB5d/e8.  
HB5d/e4 was further fractionated 10 mg through Sephadex LH20 CC (34 × 1.2 cm) was used 
to eluted with chloroform (CHCl3) and MeOH (1:1) sample collected every hour yielding 2 
fractions HB5d/e4AS and HB5d/e4BS. As an alternative approach, 60 mg with silica CC 
(1.5×30 cm, 6 g of SiO2) eluting with n-hexane-MeOH (1:0 to 1:1, 0.5% gradient, 20 mL×5 of 
each eluent) yielding 5 fractions HB5d/e4A- HB5d/e4E.  
HB5d/e6 was fractionated using preparative-thin layer chromatography (prep-TLC plates, 0.5 
mm×20 cm×20 cm coated with silica gel 60 with F254 indicator (Material Harvest Ltd)) at a 
concentration of 10 mg/mL yielding 4 fractions HB5d/e6_1 through to HB5d/e6_4. The rest 
was run through silica CC (1.5×30 cm, 5 g of SiO2) eluting with n-hexane EtOAc (1:0 to 1:1, 
0.5% gradient, 20 mL×5 of each eluent) and EtOAc-MeOH (1:0 to 1:1, 10% gradient, 500 mL 
Í2 of each eluent) yielding 4 fractions HB5d/e6A- HB5d/e6D.  
 
Part II: Chemometric approach for bioactive identification: 
Fractionation:  
A further 1g of HL was further fractionated on a silica CC (1.5Í50 cm, 50g of SiO2), eluted 
with 100% of 100mL n-hexane and EtOAc respectively, followed by EtOAc-MeOH (1:0 to 
3:2, 1% gradient 100 mL of each eluent), yielding 8 fractions (HL1 through HL8). All crude 
fractions, n-hexane fractions and HL were further run through FIE-HRMS to generate 
metabolite fingerprints (Chapter 2; See 2.2). 
Data analysis:  
Statistical tests were done using MetaboAnalyst 2.1. (Baptista et al., 2018) The data were then 
analysed using biochemometric analysis (Kellogg et al, 2016) to identify the active 
components.  
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5.3. RESULTS: 
Part I: Traditional method for isolation of bioactives: 
The crude extracts were screened for antimicrobial activities and the MIC for each was 
determined (See Chapter 3). Based on the MIC against MRSA (3.125 µg/mL) observed from 
the crude extracts we focused on the n-hexane extract for further purification. After a first round 
of purification of n-hexane extract all resulted fraction were assayed for MICs against SA and 
MRSA indicating that HB displayed the highest anti-microbial activity (Figure 5.7) HB was 
further purified, and the following anti-microbial screening suggested that fraction HB5 and 
HB6 had the highest activity against MRSA (Figure 5.7). The biochemistry of HB5 and HB6 
the extracts were assessed using UHPLC-MS (Figure 5.8). HB5 was used for further 
purification based on its larger quantity and the similarity of its mass ions with HB6. Then, 
based on the MIC values, fractions HB5d and HB5e were chosen to be further purified. 
However, the biochemical components of the fractions as detected by UHPLC-MS showed that 
they were very similar (Figure 5.9) and so were combined and further fractionated. All fractions 
were tested for antimicrobial activity.  
Figure 5.6: Bioassay guided purified fractions of n-hexane extracts (MIC µg/mL).  
Note: NA: Not active 
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Figure 5.7: Total ion count (TIC) chromatograms of HB5 and HB3 obtained by UHPLC-MS. 
A: Positive Ions of HB5 (black) and HB6 (red); B: Negative ions of HB5 (black) and HB6 (red) 
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Figure 5.8: Total ion count (TIC) chromatograms of HB5d and HB5e obtained by UHPLC-MS. 
A: Positive Ions of HB5d (black) and HB5e (red); B: Negative ions of HB5d (black) and HB5e (red) 
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All the fraction HB5d/e3-6 were further investigated via UHPLC-MS and it was observed that 
all these fractions had 2 common peaks with m/z 405.15417 and 419.16959 differing in their 
content. HB5d/e3 showed enrichment of m/z 405.15417, HB5d/e4 equal content of m/z 
405.15417 and 419.16959, and HB5d/e5 and 6 showed enrichment of m/z 419.16959. These 
fractions underwent several alternative purification techniques as described in the methods 
section but failed to separate the compounds.  
Finally, to identify the compounds HB5d/e3 were investigated via UHPLC-MS coupled with 
MS2/MS3 fragmentation (Figure 5. 10 and 5. 11). The structural information for 
characterization based on retention time, accurate mass, elemental composition, and multiple-
stage mass data, (Table VII). This suggested that compounds were phloroglucinol derivatives, 
and when compared with the literature these were identified as norflavaspidic acid AB and 
flavaspidic acid AB (Ren, Quan, Wang, & Wang, 2016) (Figure 5.12). 
 










MS2 [405]: 197 (100), MS3 [405→197]: 179 (100), 155 
(19), 151(8),113 (7) 
Flavaspidic acid AB 6.96 419.16959 
MS2 [419]: 223 (9), 211 (61), 197 (100) 
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5p #5554-6291 RT: 6.99-7.79 AV: 43 NL: 3.08E7
F: FTMS + p ESI Full ms [110.0000-1100.0000]
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5p #5310-6329 RT: 6.69-7.79 AV: 11 NL: 1.15E6
F: ITMS + c ESI r d Full ms2 405.1542@cid35.00 [106.0000-416.0000]














































5p #5395-6701 RT: 6.91-8.22 AV: 14 NL: 3.03E5
F: ITMS + c ESI r d Full ms3 405.1542@cid35.00 197.0610@cid35.00 [50.0000-208.0000]
























































Figure 5. 9 : A: represents the conventional MS/MS spectra data of norflavaspidic acid AB 
([MH]+obs. = 405.15413 amu). 
A peak at m/z 419 and 441 were contaminants from the column. B: Represents the spectrum of the 
MS/MS/MS experiment in which norflavaspidic acid AB was fragmented by in-source fragmentation and 
its product ion peak at m/z at 405 was selected by Q1 and further fragmented in Q2. A second-
generation product ion at m/z 197 was a result of breaking of the bond. C: represents the MS/MS/MS 
spectrum of the product ion peak at m/z 197. A main product ion at m/z 179 accompanied a neutral 
loss of 18 amu. The spectra also contain other peaks at m/z 154(loss of loss of 25 amu), m/z 151 (loss of 
28 amu), m/z 161(loss of 18 amu) and m/z 137 (loss of 42 amu). 
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3p-ext2 #8423 RT: 10.47 AV: 1 NL: 8.95E7
F: FTMS + p ESI Full ms [110.0000-1100.0000]
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3p-ext2 #8112-10156 RT: 10.36-12.20 AV: 25 NL: 7.40E4
F: ITMS + c ESI r d Full ms3 419.1698@cid35.00 197.0631@cid35.00 [50.0000-208.0000]
















































3p-ext2 #8039-9054 RT: 10.19-11.15 AV: 10 NL: 6.24E5
F: ITMS + c ESI r d Full ms2 419.1697@cid35.00 [110.0000-430.0000]























































Figure 5. 10: A: represents the conventional MS/MS spectra data of flavaspidic acid AB ([MH]+obs. = 
405.16965 amu). 
A peak at m/z 441 was a contaminant from the column. B: Represents the spectrum of the MS/MS/MS 
experiment in which flavaspidic acid AB was fragmented by in-source fragmentation and its product ion peak 
at m/z at 405 was selected by Q1 and further fragmented in Q2. A second-generation product ion at m/z 211 
and 197 was a result of breaking of the bond. C: represents the MS/MS/MS spectrum of the product ion peak 
at m/z 197. A main product ion at m/z 179 accompanied a neutral loss of 18 amu. The spectra also contain 
other peaks at m/z 155(loss of loss of 24 amu), m/z 151 (loss of 28 amu), m/z 161(loss of 18 amu) and m/z 
137 (loss of 42 amu). 
100 | P a g e  
 
Part II: Chemometric approach for bioactive identification: 
 
Column chromatography generated 8 fractions of HL: HL1 to HL8. Their antimicrobial activity 
was again tested with and the resulting MICs are recorded in Table VIII.  
 
Table VIII: Antibacterial activity (MIC µg/mL) of HL fractions.  








HL1 ND ND 
HL2 >25 µg/mL 25 µg/mL 
HL3 >25 µg/mL >25 µg/mL 
HL4 >25 µg/mL >25 µg/mL 
HL5 25 µg/mL 25 µg/mL 
HL6 25 µg/mL 25 µg/mL 
HL7 12.5 µg/mL 12.5 µg/mL 




Figure 5.11: The chemical structures of the bioactive natural products isolated from D. 
crassirhizoma  
A: Norflavaspidic acid AB; B: Flavaspidic acid 
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Based on these MICs, metabolomic approaches were then used to target the possible 
compounds within the fraction that might be responsible for antimicrobial activity against 
MRSA. 
Each fraction was profiled by FIE-MS and the resultant mass spectra were assessed using 
multi-variate statistical approaches. Principal component analysis (PCA) of the four fractions, 
predicting their relatedness (Figure 5.13). The n- hexane(H), DCM(D), ethyl acetate(E) and 
methanol(M) fractions showed clear separation on the PCA plot indicating that the variation in 
these sample metabolites were was significantly different from each other (Figure 5.13; A). 
Partial least square discriminant analysis (PLS - DA) of the n - hexane fractions (Figure 5.13; 
B) with significant activity showed that the HB was completely different from all the other 
fractions; especially, HA, fraction is known for its lack of active antimicrobial compounds. The 
proximity of the HH and HJ; HK and HL fractions indicates that they are groups of similar 
compounds and tellingly, all had the same MICs (Figure 5.13)  
A B 
Figure 5.12:  Multi-variate statistical approaches for different fractions of D.crassirhizoma. 
(A) Principal component analysis (PCA) of the different crude fractions score plots (n = 6 and 95% confidence 
interval illustrated, clear outliers removed) of normalized m/z intensities of metabolites extracted from the 
fractions. (B ) Partial least squares discriminant analysis (PLS-DA) of the n-hexane fractions score plot based on 
the top two components. Plots indicate metabolome differences between the different fractions 
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Next, metabolite profiles for the HL fractions were obtained and assessed by multivariate 
approaches. The PCA score plot though shows close proximity of HL5, HL6,HL7 and HL8 
forming a group while HL3 and HL4 forms another group and HL2 is completely by itself 
(Figure 5.14). The major sources of variation were between active HL and less-active HL 
fractions were defined. These were compared across the fractions using a heat-map. HL7 and 
HL8 as they had the best MIC in comparison to the rest of the fractions and sources of variation 
for these fractions were distinct from other fractions (Figure 5.15). The masses picked for 
further investigation were significantly abundant in HL7 and HL8 fractions, whilst absent in 
other fractions, based on the heatmap analysis we targeted predict that m/z 625.228 and 627.235 
as possibly could be responsible for the bioactivity.  
 
Figure 5. 13: Multi-variate statistical approaches for HL fractions of D.crassirhizoma. 
Principal component analysis (PCA) of the different HL fractions score plots (n = 6 and 95% 
confidence interval illustrated, clear outliers removed) of normalized m/z intensities of 
metabolites extracted from the fractions. Plot suggests the metabolomic differences in 
different fractions 
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The selected fractions were further analyzed under UHPLC-MS individually to identify the 
abundance of the observed m/z and underlying other masses present in the fractions. The most 
abundant peak in the HL7 extract was m/z 419.169 followed by m/z 857.299 and 649.225 
(Figure 5.16). While in extract HL8 the most abundant peak was m/z 649.225 followed by m/z 
419.169 and 857.299 (Figure 5.17). This suggests that masses other than m/z 649.225 present 
in the fraction could also contribute to the bioactivity.  
 
Figure 5. 14: Heat map showing cluster analysis of top 50 significant masses of HL7 and HL8 in 
comparision to other fractions. 





Figure 5. 15: UHPLC-MS analysis of HL7.  
A: Total positive ion count of HL7, B: Total negative ion count of HL7, C: Mass spectrum of positive 
ion mode of HL7, D: mass spectrum of negative mode of HL7 






Figure 5. 16: UHPLC-MS analysis of HL8.  
A: Total positive ion count of HL8, B: Total negative ion count of HL8, C: Mass spectrum of positive ion 
mode of HL8, D: mass spectrum of negative mode of HL8 
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On exploring previous literature and different metabolite databases we predicted that the 
structures of the compounds present in the extracts based on parental ion masses. Compounds 
detected based on ion spectrum of UHPLC-MS could be Filixic acid ABP (m/z 649.225), 
Flavaspidic acid AB (m/z 419.169), and Dryocrassin ABBA (m/z 857.299) (Na et al., 2006; 




Figure 5. 17: The chemical structures of identified compounds. 
A: Flavaspidic acid AB, B: Filixic acid ABP, C: Dryocrassin ABBA 
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5.4. DISCUSSION 
The antimicrobial screening of n-hexane and DCM extracts of D. crassirhizoma showed 
activity against MRSA (USA300). Due to its low MIC value, the n-hexane extract was further 
sequentially fractionated, guided by bioassays, to ultimately yield a pair of fractions HB5d/e3 
and HB5d/e5 with the best activities (MIC 6.25 and 12.5 µg/mL respectively).  
After several failed attempts at purification, the HB5d/e3 fraction was identified using UHPLC-
MS and MS2/MS3 and compared with the literature which indicated them to be phloroglucinols 
namely norflavaspidic acid AB and flavaspidic acid AB (Figure 5.12).  
Norflavaspidic acid AB is an example of acyl phloroglucinol dimers formed by a methylene 
linkage. It has been reported to have inhibitory effects on melanin production by melanoma 
B16F10 cells with IC50 values of 181.3 µM (Pham, Kim, Lee, Min, & Kim, 2017). It also shows 
inhibitory effects against human leukemia Reh cells with IC50 of 32.2µg/mL (Ren et al., 2016). 
It has been reported to have inhibitory activity against the pro-apoptotic factor - FAS - of IC50 
29.7µM (Na et al., 2006).  
Flavaspidic acid AB is an acyl phloroglucinol dimers, similar to norflavaspidic acid but with 
an added methylene group. It has been reported to exhibited a potent antioxidant activity 
against the LPO inhibitory test with IC50 values of 13.1 mM (Lee et al., 2003). It can induce 
IFN-α, IFN-β, and IL1-β expression in porcine alveolar macrophages, which could contribute 
to inhibition of porcine reproductive and respiratory syndrome virus (PRRSV) replication 
(Yang et al., 2013) It also shows inhibitory effects against human leukemia Reh cells with IC50 
of 35.3µg/mL (Ren et al. 2016). Its activity against the pro-apoptotic ligand FAS had an IC50 
of 28.7µM (Na et al., 2006). The effect of flavaspidic acids on cellular respiration and oxidative 
phosphorylation in isolated hepatocytes and even, at moderate concentrations, uncouples 
oxidative phosphorylation in isolated hepatocytes (Burnett, Lysenko, & Ockner, 1979). 
Flavaspidic acid AB is reported to have antibacterial activity based on when a paper disc 
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diffusion assays with MICs ranging between 12-20 µg/mL depending on the microorganism 
being tested (Lee et al., 2009).  
A key feature of TCM is the use of blends of different herbs to make a complex mixture 
representing multiple interacting components. For example, Fritillaria bulbs are frequently 
found in many proprietary formulations for acute bronchitis and tuberculosis, such as San She 
Dan Chuan Bei Mu Ye (contains Fritillaria ussuriensis and Zaccys dhymnades bile juice), Si 
Shun Tang (include Zi Wan (Purple Aster Root), Jie Geng (Platycodon), and Gan Cao (Licorice 
Root)) and Chuan Bei Pi Pa Lu (Eriobotrya japonica leaf (Pi Pa Ye) Typhonium flagelliforme 
rhizome (Shui Ban Xia) Fritillaria ussuriensis bulb (Ping Bai Mu) Platycodon grandiflorum 
root (Jie Geng)). Their therapeutic effect is often associated with the combined action of several 
active ingredients, just as it can be caused by a single compound that the herb contains (Wang 
et al., 2017). Such complexity massively impedes the definition of the active components using 
the classical, bioactivity guided fractionation and purification strategy which is ideally suited 
to defining single active chemicals. Thus, we attempted an alternative approach which 
maintains the complexity of extracted but uses metabolomic and chemometric methods to 
define active component. The expansion of the ‘omics technologies has allowed metabolomic 
approaches to be exploited in the analytical field. Thus, metabolomics can be used to explore 
the metabolite changes occurring in biological systems using chromatography techniques (LC-
MS; GC-MS), nuclear magnetic resonance (NMR) and mass spectrometry (Fiehn, 2002). 
Metabolomics is used in medicine, microbiology and genomics. In pharmacology, it is utilised 
for drug toxicity research, diagnoses, and drug discovery (Lindon et al., 2000; Xia et al., 2009). 
The second-best group of H - fractions (MIC: 6.25 µg/mL) contained HH, and HK. PLS-DA, 
indicated that HH, HG and HI formed one cluster while HK, HL and HM formed another. The 
HL fraction was chosen to be the one to be subjected to further fractionation due to the amount 
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of material in the extract and as it was extracted with different polarity of solvents to HB, would 
be unlikely to contain similar active metabolites.  
The fractionation followed by antimicrobial assay performed on HL yielded the MICs that are 
presented in Table VIII. It was separated into 8 fractions (HL1 to HL8) by column 
chromatography, with varying MICs (from 12.5 µg/mL to >25 µg/mL) against the two bacterial 
strains. The differences in the MICs between the HL fraction (6.25 µg/mL) and the following 
separated HL2 to HL8 might be due to acting in synergy against MRSA in HL and this 
interaction is lost with fractionation. This highlights the need to develop a chemometric 
approach to bioactive discovery as attempted in this chapter.  
In this study, data acquired from FIE-HRMS of HL fractions of D. crassirhizoma were first 
assessed by PCA. The data from D. crassirhizoma indicated that the clusters formed from n - 
hexane, DCM, EtOAc and methanol fractions with each being significantly different from the 
other (95% CI) (Figure 5.13). 
Another chemometric analysis was performed on the data from n - hexane fractions of D. 
crassirhizoma. PLS - DA uses many linear regression models to find the largest covariance of 
the data set (X) and the class (Y) (Xia et al., 2009). The variables of the data set are grouped 
into averages called scores. The analysis therefore provides a “supervised” view of the data 
where class differences are highlighted. The 2D biplot showed the HA - HP fraction grouping 
(Figure 5.13) shows that the HB activity is the highest, confirming the data from the MICs. HL 
and HK clusters are close to that of HB; where the active compounds have been defined. It may 
be assumed that due to the proximity of the HL, HK and HB fractions, they share common 
antimicrobial compounds. PLS - DA of HL fractions showed that these were distinctive (Figure 
5.13).  
Further investigation of HL involved further fractionation based on polarity with subsequent 
estimations of MICs for each fraction. All the fraction was run through FIE-HRMS and the 
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major sources of variation assessed (Figure 5.15). Later the most active fractions HL7 and HL 
8 was run through UHPLC-MS to further select the abundant mass ions. Based on the data 
obtained and searching the databases and previous literature, 3 compounds were identified. 
Flixic acid ABP is the second most abundant compound in HL7 and HL8 (Figure 5.16 and 
Figure 5.17), in the UHPLC-MS spectra. Flixic acid ABP is known for its antimicrobial 
properties and has been identified in D. crassirhizoma. Its MIC against S. aureus strains was 
reported to be 2.5 µg/mL (Qi et al., 2017) 
Flavaspidic Acid AB, the most abundant compound according to UHPLC-MS, is also known 
for its antimicrobial and antioxidant activities (Figure 5.16 and Figure 5.17). It is a metabolite 
that can be found in the rhizomes of D. crassirhizoma and inhibits the replication of respiratory 
syndrome virus (PRRSV) (Yang et al., 2013). It was first defined in an ethyl acetate - soluble 
fraction of the rhizomes of D. crassirhizoma based on its property as a potent antioxidant based 
on a Lipid Peroxidation (LPO) inhibition assay with IC50 values of 12.9 µm, (Lee et al., 2003). 
This activity may be due to the iron chelating activity of phenolic compounds which will 
suppress the ability to generate free radicals (Van Acker, 1998). Considering its anti-microbial 
properties, disk diffusion tests against two strains of S. aureus: Staphylococcus aureus KCTC 
1916 and Staphylococcus aureus KCTC 1928 mutants suggested inhibition zones of 16 and 19 
mm respectively. As Staphylococcus aureus KCTC 1928 mutant is a MRSA bacterium this 
shows the clinical potential of flavaspidic acid AB (Lee et al., 2009). Given these observations, 
flavaspidic acid AB is likely to contribute to the anti- S. aureus and MRSA activities in the HL 
fraction of the n - hexane fraction.  
Dryocrassin ABBA, is third targeted compound (Figure 5.16 and Figure 5.17), This has already 
shown an antimicrobial activity for bird flu virus and the downregulation of cytokines IFN - γ 
and TNF - α, which are associated with the development of influenza virus (Hagau et al., 2010). 
A possible connection of dryocrassin and the suppression of S. aureus and MRSA infections 
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has been suggested in a recent study where dryocrassin ABBA has a strong inhibitory action 
on Von Willebrand factor-binding protein (vWbp), a protein secreted by S. aureus and has been 
considered a factor for the decrease of emerging resistance strains such as MRSA (Li et al., 
2019). However, such activities would be not have been revealed by the screens used in the 
experiments used in this chapter but highlight the potential of TCM based on D. crassirhizoma.  
MS based techniques to provide a rapid investigation to any new natural product identification, 
as it is more sensitive compared to other analytical methods. High resolution MS (3-5 ppm 
resolution) as used allows the identity of the metabolites to be suggested but depends on the 
metabolite being already lodged in databases. Therefore, high-resolution MS suffers from not 
providing an unambiguous identification of m/z and a failure to report novel compounds. For 
unknown compounds, not contained in the libraries, their structure assignment by MS is still 
considered a challenge(Wang et al., 2017). As a result, Currently, MS/MS fragmentation is 
routinely applied in natural product identification and characterization, in which MS/MS data 
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5.5. CONCLUSION 
The increasing interest the world is showing into TCM is due to its undiscovered potential as 
a multi-target therapeutic. D. crassirhizoma has been demonstrated to contain multiple 
antimicrobial components that either in association with each other, or separately, can 
successfully target MRSA and be potentially turned into a novel drug. Based on the MIC of D 
crassirhizoma against MRSA obtained in Chapter 3, the objective of this chapter was to 
characterize the bioactive responsible for the activity. Part I of the the chapter demonstrated 
the novel bioactive fraction of D. crassirhizoma. The fraction showed MIC 6.25 µg/mL was 
further characterized using UHPLC-MS coupled with MS2/MS3. Norflavaspidic acid AB and 
Flavaspidic acid AB was identified as the major components of the fractions. There were 
several alternative methods used to separate the fraction but failed. Therefore, we tentatively 
conclude the two compounds identified are responsible for the anti-MRSA activity.  
The mode of action of norflavaspidic acid AB and flavaspidic acid AB need to be investigated 
and in the next chapter, this will be explored using metabolomics.  
Part II of the chapter, chemometric assessments of metabolomic data been demonstrated as a 
potential method to identify bioactives in a chemically complex fraction. The success of this 
approach was aided by the existence of a comprehensive literature which allowed the key 
sources of variation to be identified and linked to known anti-microbial activities. Clearly, this 
prevents the rapid definition of novel compounds. However, this approach could be extended 
to unknowns. Thus, some novel compounds could be present in active fractions and only 
indicated by their m/z. These would be still targeted for identification by tandem MS or NMR. 
They could still be purified, and their effects assesses using standard synergistic assays with 
bioactives from the extract or TCM mix. Finally, the chemometric process could be further 
improved to make it much more efficient. For example, machine learning approaches could be 
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used to identify variables present only in active fractions which could be immediately be used 
to interrogate natural product databases.  
  























Assessments of mode of action  
 
  




In response to the global need for new anti-microbial that can effectively combat the new 
strains of drug-resistant “superbugs”, our study uses metabolomic approaches to exploit the 
potential of TCM. There are several strategies that can be used to define drug modes of actions. 
Traditional means include simple assessments of changes in cell phenotype upon drug 
treatment, drug bioactivity but more molecular approaches include affinity chromatography, 
radio-labelling, and cell-based affinity tagging. However, genomic and post-genomic 
approaches could provide wider assessments of many effects on a given drug lead on the target 
organism or cell (Baptista et al. 2018). 
Extracts from Dryopteris crassirhizoma Nakai exhibited potent activity (MIC 3.125 µg/mL); 
bioassay-guided purification led to their chemical identification. High-resolution electrospray 
ionisation mass spectrometry (HR-ESI-MS) indicated the key bioactive to be phloroglucinols. 
We here use metabolomic approaches based on flow infusion ionisation electrospray high-
resolution mass spectrometry (FIE-HRMS). to suggest possible mode(s) of action for the 
bioactive fractions HB5d/e3(A3) and HB5d/e5 (A5) fraction of Dryopteris crassirhizoma.  The 
major sources of variation and biochemical pathway assessments, anti-MRSA activity was 
linked to the altered amino acid processing. Genomic assessments of resistant mutants will be 
used to further confirm the predicted target.  
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6.1. INTRODUCTION 
A vitally important aspect of research leading to new drug leads or the repurposing of existing 
drugs is to fully comprehend, at least as far as possible, their mechanisms of action. This can 
prevent problems with toxicity at the early stages of clinical trials. For example, the drug target 
must not show such similarity with human homologues so that is could compromise the drug 
safety. There some key features that the drug targets should display to improve the likelihood 
of a drug-lead being taken forward for development as an anti-microbial. Kana et al. defines 
the “ideal” target as a macromolecule that 1) acts in the growth, survival and latency of the 
bacteria, 2) regulates crucial checkpoints of bacterial metabolism, 3) has a low tolerance for 
mutation and 4) is found at targetable locations within the cell. Given the importance of 
defining the mode of action and likely targets for new drug leads, we here consider the known 
modes of action for existing MRSA targeting drugs prior to moving to assess likely mode(s) of 
action for the A3 fraction of Dryopteris crassirhizoma (See 5.1).  
 
Different means of mode of action studies  
There are several strategies to define mode of actions. Traditional means include simple 
assessments of changes in cell phenotype upon drug treatment, drug bioactivity but more 
molecular approaches include affinity chromatography, radiolabeling, and cell-based affinity 
tagging (Azad & Wright, 2012). However, it is increasingly being understood and genomic and 
post-genomic approaches could provide wider assessments of many effects on a given drug 
lead on the target organism or cell  
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Omics technologies have revolutionized many fields of biology and are expected to play a key 
role in the effective control of pathogens through the development of highly specific 
antimicrobial agents (Figure 6.1). High-throughput molecular techniques, colloquially called 
“omics” methods, have greatly increased our ability to characterize the taxonomic and genetic 
structure of bacterial communities, to estimate their functional capabilities and to evaluate their 
responses to stressors or pathogens (Tsouh Fokou et al., 2015). Some of the omics methods 
developed to date are gene amplicon sequencing, shotgun metagenomics, transcriptomics, 
proteomics, and metabolomics.  
Figure 6.1: Timeline of the different omics methods.  
The milestones are shown in different colours for the works in genomics, transcriptomics, proteomics, 
metabolomics, and single cells (Chernov, Chernova, Mouzykantov, Lopukhov, & Aminov, 2019) 
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Genomics: The tremendous progress in genome analysis in the past decade has had a major 
impact on all biological sciences, including drug characterization (Figure 6.2). Genomic 
information is important in the identification of promising candidate targets for antimicrobials. 
Identification of genes essential for the survival of pathogens is clearly important for the 
development of screening platforms to discover antimicrobial compounds targeting the 
corresponding products encoded by these genes (Brown & Wright, 2016; Fields, Lee, & 
McConnell, 2017). Several pharmaceutical companies have started sequencing programs and 
have adapted their antibacterial drug discovery process to maximize the use of this 
unprecedented information. With the ever-increasing number of multidrug-resistant bacterial 
Figure 6.2: Various functional genomics techniques implemented in the modern antibacterial drug 
discovery process. 
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isolates, the pharmaceutical industry has embraced genomic information as the basis for a 
rational, target-directed antibacterial drug discovery strategy to complement the classic 
empirical approach (Freiberg & Brötz-Oesterhelt, 2005; Livermore, 2003; Spellberg, Powers, 
Brass, Miller, & Edwards, 2004). Comparative genomic analysis of strains with different 
sensitivities to antimicrobials is of importance for the identification of complex antimicrobial 
resistance mechanisms. Other components of microbial communities are the virome and 
vesicles which affects the population density of cellular organisms and, via transduction, 
provides horizontal gene transfer (HGT), including transfer of genes encoding antimicrobial 
resistance (Haaber et al., 2016; Kim et al., 2018). Genomics studies have also made a 
significant contribution to the understanding of the role played by membrane vesicles in 
antimicrobial resistance. 
The efforts undertaken by GlaxoSmithKline (GSK) between 1995 and 2001 offers a good 
example of the use of comparative genomics in identifying targets for the development of 
broad-spectrum antimicrobials. Over this period, researchers at GSK mined the genomes of 
Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumonia, Staphylococcus 
aureus and Enterococcus faecalis to identify highly conserved genes. In total, more than 300 
genes were identified as potential targets, resulting in 67 high throughput screens. These 
screens led to the identification of sixteen hits that gave a positive result in vitro, five of which 
were developed as lead compounds. However, none of these compounds advanced into clinical 
testing. GSK subsequently reorganized its antibiotic discovery program to employ more 
traditional methods based on using chemical synthesis to develop novel agents that inhibit 
known targets using novel mechanisms (Payne, Gwynn, Holmes, & Pompliano, 2007). 
Transcriptomics: is the analyses of a complete set of transcripts produced by the cell under 
defined environmental conditions. Transcripts are assessed as a genome-wide level, both 
qualitatively (which transcripts are present, identification of novel splice sites, RNA editing 
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sites) and quantitatively (how much of each transcript is expressed). Analysis of gene 
expression in response to antimicrobials in conjunction with bioinformatics resources may help 
to reveal the mechanisms of antimicrobial action. Microchip technology based on hybridization 
of cDNA with oligonucleotide probes can be used for large-scale gene expression studies 
(Batchelor et al., 2008; Bruant et al., 2006; Freiberg & Brunner, 2002). Gmuender and others 
revealed differences in the cellular response of Haemophilus influenzae to DNA gyrase 
inhibitors (novobiocin and ciprofloxacin) using DNA microarrays (Affymetrix chips) and 2D-
PAGE (Gmuender et al., 2001). This study was one of the earliest works suggesting that the 
microbial response to antimicrobials and mechanisms of antimicrobial resistance are not simply 
limited by the boundary’s antimicrobial-target interaction and could be more complex, 
involving a multitude of other genes. 
The use of hybridization-based techniques in transcriptome analysis is gradually being replaced 
by global RNA sequencing (Duggan, Bittner, Chen, Meitzer, & Trent, 1999; Ozsolak & Milos, 
2011; Schulze & Downward, 2001; Wang, Gerstein, & Snyder, 2009). The RNA-seq method 
provides a deep quantitative analysis of gene expression and allows the profile of non-coding 
RNAs involved in the regulation of gene expression to be evaluated. Small RNAs (sRNAs) in 
the extracellular vesicles of microorganisms are of particular interest because they are 
considered to be mediators of cell reprogramming in response to changes in environmental 
variables (Choi, Kim, Hong, & Lee, 2017; Dersch, Khan, Mühlen, & Görke, 2017). The 
involvement of vesicular sRNAs in response to antimicrobial agents and the corresponding 
development of resistance has recently been demonstrated for Acholeplasma laidlawii, where 
the wild-type and resistant strains were grown under antibiotic-free and antimicrobial treatment 
(ciprofloxacin, tetracycline, and melittin) conditions. Some differentially expressed sRNAs 
were associated with genes conferring antimicrobial resistance, including metal-dependent β-
lactamases, MATE-family proteins, and ABC-transporters (Chernov et al., 2018). Validation 
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of transcriptome analysis can be provided by RT-PCR and using mutagenesis techniques such 
as Tn-seq, INseq, TraDIS, or HITS (Moule et al., 2014; Rajagopal et al., 2016; Slavokhotova, 
Shelenkov, & Odintsova, 2015; Van Opijnen & Camilli, 2013). 
Proteomics aims to quantify large numbers of peptide and protein abundance, modification, 
and interactions in cells, tissues, biological fluids or the whole body. Advances in proteomics 
have been largely driven by the development of mass spectrometry and two-dimensional 
electrophoresis (2DE). The analysis and quantification of proteins has been revolutionized by 
MS-based methods and, recently, these have been adapted for high-throughput analyses of 
thousands of proteins in cells or body fluids (Hein, Sharma, Cox, & Mann, 2013; Selevsek et 
al., 2015). The functions of a large fraction of proteins are mediated by post-translational 
modifications such as proteolysis, glycosylation, phosphorylation, nitrosylation, and 
ubiquitination (Beck et al., 2006; Mann & Jensen, 2003). Therefore, proteomics can reveal 
most translational, translational and post-translational changes. Recently, a shotgun proteomic 
strategy combined with high-accuracy mass spectrometry has been used to study a bacterial 
phosphor-proteome. The study revealed that phosphorylation of A. baumannii β-lactamase at 
the active site of the protein leads to an imipenem-sensitive phenotype, whereas the non-
phosphorylated enzyme exhibits a high β-lactamase activity and provides resistance against 
imipenem (Lai et al., 2016; Lai et al., 2017). Zhou and others established that succinylation of 
different lysine residues in isocitrate lyase of M. tuberculosis is associated with resistance to 
different anti-bacterial compounds (Zhou, Xie, Yang, Zhou, & Xie, 2017). 
Another useful aspect of proteomics is the identification of extracellular proteins that either 
could be secreted freely or confined within extracellular vesicles. Investigation of cellular 
proteomes and extracellular vesicles in Pseudomonas aeruginosa grown in biofilm or 
planktonic culture revealed that the development of antibiotic resistance in biofilms is 
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associated with modulation of both the cellular and vesicular proteomes (A. J. Park, Surette, & 
Khursigara, 2014). The classification of differentially expressed microbial proteome profiles 
could reveal specific signatures that occur in response to drugs and help prioritize the 
compounds being tested for their selectivity and specificity. One of the options for 
classification of the large data sets obtained using omics technologies is the construction of 
molecular networks and pathways (Anitha, Anbarasu, & Ramaiah, 2014; Villaveces, Koti, & 
Habermann, 2015; Wenzel & Bandow, 2011). 
Metabolomic approaches can be targeted or untargeted; Targeted metabolomics is increasingly 
popular for studies of metabolic changes associated with antimicrobial resistance. Schelli et 
al., have used HPLC on a HILIC (hydrophilic interaction chromatography) column in 
combination with mass-spectrometry to monitor metabolites in two isogenic S. aureus strains 
with differential susceptibility to methicillin that were treated with sub-lethal doses of 
ampicillin, kanamycin, and norfloxacin. The treatment resulted in a set of similar and divergent 
metabolic alterations involving the metabolism of purines, pyrimidines, and amino acids 
(Schelli, Zhong, & Zhu, 2017). 
The targeted approach can be supplemented with untargeted LC-MS to identify further targets 
to address concerns about potentially missing metabolites. Untargeted LC-MS is a method of 
choice if unusual metabolites are expected, as in the case of chemical transformation of 
antimicrobials, or if the range of metabolites affected is difficult to predict. One version of 
untargeted mass spectrometry involves direct sample injection into a mass spectrometer, 
without the LC-separation step (Pinu & Villas-Boas, 2017; Zampieri et al., 2017). The 
popularity of untargeted LC-MS for metabolomics has been supported by the rapid 
development of efficient and user-friendly bioinformatics tools. Powerful and flexible 
bioinformatics platforms such as OpenMS, mzMine2, MAVEN, MetaboAnalyst2, and XCMS 
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ensure the efficient and comprehensive analysis of large amounts of data obtained using 
untargeted LC-MS (Baptista, Fazakerley, Beckmann, Baillie, & Mur, 2018).  
Nuclear Magnetic Resonance (NMR) is a very attractive technique for metabolomics because 
it provides broad coverage of metabolites, does not require prior separation of the metabolites, 
and is non-destructive, so samples can be retained for other analyses. 1D-NMR and 2D-NMR 
are currently being used for high-throughput metabolomics studies. For example, 1D 1H NMR 
metabolomics has been used to monitor intra- and extra-cellular metabolites of E. coli upon the 
exposure to ampicillin, carbenicillin, tetracycline, doxycycline, kanamycin, streptomycin, 
ofloxacin, cefalexin, and ciprofloxacin, revealing specific patterns of metabolites by 
intracellular fingerprinting and extracellular foot printing is a valuable technique for the 
identification of bacterial cell responses to a specific antimicrobial and for predicting the effects 
of combinations of antimicrobials (Hoerr et al., 2016).  
Monitoring the metabolome during exposure to different antimicrobials may help to identify 
metabolic processes contributing to the global cell response to antimicrobials. Recent studies 
have suggested that antimicrobial drugs may significantly modulate antimicrobial 
susceptibility and resistance of the phenotype (Baptista, et al. 2018; Crusco et al. 2019). For 
example, Zampieri and others have found that resistance to three different antimicrobials may 
evolve much more rapidly on glucose than on acetate, because of greater metabolic plasticity 
during respiro-fermentative metabolism on glucose than purely respiratory metabolism on 
acetate (Zampieri et al., 2017). 
Additionally, metabolomics in combination with modelling has been used extensively to study 
metabolite flux. (Dettmer, Aronov, & Hammock, 2007; Madsen, Lundstedt, & Trygg, 2010; 
Mathew & Padmanaban, 2013; Zampieri et al., 2018). Crucially, metabolomics reflects the 
summation of transcriptional and post/translational control as well as such as allosteric control 
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of biochemical pathways. It is therefore perhaps the most informative ‘omics’ level in terms of 
describing the functions of a cell. In summary, a knowledge of the metabolic responses of both 
micro- and macro-organisms to biotic and abiotic stress factors, including antimicrobials, may 
contribute significantly to the development of new antimicrobials (Aros-Calt et al., 2015; 
Belenky et al., 2015). 
This study assessed if the HB5d/e3 (A3) and HB5d/e5 (A5) fraction of Dryopteris 
crassirhizoma acts differently from established antibiotics on MRSA using metabolomics. 
Another aim is to use metabolomics to define the mode of action of the bioactive molecule(s) 
in HB5d/e3 (A3) and HB5d/e5 (A5).  
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6.2. MATERIALS  
Chemicals: 
HB5d/e5 (A5), Hb5d/e3 (A3), were extracted from D. crassirhizoma (See Chapter 5). 
Chloramphenicol (CH), Gentamicin (G), Levofloxacin (L), Nalidixic acid (N), Streptomycin 
(S), Vancomycin (V), were obtained from Sigma-Aldrich. The established antibiotics have 
accepted mode of actions (Table IX). Glutaraldehyde and sodium cacodylate (Agar Scientific 
Ltd, UK), ultra-low gelling temperature agarose solution (Sigma Aldrich Cat. No. A-5030), 
syringe filter (Whatman Ltd, UK), % osmium tetroxide (Agar Scientific Ltd), Hettich 
Mikroliter D-7200 micro-centrifuge, AMB stain Azur II & Methylene blue (Sigma Aldrich 
Ltd, UK), Butvar B98 polymer (Agar Scientific), uranyl acetate (Agar Scientific). 
 
6.3. METHODS 
Determination of in vitro antibacterial activity and dosage  
To access the concentration of antibiotics required to inhibit the bacterial growth by 50%, a 
micro dilution of all antibiotics in a bacterial culture of OD600 0.6 was performed. The optical 
density OD600 was measured after 6 h of treatment (Baptista, Fazakerley, et al., 2018). 
 
Examination of bacterial samples by transmission electron microscopy (TEM): 
Bacterial cells were cultured with A3 and A5 at concentrations which had an MIC50 at 6 h and 
also higher concentration (equivalent to an MIC90 at 24 h) and an untreated control. The 
cultures were samples at 6 h which represented mid-exponential phase. At 6 h, 1 mL of the 
culture was collected and centrifuged at 10,000 × g for 10 min. The supernatant was discarded, 
and cell pellets used for fixing. The whole contents of the microcentrifuge tubes were mixed 
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by vertexing with 1 mL of a primary fixative consists of 2.5 % glutaraldehyde in 0.1M sodium 
cacodylate at pH 7.2 (Agar Scientific Ltd, UK). These are be kept in the fridge until use. 
Then, samples were centrifuged and the supernatant discarded following with the cells were 
re-suspended in fresh fixative. After 30 min fixation, the samples were centrifuged, and the 
supernatant discarded. The pellets were re-suspended in another 1ml of fresh fixative as above 
and left for 30 minutes, the previous step was repeated but they were re-suspended in 1ml 0.1 
M sodium cacodylate wash buffer pH at 7.2 for 30 min. The samples were centrifuged, and the 
supernatant discarded. They were re-suspended in 1 mL of a secondary fixative consisting of 
1 % osmium tetroxide made up in 0.1 M sodium cacodylate buffer pH 7.2. After 30 min, the 
samples were centrifuged, and the supernatant was carefully discarded. It was replaced with a 
quick rinse in 1 mL of 1 M sodium cacodylate wash buffer as above. After 5 min rinse, the 
samples were centrifuged, and the supernatant discarded. The pellets were re-suspended in 
another 1 mL of wash buffer. The samples were centrifuged, and the supernatant discarded. 
The samples were re-suspended in 100 µL 2 % ultra-low gelling temperature agarose solution 
(Sigma Aldrich) was made up in ultra-pure H2O at 25⁰C and placed in a refrigerator to gel at 
4⁰C.  
After gelling overnight, the agarose containing the bacteria was cut from the microcentrifuge 
tubes with single-sided razor blades and transferred into 1 mL wash buffer in 5 mL glass vials 
with push-on lids (Scientific Glass Laboratories Ltd) at 4 ⁰C. After 30 min the gelled agarose 
pellets were placed in fresh wash buffer. The samples were then passed through a sequential 
ethanol series of 30, 50, 70, 95% (v/v) and finally three changes of 100 %. Each step lasted for 
at least a 1 h. The samples were transferred to a 1:2 mixture of ethanol to LR White - Hard 
Grade (London Resin Company, UK) resin then a 2:1 mixture of ethanol to resin and finally 
100 % resin overnight @ 4⁰C. The resin was removed and replaced with fresh resin and later 
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that day the samples were then placed in size 4 gelatine moulds (Agar Scientific, UK), filled 
up with fresh resin and polymerised overnight in an oven at 60 ºC.  
Sections (2µm thick) which contained the bacteria were cut and dried down on drops of 10 % 
ethanol on glass microscope slides. Sections were stained with AMB stain (Azur II & 
Methylene blue, both Sigma Aldrich Ltd, UK), and photographed using a Leica DM6000B 
microscope. Ultrathin 60-80 nm sections were then cut on a Reichert-Jung Ultracut E 
Ultramicrotome with a Diatome Ultra 45 diamond knife and collected on Gilder GS2X0.5 3.05 
mm diameter nickel slot grids (Gilder Grids, Grantham, UK) float-coated with Butvar B98 
polymer films. All sections were double stained with uranyl acetate and Reynold's lead citrate 
(TAAB Laboratories Equipment Ltd, Aldermaston, UK) and observed using a JEOL JEM1010 
transmission electron microscope (JEOL Ltd, Tokyo, Japan) at 80 kV. The resulting images 
were photographed using Carestream 4489 electron microscope film (Agar Scientific, UK) 
developed in Kodak D-19 developer for 4 min at 20 °C, fixed, washed and dried according to 
the manufacturer's instructions. The resulting negatives were scanned with an Epson Perfection 
V800 film scanner and converted to positive images. 
Metabolomics 
Sample preparation: The bacterial incubation constant shaking at 200 rpm at 37 °C. Six 
biological replicates of each isolate treated with antibiotic and the untreated control group were 
independently cultured. The sample preparation was done with some alteration from Baptista, 
et al. 2018. All samples were collected during mid-exponential growth phase. A 3 mL aliquot 
of bacterial culture (OD600 at time 0 h was 0.6) was harvested at 0, 2, 4 and 6 h after the 
treatment with the respective antibiotic. The samples were centrifuged at 10 °C at 4500 
rpm. The yielded pellet was then resuspended with 3 mL of cold saline solution (0.85 % NaCl 
in H2O w/v) and OD was noted, with consequent centrifugation at 10 °C at 4500 rpm. The 
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samples were stored at −80 °C after the cellular metabolism was rapidly quenched with liquid 
N2. After thawing, the samples were centrifuged at 10 °C at 4500 rpm. The yielded pellet was 
then washed with 4 mL of cold saline solution (0.85 % NaCl in H2O w/v) with consequent 
centrifugation at 10 °C at 4500 rpm. All samples were adjusted to an OD600 of 1. The samples 
were centrifuged and 70 µL of a chloroform/methanol/water (1: 3: 1) mixture was added. The 
extractions involved four freeze-thaw cycles with periodic vortexing. After final centrifugation 
at 4500 rpm, 60 µL of the particle-free supernatant was transferred into a micro centrifuge tube. 
An additional extraction with 50 µL of chloroform/methanol/water (1: 3: 1) was done and the 
new supernatant, after final centrifugation, was combined with the supernatant from the first 
extraction. From this mixture, 50 µL were transferred into an HPLC vial containing a 0.2 mL 
flat-bottom micro insert for FIE-HRMS analysis (See 2.2).  
 
Metabolomics data annotation: MetaboAnalyst 4.0. - Statistical analysis (Chong et al., 2018) 
was used to perform principal component (PCA). MetaboAnalyst 4.0 - MS peaks to 
pathway(Chong et al., 2018) was used to identify metabolites (tolerance = 3 ppm) and 
significant affected metabolic pathways (model organism = S. aureus). MetaboAnalyst 
pathway identification is based on mummichog, an algorithm able to predict biological activity 
directly from mass spectrometry data, avoiding the a priori identification of metabolites (S. Li 
et al., 2013). Mummichog plots all possible matches in the metabolic network and then looks 
for local enrichment, providing reproduction of true activity, as the false matches will distribute 
randomly (S. Li et al., 2013). Examples of key-metabolites in local enrichment were analysed 
for significant difference (t-test) between control and treatment using Microsoft Excel.  
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6.4. RESULTS 
In this study, intracellular metabolic profiles were exploited to investigate the impact of 
antibiotic compounds with different known cellular targets on the metabolome 
of Staphylococcus aureus USA300 in comparison to the anti-MRSA compounds obtained from 
D. crassirhizoma. Alterations within the metabolic pool represent the physiological status of 
the bacteria as the result of the adaptive cascades comprising both the transcriptome and 
proteome levels. Moreover, metabolites with regulatory and signaling functions act as 
important links between the metabolome, gene transcription, and protein biosynthesis. Thus, 
to understand the mode of action of A3 and A5 its metabolic response of MRSA was compared 
to a range of antibiotics, which were selected based on their different targets (Table IX). 
 




RNA - Binds 50S subunit (L16) or rRNA inhibiting protein synthesis. 
Gentamicin (G), 
RNA - aminoglycoside - Binds 30S subunit (S12) of rRNA misreading mRNA and 
incorrect amino acid insertion. 
Levofloxacin (L), 
DNA - 4-quinolone - Inhibition of the enzyme topoisomerase II (DNA gyrase) & 
IV preventing DNA replication and transcription (Drlica & Zhao, 1997). 
Nalidixic acid (N), 
DNA - 4-quinolone - Inhibition of the enzyme topoisomerase II (DNA gyrase) & 
IV preventing DNA replication and transcription (Drlica & Zhao, 1997). 
Streptomycin (S) 
RNA - Binds 30S subunit (S12) of rRNA misreading mRNA and incorrect amino 
acid insertion. 
Vancomycin (V), 
Cell Wall - Prevents incorporation of N-acetylmuramic acid (NAM) and N-
acetylglucosamine (NAG) peptide subunits from being incorporated into the 
peptidoglycan matrix. In addition, altering bacterial-cell-membrane permeability 
and RNA synthesis. 
Standardisation of antibiotic treatments: This mode of action study included comparison 
with other antibiotics which have difference MICs (Table X). Antibiotic treatments need to be 
standardized so that each antibiotic is having an equal suppressive effect on the bacterial 
growth over 6 h. In addition to the standardisation of treatments, a more concentrated bacterial 
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culture was required for metabolomics as 1x108 CFU/mL was found to be insufficient 
concentration of metabolites after extraction for metabolomic analysis. Therefore, initial 
experiments were carried out to calculate the antibiotic concentrations required to suppress 
bacterial growth by 50% at 6 h following inoculated (MIC50) and also aby 90% at 24 h 
following inoculation (MIC90).  
Table X: Standardisation of antibiotics based on MIC. 
Concentration of antibiotic required to inhibit growth of USA300 MRSA at 24hours and by 50% over 6 hours at a bacterial 
concentration of 1x108 CFU/mL. Note: HB5d/e5 (A5), Hb5d/e3 (A3), chloramphenicol (CH), Gentamicin (G), levofloxacin 
(L), nalidixic acid (N), streptomycin (S), vancomycin (V). 
Compounds MIC90 24h (µg/mL) MIC50 6h (µg/mL) 
A5 12.5 0.1 
A3 6.25 0.49 
L 0.17 0.49 
S 125 0.166 
V 1.33 0.33 
CH 3.90 1.95 
N 31.25 7.8125 
G 7.81 0.49 
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Transmission electron microscopy: Phenotypic changes in cells after drug treatment can give 
a broad indication of the possible mode of actions. Therefore, TEM was initially used to 
visualise the effect of A3 and A5 on MRSA cells. Two different concentrations were assessed. 
The lower concentration of both A3 and A5 was the MIC50 value at 6h (0.49 µg/mL and 0.1 
µg/mL respectively) and the higher concentration was the MIC90 value at 24h (6.25 µg/mL and 
Figure 6.3: Transmission electron microscope images of MRSA:USA 300 treated with two 
different concentration of A3 and A5  
Left: low concentrations: MIC50 of 6h, right: high concentration: MIC90 of 24h; Arrow shows the 
cell membrane disruption and lysis. 
A5: MIC90 of 24h 
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12.5 µg/mL respectively) (Table X). These two concentrations were added individually to 
exponentially growing MRSA cultures and the cells were harvested after 4 h. It should be noted 
that this would result in microbial populations where a proportion of cells would still be viable. 
Another set with no antibiotics containing cells from the same culture and growth time was 
treated as a control. TEM of the control MRSA showed the expected rounded cells (Figure 
6.3). At the lower concentrations of A3 (MIC50) there was no appreciable difference to the 
controls and there was evidence of cell division occurring in this sample as evidenced by the 
formation of internal septa. Increasing the concentration to MIC90 had clear effects with no 
sign of septa formation but instead they were signs of cell membrane degradation as indicted 
by the electron-dense structures linked to the outer envelope (Figure 6.3, arrowed). Considering 
A5, the (MIC50 value) had little observable effect on cellular structure. However, increasing the 
concentration to the MIC90 value resulted in complete rupture of some cells (Figure 6.3, 
arrowed). 
Metabolomics: Using the antibiotic concentrations required to suppress 50 % of MRSA 
growth at 6 h (Table X), a series of cultures were initiated treatment with these concentrations 
along with untreated controls. Samples were harvested at 0, 2, 4 and 6 h for the treated and 
control and prepared for metabolomic assessment. Metabolites derived from treated vs control 
MRSA were profiled by using FIE-HRMS in negative and positive ionization modes.  
Unsupervised PCA indicated that the MRSA metabolome following treatment with fraction 
A3 at 2, 4 and 6 h was quite distinct from those of established antibiotics considering their 
mode of action (Figure 6.5). It was notable that the metabolomes of the established antibiotics 
clustered together and were therefore fundamentally similar, irrespective of their different 
models of action. This did not arise from the MRSA cells being all dead, as the concentrations 
of antibiotic only suppressed bacterial growth by 50 % at 6 h (Table X). A similar examination 
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Figure 6.4: Principal component analysis (PCA) of antibiotic treated MRSA metabolomes. 
PCA score plots (95% confidence interval illustrated, clear outliers removed) of normalized m/z 
intensities of metabolites extracted from MRSA treated with A3 and compared to control bacteria 
(CC) and to bacteria treated with antibiotics with similar mechanism of action, grouped into those 
with activity on cell wall (vancomycin, CW), on DNA (Levofloxacin and Nalidixic acid) and on RNA 
(Chloramphenicol, Gentamicin and Streptomycin) for both positive and negative mode. for time 
points 0,2,4 and 6 h. Plots indicate metabolome differences between treatment groups based on 
metabolite features detected by flow infusion electrospray high-resolution mass spectrometry 
(FIE-HRMS). 
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Further investigations aimed to assess the potential of metabolomics to indicate mode of actions 
of established antibiotics. Thus, the metabolites significantly different between control and 
Figure 6.5: Principal component analysis (PCA) of antibiotic treated MRSA metabolomes. 
PCA score plots (95% confidence interval illustrated, clear outliers removed) of normalized m/z 
intensities of metabolites extracted from MRSA treated with A5 and compared to control bacteria 
(CC) and to bacteria treated with antibiotics with similar mechanism of action, grouped into those 
with activity on cell wall (vancomycin, CW), on DNA (Levofloxacin and Nalidixic acid) and on RNA 
(Chloramphenicol, Gentamicin and Streptomycin) for both positive and negative mode. for time 
points 0,2,4 and 6 h. Plots indicate metabolome differences between treatment groups based on 
metabolite features detected by flow infusion electrospray high-resolution mass spectrometry 
(FIE-HRMS). 
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treated with the listed antibiotics at different time points were mapped on to KEGG pathway 
using the “MS peaks to pathway” function on MetaboAnalyst 4.0. 
Chloramphenicol is known to block peptidyl transferase activity by hindering the binding of 
tRNA to the A site (Moazed & Noller, 1987). Figure 6. 6 shows the vast majority of the 
significantly affected pathway involves amino acids and aminoacyl tRNA biosynthesis a clear 
indication of the effect of chloramphenicol on MRSA cells. It also shows cell dysregulation in 
pathways involved in general cellular homeostasis and energy metabolism such as butanoate 
metabolism and CoA biosynthesis. 
Figure 6. 6: MRSA metabolic networks affected by Chloramphenicol. 
All the significantly affected pathway (p<0.15) based on the increasing p.value of negatively ionised 
metabolites. Amino acids are coloured in red; carbohydrate metabolism as black, and energy 
metabolism as light blue (when compared to the control MRSA samples). 
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Streptomycin causes mismatches between codons and anticodons, leading to faulty proteins 
that insert into, and disrupt, cytoplasmic membranes. Figure 6. 7 indicates the significant effect 
in the aminoacyl tRNA biosynthesis, amino acid pool along with lysine biosynthesis of MRSA 
when treated with streptomycin. As with chloramphenicol, these amino acid changes appeared 
to align with the established mode of action for streptomycin.  
  
Figure 6. 7: MRSA metabolic networks affected by Streptomycin 
All the significantly affected pathway (p<0.15) based on the increasing p.value value of negatively ionised 
metabolites. Amino acids are coloured in red; energy metabolism as light blue (when compared to the 
control MRSA samples). 
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Gentamicin being in the same class of aminoglycoside antibiotic as streptomycin and 
chloramphenicol binds to the 16s rRNA at the 30s ribosomal subunit, disturbing the translation 
of mRNA(Beganovic et al., 2018) and, thus, leading to the formation of truncated or 
nonfunctional proteins. Significant effect on the amino acid pool of MRSA cells on treatment 
with gentamycin is clearly indicated in both negative and positive ionisation mode metabolites 
(Figure 6. 8 and Figure 6. 9). It was also noted in Figure 6. 9 that there was a change in 
nucleotide (purine) biosynthesis. Amino acids, particularly, glutamate and glutamine, feed into 
the de novo biosynthetic path for nucleotides and perturbations of this effect could be being 
observed here.  
 
  
Figure 6. 8: MRSA metabolic networks affected by Gentamicin. 
All the significantly affected pathway (p<0.15) based on the increasing p.value of negatively ionised metabolites. 
Amino acids are coloured in red and energy metabolism as light blue (when compared to the control MRSA samples). 
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Nalidixic acid selectively inhibits the activity of bacterial DNA gyrase, blocking DNA 
replication. Figure 6.10 and Figure 6.11 shows the effect on nucleotides, amino acid pool, and 
cell dysregulation.  
 
 
Figure 6. 9: MRSA metabolic networks affected by Gentamicin. 
All the significantly affected pathway (p<0.15) based on the increasing p.value of positively ionised metabolites. 
Amino acids are coloured in red and Nucleic acid pathways as yellow (when compared to the control MRSA 
samples). 
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Figure 6.10: MRSA metabolic networks affected by Nalidixic acid. 
All the significantly affected pathway (p<0.15) based on the increasing p.value of negatively ionised 
metabolites. Amino acids are coloured in red; carbohydrate metabolism as black, and energy metabolism as 
light blue (when compared to the control MRSA samples). 
Figure 6.11: MRSA metabolic networks affected by Nalidixic acid. 
All the significantly affected pathway (p<0.15) based on the increasing p.value of positively ionised 
metabolites. Amino acids are coloured in red; cofactor and vitamin metabolism as blue, and nucleotide 
metabolism as yellow (when compared to the control MRSA samples). 
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Levofloxacin a fluoroquinolone generally targets chromosome replication and in particular, 
DNA gyrase, which allows DNA unravelling before replication (Figure 6.12). 
  
Figure 6.12: MRSA metabolic networks affected by Levofloxicin. 
All the significantly affected pathway (p<0.15) based on the increasing p.value of negatively ionised 
metabolites. Amino acids are coloured in red; carbohydrate metabolism as black, fatty acid metabolism as pink 
and energy metabolism as light blue (when compared to the control MRSA samples). 
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A3 at different time points which significantly differ from control and other antibiotics. They 
are further mapped on the KEGG general metabolism map. It was notable that the vast majority 
of the significantly affected pathway involved glycolysis (Figure 6.13). To provide further 
insights into the effects of A3 on MRSA metabolism, the significantly differing metabolites 
were mapped on to heatmap in order to compare to untreated control are shown in Figure 6. 
14. 
 
Figure 6.13: MRSA metabolic networks affected by A3. 
All the significantly affected pathway (p<0.15) based on the increasing p.value of negatively ionised 
metabolites. Glycolysis pathway as black when compared to the control MRSA samples. 
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A5 significantly effects variety of metabolic pathways including amino acids, fatty acid 
metabolism, nucleotide metabolism, carbohydrate metabolism and energy metabolism as 
observed in Figure 6. 15 and Figure 6. 16. 
Figure 6. 14: Heatmap of all the significantly different metabolite changes of glycolysis and 
gluconeogenesis pathway happening at different time points in both treated (A3) and non-treated 
cells (CC). 





Figure 6. 15: MRSA metabolic networks affected by A5. 
All the significantly affected pathway (p<0.15) based on the increasing p.value of negatively ionised 
metabolites. Amino acids are coloured in red; fatty acid metabolism as pink; cofactor and vitamin metabolism 
as blue; energy metabolism as light blue and carbohydrate metabolism as black (when compared to the control 
MRSA samples) 
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To provide further insights into the effects of A5 on MRSA metabolism, the significantly 
differing metabolites effecting different pathways were mapped on to heatmap in order to 
compare levels to untreated control are shown in Figure 6. 17 and Figure 6. 18. 
 
 
Figure 6. 16: MRSA metabolic networks affected by A5. 
All the significantly affected pathway (p<0.15) based on the increasing p.value of positively ionised metabolites. 
Amino acids are coloured in red; fatty acid metabolism as pink; cofactor and vitamin metabolism as blue; 
nucleotide metabolism as yellow and carbohydrate metabolism as black (when compared to the control MRSA 
samples). 
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A B 
Figure 6. 17: Metabolite changes of MRSA treated with A5 in comparison to untreated cells 
A: Heatmap of all the significantly different metabolite changes happening at different time points in both treated (A5) and non-treated cells (CC) in fatty acid 
metabolism; B: Heatmap of all the significantly different metabolite changes happening at different time points in both treated (A5) and non-treated cells (CC) in 
carbohydrate metabolism. 
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A B 
Figure 6. 18: Metabolite changes of MRSA treated with A5 in comparison to untreated cells 
A: Heatmap of all the significantly different metabolite changes happening at different time points in both treated (A5) and non-treated cells (CC) in nucleotide 
metabolism; B: Heatmap of all the significantly different metabolite changes happening at different time points in both treated (A5) and non-treated cells (CC) in 
energy metabolism. 
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The metabolism map with the metabolites of the treated cells suggest that A3 specifically 
affected the glycogenesis pathway. We can also notice that the downregulation of metabolite 
takes place at 2h indicated by the heatmap. While in case of A5, we see several other pathways 
been affected namely fatty acid metabolism, nucleotide metabolism and energy metabolism 
along with carbohydrate metabolism downregulation at 2h and the presence of common 
metabolites such as acetic acid and phosphoenolpyruvic acid in the carbohydrate metabolism 
could be due to the presence of similar compounds. 
Observing the overall metabolite changes and the pathways related it can be assumed that A3 
massively alters the central metabolism of MRSA. While in case of A5, effects on carbohydrate 
metabolism including lactic acid production suggest that a switch to anaerobic respiration. 
Alongside metabolites changes in purine biosynthesis. 
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6.5. DISCUSSION 
In Chapter 5, HB5d/e3(A3) and HB5d/e5 (A5) was demonstrated to have a substantial 
antimicrobial activity against MRSA, thus it was important to understand their mode of action. 
Understanding the effects of any antibiotic could be aided if any impact were seen on the 
ultrastructure of the bacterial cell wall (Alharbi et al., 2017). One method to assess such effects 
is to use TEM to observe morphological changes in bacterial cells provides useful insights into 
the mechanism underlying the activity of antibacterial agents (Joung et al., 2014). When 
bacteria cells were treated with A3 and A5, cell membrane disintegration, cell lysis, and release 
of cytoplasmic contents were observed (Figure 6.3) and the ultrastructural impact on bacteria 
cells indicated A3 had stronger antibacterial effects than A5. 
Our group has recently applied metabolomic approaches to define the mode of action the 
pretomanid, a promising anti-tubercular drug currently at clinical phase III. Therefore, 
metabolomic approaches were employed to define possible modes of action for A3 and A5 on 
MRSA. We also compared the metabolomic effects of A3 and A5 with those of other 
antibiotics whose mode of action was more clearly established (Table X). This aimed to link 
the metabolomic effects on either A3 and A5 with a particular antibiotic and thereby suggest a 
common mode of action. In the event, the metabolomic approach failed to discriminate between 
the impacts of the established antibiotics on the MRSA metabolomes, even though their modes 
of actions were very different (Table X). This could indicate that in these instances the MRSA 
metabolomes were reflecting a common stress response by the bacteria. However, mapping the 
significant metabolite changes between the antibiotics and controlled cell, directed towards the 
potential mode of action for the antibiotics (Figure 6. 6-Figure 6.12).  
In this study, we were interested in the metabolic changes brought about by A3 and A5 in the 
MRSA. We performed extensive characterization and identification of the derived 
metabolomes, mostly using MetaboAnalyst and the resources of the KEGG database 
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(https://www.genome.jp/kegg/).  On mapping the significant metabolites effected by A3 onto 
the general metabolic pathway of S. aureus we found that glycolysis intermediates —such as 
phosphoenolpyruvate (PEP) and 3-phosphoglycerate (3-PG)—had highly decreased levels in 
cells treated with A3. Although the levels of lactate remain unaffected. Interestingly, the levels 
of pyruvate were increased at 2h and 6h, and the secretion of this metabolite to the medium 
was also elevated in infected cells (Figure 6. 14). This is suggestive of an upstream block 
explaining the accumulation of pyruvate. While the nature of this block is unknown, potential 
targets could be (partial) inhibition of pyruvate kinase and/or the pyruvate dehydrogenase 
complex. 
However, mapping of metabolites effected by A5 onto the general metabolic pathway of S. 
aureus suggested its effects on carbohydrate metabolism as well as different other pathways, 
including fatty acid metabolism, nucleotide metabolism and energy metabolism. Our results 
showed that upstream metabolite succinate and downstream metabolite fumarate and malate 
detected increased levels in TCA cycle, indicating that the TCA pathway might be disrupted 
and thus in turn effects the energy metabolism at 2h. The presence of lactic acid indicates 
anaerobic conditions been created at 2h (Krebs, 1937).   
Purine biosynthesis contributes to the synthesis of DNA and RNA which, in turn, drives the 
synthesis of proteins, decreased levels of upstream metabolites such as Ribose-5-phosphate 
and AICAR indicate disruption in the nucleotide synthesis at 2h. While increased levels of 
guanine and guanosine indicated alteration in purine nucleoside phosphorylase enzyme at 4h. 
Overall evaluation of the related pathways indicated and the significant metabolite changes, it 
can be assumed that that A3 might alter pyruvate levels in the cells resulting in affecting the 
overall glycolysis pathway. While A5 results in creating an anaerobic condition thus utilizes 
energy production through TCA cycle. Confirmation of these modes of action could entail 
assays of the purified enzymes. However, it is was confirmed that would represent a novel 
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mode of action not shared by the established antibiotics considered here or the anti-MRSA 
drugs described in the introduction.   
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6.6. CONCLUSION 
Although it is currently not unequivocally established how A3 and A5 cause the observed 
MRSA cell death, our metabolomic approach suggested some candidate mechanisms. To what 
extent these factors are responsible for the main effects or are so-called off-target effects needs 
further research. Equally, our time course analyses were too crude to define which effect could 
be happening first and would probably require the use of label substrates and timepoints 
gathered seconds after application of A3 and A5. However, these could confirm that A3 and 
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The use of Traditional Chinese medicine (TCM) has been extensively documented over 
thousands of years (Kuriyama, 1988), as does the use the Indian Ayurveda system which dates 
back to the 1st millennium BC (Patwardhan, 2005). The Western world knowledge is mainly 
based on the Greek and Roman culture where medicinal plants were only applied on an 
empirical basis, without the knowledge on their pharmacological activities or active 
constituents (Roche, 2006). It was only in the 18th century that Anton von Störck, who 
investigated poisonous herbs such as aconite and colchicum, and William Withering, who 
studied foxglove for the treatment of oedema, laid the basis for the rational clinical 
investigation of medicinal herbs (Roche, 2006). drug discovery from plants started at the 
beginning of the 19th century, when the German apothecary assistant Friedrich Sertürner 
succeeded in isolating the analgesic and sleep-inducing agent fromopium which he named 
morphium (morphine) (Sertuerner, 1817). This triggered the examination of other medicinal 
herbs, and during the following decades of the 19th century, many bioactive natural products, 
primarily alkaloids (e.g., quinine, caffeine, nicotine, codeine, atropine, colchicine, cocaine, 
capsaicin) could be isolated from their natural sources.  
However, several challenges contribute to the decline of plant-derived natural products as drug 
discovery source. The first important challenge is the accessibility of the starting material 
considering the ecological and legal considerations especially laws dealing with plant access 
and sharing of benefits, and patentability issues with local governments in the countries of 
origin. Thereafter, often the available content of natural products is low insufficient for testing 
for a wide range of biological activities. Besides the accessibility of the plant material, also its 
quality that is of great importance, available plant material often varies on quality and 
composition and this can hamper the assessment of its therapeutic claims. Although, a detailed 
knowledge of the interaction of a drug candidate compound with its molecular target is 
advantageous for the drug development process, but working on plants makes it challenging to 
determine the precise molecular mechanism of action of natural products (Corson & Crews, 
2007). 
In this study we examined TCM’s for its antimicrobial properties. This involved the use of 
several different methodologies were employed in addition to the usual bioactivity guided 
fractionation strategy. Thus, to overcome the problem of availability of the plant material and 
low quantity of isolated natural product we tried to establish a method using metabolomics to 
identify bioactives in a low quantity plant extract. This type of approach has not been used 
before and can provide novel relevant insights. Additionally, we sought to use computational 
and metabolomic approaches to understand the interaction between cells and the drug 
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candidate. These were used to suggest mode of actions that could be used to develop the 
isolated product into a potential drug lead.  
Our first approach was to select TCM’s relevant to our study. Our collaborators in China 
provided us with a list of names randomly selected on the basis of their availability. Although 
randomly selected plants could have been advantageous in assessing biochemical diversity, but 
we preferred undergoing a knowledge-based approach, where the TCM’s had previous 
traditional use and some crude scientific data. Based on the ethnopharmacological data, we 
selected 16 plants and 2 fungal species to screen for antimicrobial components (Chapter 3). As 
the TCMs were commercially obtained by our collaborators it was essential to authenticate 
them. We used DNA barcoding approach to authenticate the material where we came across 
several mislabeling which were confirmed with the difference in their biological activities.  
It had been previously reported that although the antimalarial agent artemisinin itself is not 
active against tuberculosis, conjugation to a mycobacterial-specific siderophore analogue 
induces significant and selective anti-tuberculosis activity, including activity against multi-and 
extensively drug-resistant strains of Mycobacterium tuberculosis (Miller et al., 2011). This led 
us to explore Artemisia annua as a source of antimycobacterial components, as A. annua 
produces several artemisinin derivatives in its natural pathway (Chapter 4). We took the 
traditional approach to start pharmacological testing with crude extracts and subsequently 
isolate and characterize the constituents responsible for the activity of the extract. We selected 
solvent from non-polar to polar for the crude extraction, crude extracts exhibiting biological 
activity are subjected to iterative bioactivity-guided fractionation cycles until the respective 
pure bioactive compounds are identified. Two artemisinin derivatives were isolated with some 
antimycobacterial activity (dexyartemisinin:0.5 µg mL-1 artemisinic acid:0.5 µg mL-1). A. 
annua had not been previously examined for its antimycobacterial properties. However, the 
problem we faced here were the low insufficient quantity of the compounds to use in mode of 
action studies. We did attempt to obtain more starting material from a different source but there 
was a difference in the pharmacological data of the crude extract (Chapter 3). Another problem 
was that we observed an increased MIC after fractionation, this may be the result of synergistic 
interactions being isolated in different fractions. We undertook computational modeling to 
predict a drug target for both the compounds among known six mycobacterial targets, which 
suggested that MtKasA could be a drug target for artemisinic acid.  
The next plant that was worked on was Dryopteris crassirhizoma Nakai traditionally used for 
viral treatments (Chapter 5). Phytochemical studies have shown that D. crassirhizoma is rich 
in triterpenes, flavonoids and phloroglucinols. Based on the anti-MRSA data obtained while 
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screening the crude extract in chapter 3, we undertook bioassay guided purification to find the 
key metabolites same as we did for A. annua. Unfortunately, even after undergoing successive 
series and different methodologies of chromatographic separation, we failed to isolate a pure 
compound to that it could be identified by NMR. However, given the substantial anti-microbial 
activity, we attempted to identify the targeted key metabolites using UHPLC-MS and tandem 
mass spectroscopy (MS2/MS3) data. Comparison of the data with several literature we 
identified them as phloroglucinol derivatives norflavaspidic acid AB and flavaspidic acid AB. 
Although flavaspidic acid AB has been previously reported to have anti-MRSA activity (MICs 
ranging between 12-20 µg/mL), this was the first time that his has been reported for 
norflavaspidic acid AB. Thus, it was essential to investigate the mode of action of 
norflavaspidic acid AB and flavaspidic acid AB. We intended to undergo cytotoxic and 
antischistosoma assessments as described chapter 4, but these were not undertaken due to time 
restrain. 
Metabolomics approaches are increasingly playing important role in drug discovery. Unlike 
targeted approaches, nontargeted metabolomics allows the detection and analysis of large 
numbers of features, providing a fingerprint or ‘global profiling’ of the sample being studied. 
In this thesis, this approach was followed to describe microbial pathways disturbed by a drug, 
after metabolomics analysis by FIE-HRMS. We intended to explore this property of 
metabolomics in identifying key metabolites responsible for the activity. In chapter 5 we came 
across several active fractions (MIC<50 µg/mL) of D. crassirhizoma, the best (HB fraction) 
one was chosen for the traditional way to isolate pure compound, while another fraction (HL 
fraction), due to its availability, and difference in polarity was chosen to identify compounds 
via metabolomics. One step of column chromatography followed by FIE-HRMS was 
undertaken. Based on statistical tests done using MetaboAnalyst, searching the databases and 
previous literature, 3 compounds were identified filixic acid ABP, flavaspidic Acid AB, and 
dryocrassin ABBA. This approach was taken mainly to focuses on the fact that the bioactivity 
of a plant extract may be the result of synergistic interactions of several components, and in 
this case bioactivity guided fractionation might fail, as observed in case of A. annua. However, 
more research is needed in this direction in understanding the stability and enhanced 
bioavailability in the extract. 
The use of metabolomics in drug target discovery is considered as central for an effective 
investigation for new antibiotics against multi-resistant microorganisms. This approach has 
been previously demonstrated in our group where a new mode of action was determined for 
anti-mycobacterial pretomanid (Baptista, Fazakerley, et al., 2018). We used the same approach 
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with some modifications to understand the mode of action of the fraction HB5d/e3 and 
HB5d/e5 containing different concentrations of norflavaspidic acid AB and flavaspidic acid 
AB (Chapter 6). Flow infusion ionization electrospray high-resolution mass spectrometry (FIE-
HRMS) and biochemical pathway assessment indicated the anti-MRSA activity of HB5d/e3 
was strictly linked to the central glycolysis pathway, possibly including the inhibition of 
pyruvate kinase and/or the pyruvate dehydrogenase complex. While HB5d/e5 showed the 
effect on variety of metabolic pathways including amino acid biosynthesis, nucleotide 
biosynthesis, fatty acid biosynthesis and energy. Considering the concentration of 
norflavaspidic acid AB and flavaspidic acid AB in both the fractions, HB5d/e3 shows higher 
quantity of norflavaspidic acid AB, while HB5d/e5 shows equal quantity of both compounds. 
Presence of similar metabolite changes of the central metabolism in the biochemical pathway 
assessment of both the fractions suggests that the anti-MRSA activity of norflavaspidic acid 
AB might be selectively affecting the glycolysis pathway to influence the bacterial bioenergetic 
metabolism.   
Glycolysis is an important process of ATP generation via the substrate level of 
phosphorylation. The breakdown of glucose generates more ATP in oxidative phosphorylation 
while the same monosaccharides produce only two net ATP in glycolysis (Flamholz, Noor, 
Bar-Even, Liebermeister, & Milo, 2013). Also, it has been reported that glycolytic enzymes 
constitute a large fraction of microbial proteomes and lowering their levels (i.e., by using the 
Entner-Doudoroff Pathway (ED Pathway) as an alternative to glycolytic pathway) could allow 
cells to increase their growth rate. Thus, there could be a tradeoff between a glycolytic 
pathway’s ATP yield and the growth rate it can support. It should be noted that glycolytic 
metabolites were increased with A3 treatment. This could be linked to a suppression of 
bacterial growth. However, this needs to be further investigated to confirm the exact or multiple 
enzymes effected by the A3. 
In summary, against all the challenges faced throughout this project’s results and findings was 
to revisit traditional medicine and using western approaches to of their effective use of as 
antimicrobials. Our pipeline for the analysis of commercially brought TCM’s (Chapter 3) 
attempts to overcome some challenges usually faced working with plant based natural products 
and was successfully in certain cases. Given more time and resources, various other aspects of 
the study could have been improved such as the major drawbacks in this study was the 
incomplete databases with ethnopharmacological information of medicinal plant, mainly due 
to language barriers in terms of literature studies and restricted access to Chinese websites. 
These barriers prevent the ready assessment of compounds that could be therapeutically 
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effective in humans. Using untargeted metabolomics solely has challenges such as robust and 
rapid compound identification, more complete metabolome coverage hinder confidence in this 
approach and its widespread adoption. Thus, undergoing validation of the metabolites and 
pathways using functional genomics, proteomics and in-silico approaches are required.  
Future work, needs to purify norflavaspidic acid AB and flavaspidic acid AB to high yields so 
that cytotoxicity studies and animal studies can be attempted. The latter could incorporate 
pharmacokinetic studies that are required to consider these as potential drug leads. Of equal 
importance is the use of genomics and molecular docking so that mode of action studies can 
be undertaken. These should inform the design and testing of derivative molecules. This is 
important as neither norflavaspidic acid AB and flavaspidic acid AB conforms to the Lipinski's 
rule of five which is used to evaluate drug likeness or an orally active drug in humans(Lipinski, 
Lombardo, Dominy, & Feeney, 2012). This point notwithstanding, this study has demonstrated 
how scientific approaches can be employed to define the molecular basis of medicinal 































159 | P a g e  
8.1. PUBLICATIONS 
 
§ Bhowmick et al. (2020) 
Bhowmick S, Baptista R, Fazakerley D, Whatley KCL, Hoffmann KF Shen J, Mur LAJ. (2020) 
The anti-mycobacterial activity of Artemisia annua L is based on deoxyartemisinin and 
artemisinic acid. (In preparation) 
Abstract 
The development of anti-parasitic artemisinin from Artemisia annua L. is an example of how 
Traditional Chinese Medicine (TCM) may be exploited to meet a recognized need. We 
systemically investigated A. annua for its antimicrobial activity which has not previously 
reported. In this study, we assessed A. annua as a source of bioactive natural products for anti-
mycobacterial activity. 
Anti-mycobacterial activity-guided purification of the A. annua leaf on a silica gel column and 
structure elucidation using UHPLC-HRMS and NMR resulted in the identification of active 
compounds. Crude extracts, isolated compounds and artemisinin (Apollo Scientific Ltd) used 
as positive control were assessed against Escherichia coli, Pseudomonas aeruginosa, 
Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium 
smegmatis strains by serial micro dilution method (31.25-1000 µg/mL). Anthelmintic activity 
of isolated compounds and artemisinin against Schistosoma mansoni was analyzed by the 
Roboworm anthelmintic discovery platform. The isolated compounds were tested for 
synergistic effects against mycobacterium. We also used a molecular docking approach to 
investigate the interactions between selected anti-mycobacterial compounds and proteins 
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involved in vital physiological functions in M. tuberculosis, namely MtPks13, MtPknB, 
MtPanK, MtKasA, MtInhA and MtDprE1. 
Identity of A. annua was confirmed by rbcL DNA barcoding, bioactive compounds were 
purified and identified as deoxyartemisinin and artemisinic acid. Artemisinic acid (MIC 250 
µg/mL) was more effective in comparison to deoxyartemisinin (MIC 500 µg/mL) and 
artemisinin (MIC 1000 µg/mL) against M. smegmatis. These did not exhibit any anthelmintic 
activity against S. mansoni. The docking score for ligands towards each protein was calculated 
to estimate the binding free energy, with the best docking score (lowest energy value) 
indicating the highest predicted ligand/protein affinity. Artemisininc acid. Considering the 
MIC, artemisinic acid showed docking scores superior to the control inhibiters for MtKasA, 
and can be a potential nick for further in vitro biological evaluation and anti-TB drug design. 
§ Bhowmick et al. (2020) 
Bhowmick S, Baptista R, Han J, Li F, He W, Shen J, Mur LAJ. (2020) Traditional Chinese 
medicinal herbs: a potential source of anti-microbials (In preparation) 
Abstract 
Ethnopharmacological relevance: With the increased emergence of antimicrobial resistant 
bacterial strains, it is important to find new drugs. Identifying drug leads from natural products 
has proven to be an important strategy in anti-infectious drug research. Natural products have 
a privileged role in drug discovery due to their intrinsic cell permeability, structural diversity, 
rich functionality and stereochemistry. They also provide scaffolds for further drug 
optimisation towards increased potency and selectivity. China has been using herbs in medicine 
for centuries (Traditional Chinese Medicine) and these are now attracting global interest 
information regarding their use is often inaccessible to the wider scientific community 
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Aim of the study: Our project focused on 18 Chinese herbs, traditionally used to treat 
infections, which were assessed for their anti-microbial properties. 
Materials and Methods: Following interrogation of Chinese sources, commercially sourced 
samples of targeted species were assessed using rbcL and ITS barcoding. Extracts with 
different polarities for selected species were screened for their anti-microbial activity against 
E. coli, S. aureus, methicillin-resistant S. aureus, M. smegmatis, P. aeruginosa and C. albicans 
using the 96-well plate micro-dilution method. 
Results and Discussion: DNA barcoding indicated that some herb samples were mislabelled. 
In vitro studies for anti-microbial activity demonstrated that some extracts showed activity 
against Gram-positive bacteria (S. aureus, methicillin-resistant S. aureus), M. smegmatis and 
C. albicans, while all tested Gram-negative bacteria were resistant to all the extracts. The 
highest activities were shown by n-hexane and ethyl acetate extracts of Dryopteris 
crassirhizoma against S. aureus and methicillin-resistant S. aureus (MIC= 6.25µg/mL) and n-
hexane fraction of Oldenlandia diffusa was against S. aureus (MIC= 62µg/mL). However, 
some samples exhibited sample-to-sample variation in activities. 
Conclusion: Our studies target new herb sources of anti-microbial activity that can be further 
characterised by the scientific community. We also show how rigour is required in sample 
identification if obtained from commercial sources and confirmation of activities from different 
sample sources is required before robust conclusions of any intrinsic anti-microbial activities 
can be made. 
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§ Bhowmick et al. (2020) 
Bhowmick S, Baptista R, Robert E, Bozhilova KS, Mur LAJ. (2020) Robust identification of 
bioactives using FIE-HRMS and UHPLC-HRMS. (In preparation) 
Abstract: 
Antimicrobial resistance is a global threat to the health systems and the individual well - being, 
for example, the methicillin - resistant strain of Staphylococcus aureus (MRSA) is known to 
cause over 11,000 deaths and 80,000 invasive infections every year. New antibiotics and 
antimicrobials are required but current strategies for their development is failing to keep up 
with demand. Therefore, researchers are searching for alternative sources for new antimicrobial 
substances and antibiotics. Eastern medicine and the traditional Chinese medicine have been 
proven effective against infections and diseases that the Western medicine is still developing 
cures for. The current research looks into the rhizomes of Dryopteris crassirhizoma - an 
evergreen fern that is known for its anti - inflammatory and antimicrobial properties. DNA 
barcoding, column chromatography and antimicrobial assays established that the authenticity 
of the plant and a n - hexane fraction exhibits the highest antimicrobial activity against two 
strains of S. aureus and MRSA. The n- hexane fraction underwent fractionation and one- 
designated - HL - was chosen to be further assessment. UPLC-MS and FIE-HRMS followed 
by metabolomic comparison of active and non-active sub-fractions of HL coupled with 
interrogation of databases lead to the tentative identification of some of the bioactives. Three 
compounds, flavaspidic acid AB, filixic acid ABP and dryocrassin ABBA were targeted as, in 
least in part, responsible for its antimicrobial activity against S. aureus and MRSA. Further 
purification using preparative-HPLC and tests such as IR, 1H- and 13C -NMR, 2D-NMR and 
circular dichroism (CD) are required for full structural elucidation. In conclusion the aim of 
this project was to find a rapid method for the tentative identification of bioactive compounds.  
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8.2. POSTER PRESENTATION 
 
§ Bhowmick et al. (2017) 
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§ Bhowmick et al. (2018) 
Abstract:
Traditional Chinese Medicines (TCM) ; derived following generations of practice
represent an excellent source of potential drug leads; but often these are poorly
characterised. We are Chinese-UK collaborative team that is aiming to define the
biochemical basis of anti-microbial and anti-parasite TCM, focusing on defining
mode-of-action (MoA) in order to provide a firm basis for drug development. We
have developed a robust discovery pipeline that 1) catalogues and validates
(through sequencing) targeted TCML 2) uses bioactivity based assays to identify
the biochemical basis of the TCM and 3) post/genomic approaches to define the
MoA.
Keywords: Traditional Chinese medicine, plant extracts, antimicrobial, natural
products.
Our collaborative team has examined the Chinese
literature to target TCM which have been used to
treat infectious disease or wounds.
The TCM is sources from Chinese sources and it
identity is confirmed by DNA ba coding based on
the rbcS gene for plants (Fig. 2A) and the rRNA
internal spacer region (ITS) for fungi (Fig 2B) . Our
TCM products are indicated in red.
Solvent extracted samples are tested for activity
in high throughput screens against clinical
relevant strains of
E.coli, Pseudomonas aeruginosa, Multi-drug
resistant Staphylococcus aureus (MRSA),
Mycobacterium smegatis. (Table 1)
The most highly active TCM are indicated in red.
Also against the parasite, Schistosoma mansoni ,
a water-borne parasite of humans, using the
Roboworm platform (left).
The active compounds  are
purified  through sequential 
Rounds of semi-preparative
HPLC and identified by NMR
and high resolution mass 
spectroscopy. 
Mode of action studies involve
Genetic assessment of derived 
TCM Resistant bacterial  mutants , proteomics and 
metabolomics  as we have recently demonstrated 
or pretomanid (Baptista  et al., 2018) ; as well as 
computer modeling of target interactions 
Introduction:
The traditional use of herbs as medicine in China dates back more than 3000 years.
TCM represent an important corpus of folk-medicine . The Chinese Materia
Medica describes thousands of medicinal substances primarily plants which are
often combined in formulas and given as teas, capsules, liquid extracts, granules,
or powders. TCM however, are often relatively uncharacterised using modern
pharmacological methods. As a result drug leads that could be developed to mean
globally important health issues; cancer, diabetes, Alzheimer's and infectious disease,
are missed. Further, innovation in -omic technologies, chemical biology and
genetics with the knowledge of TCM will help in the discovery of new drugs and new
drug targets. In this current work we describe how a Chinese- UK collaborative team
has developed a pipeline (Fig. 1) for anti-microbial and parasite TCM drug discovery.
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Figure1:  TCM bioactives discovery pipeline Plants Solvents E. coli P. aeruginosa S. aureus MRSA M. smegmatis C. albicans
n-Hexane 500 500 500 500 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 250 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 500 500
DCM 500 500 250 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 250 250 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 62.5 125 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 250 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 250 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 250 500
DCM 500 500 250 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 125 500 500 250
n-Hexane 500 500 500 500 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 500 500 500 500
DCM 500 500 500 500 500 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 250 250 250 500
DCM 500 500 500 250 250 500
EtOAc 500 500 500 500 500 500
MeOH 500 500 500 500 500 500
n-Hexane 500 500 15 15 500 500
DCM 500 500 125 62.5 500 500
EtOAc 500 500 31.25 15 500 500
MeOH 500 500 500 500 500 500


















TABLE 1 : Minimum inhibitory concentrations for targeted TCM  
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8.3. NON-THESIS RELATED OUTPUT 
 
§ Baptista et al. (2018)  
Baptista R, Bhowmick S, Nash RJ, Baillie L and Mur LAJ (2018). Target discovery focused 
approaches to overcome bottlenecks in the exploitation of antimycobacterial natural products. 
Future Medicinal Chemistry 10(7), 811-822.  
Abstract:  
Tuberculosis is a major global health hazard. The search for new antimycobacterials has 
focused on such as screening combinational chemistry libraries or designing chemicals to target 
predefined pockets of essential bacterial proteins. The relative ineffectiveness of these has led 
to a reappraisal of natural products for new antimycobacterial drug leads. However, progress 
has been limited, we suggest through a failure in many cases to define the drug target and 
optimize the hits using this information. We highlight methods of target discovery needed to 
develop a drug into a candidate for clinical trials. We incorporate these into suggested analysis 
pipelines which could inform the research strategies to accelerate the development of new drug 
leads from natural products. 
 
§ Crusco et.al. (2019) 
Crusco, A.; Baptista, R.; Bhowmick, S.; Beckmann, M.; Mur, L. A. J.; Westwell, A. D.; 
Hoffmann, K. F. The Anti-Mycobacterial Activity of a Diterpenoid- Like Molecule Operates 
through Nitrogen and Amino Acid Starvation. Front.Microbiol. 2019. 
https://doi.org/10.3389/fmicb.2019.01444. 
Abstract: 
A library of 14 minimally cytotoxic diterpenoid-like compounds (CC50 > 70 µM on HepG2 
human liver cells) was screened against Mycobacterium smegmatis, Staphylococcus aureus, 
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and Escherichia coli to determine antimicrobial activity. Some compounds with a phenethyl 
alcohol (PE) core substituted with a β-cyclocitral derivative demonstrated anti-mycobacterial 
activity, with the most active being compound 1 (MIC = 23.4 mg/L, IC50 = 0.6 mg/L). Lower 
activity was exhibited against S. aureus, while no activity was displayed against E. coli. Low 
cytotoxicity was re-confirmed on HepG2 cells and additionally on RAW 264.7 murine 
macrophages (SI for both cell lines > 38). The sub-lethal (IC50 at 6 h) effect of compound 1 
on M. smegmatis was examined through untargeted metabolomics and compared to untreated 
bacteria and bacteria treated with sub-lethal (IC50 at 6 h) concentrations of the antituberculosis 
drugs ethambutol, isoniazid, kanamycin, and streptomycin. The study revealed that compound 
1 acts differently from the reference antibiotics and that it significantly affects amino acid, 
nitrogen, nucleotides and folate-dependent one-carbon metabolism of M. smegmatis, giving 
some insights about the mode of action of this molecule. A future medicinal chemistry 
optimization of this new anti-mycobacterial core could lead to more potent molecules. 
 
§ Baptista et al. (2019) 
Baptista R, Fazakerley DM, Bhowmick S, Piński A, Pires D, Anes E, Catalão MJ, Macedo AR, 
Lloyd DG, Taylor EJ, Whatley KCL, Hoffmann KF, Nash RJ, Fernandez-Fuentes N, 
Beckmann M, Baillie L, Mur LAJ. (2018) Lupulone targets mycobacterial cell membrane 
homeostasis through interaction within the MlaDc subunit of the virulence factor mammalian 
cell entry. (In preparation) 
Abstract: 
Tuberculosis represents a major global threat due to the prevalence of both drug-resistant and 
multi-drug resistant TB strains. This requires the development of novel drug classes. Hop α-
acid lupulone has established activity against mycobacterial species and we here define it 
molecular target representing a novel mode of action. Subsequent to confirming lupulone’s 
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activity against Mycobacterium species including M. tuberculosis, we employed the model 
species M. smegmatis. Thus, we derived five spontaneously mutant lupulone-resistant M. 
smegmatis strains whose genomes were sequenced. Three mutations where observed that were 
consistently present in all strains: a hypothetical protein, an efflux pump and a component of 
the virulence factor mammalian cell entry (MCE) complex, MlaD subunit C. Only over 
expression with MlaDc in M. smegmatis could increase the minimum inhibitory concentration 
(MIC) against lupulone. Protein modelling revealed lupulone interaction sites that were 
abolished in mutated MlaDc alleles. MlaD is predicted to transport phospholipids to the 
bacterial inner membrane and metabolomic and lipidomic approaches indicated that lupulone 
imposed changes of M. smegmatis metabolism that were distinctive to any other tested 
antibiotics (linezolid, isoniazid, kanamycin, ethionamide, rifampicin and streptomycin) and 
perturbed phospholipid accumulations patterns. Thus, we have identified a new druggable 
target for anti-mycobacterial activity which mediates bacterial membrane processing. 
 
§ Molehin et al. (2018) 
Molehin O, Baptista R, Bhowmick S, Mur LAJ, Oloyede O. (2018) Clerodendrum volubile 
(P.) Beauv, a case study of a traditional West African medicinal plant with important 
pharmacological activities.(In Preparation) 
Abstract:  
Aim of the study: In this review, we provide an overview of C. volubile as an exemplar of a 
West African traditional medicinal plant highlighting its potential significance but equally the 
remaining challenges before it, and other medicinal plants, can be exploited. Materials and 
Methods: A review of the literature (ethnobotanical books and publications 
(published/unpublished resources) reporting traditional plant use in West Africa) was 
undertaken related to specific medicinal use for Clerodendrum volubile. An in-depth analysis 
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of earlier studies was undertaken and future considerations are highlighted. Results: Scientific 
studies on extracts of plants have suggested antioxidant, anti-inflammatory, antidiabetic, 
antihypertensive, hypoglycemic and hypolipidemic properties of the extracts of C. volubile. 
Isolated bioactives include protocatechuic acid, iridoid glycosides, pectolinagarin, biochanin 
which exhibit antidiabetic, anti-inflammatory, anti-carcinogenic and hepatoprotective 
activities. Therefore, whilst a few ethnobotanical claims for C. volubile have been validated by 
pharmacological studies, much more work is still required. Conclusions: As this situation is 
not unique to C. volubile, we suggest how West African medicinal plants could scientifically 
developed into an important international resource for potential drug leads. 
 
§ Baptista et al. (2020) 
Baptista R Bhowmick S, Mur LAJ. (2020) In silico approach to suggest molecular targets of 
selected anti-mycobacterial natural products (In preparation)  
Abstract:  
Tuberculosis (TB) is a major global threat mostly due to the development of antibiotic resistant 
forms of Mycobacterium tuberculosis, the causal agent of the disease. Driven by the pressing 
need for new anti-mycobacterial agents, several natural products (NPs) have been assessed for 
their in vitro against M. tuberculosis. However, the utility of any NP as a drug lead will be 
augmented if the anti-mycobacterial target(s) is unknown. To accelerate the develop of new 
NP-based drug lead, we used a molecular docking approach to predict the interactions of 53 
anti-mycobacterial NPs against known ‘druggable’ mycobacterial targets ClpP1P2, DprE1, 
InhA, KasA, PanK, PknB and Pks13. The docking scores / binding free energies- were 
predicted using AutoDock Vina were calculated along with physicochemical and structural 
properties of the NPs, using PaDEL descriptors. The specific interactions of the 
bisbenzylisoquinoline alkaloids 2-nortiliacorinine, tiliacorine and 13’-bromotiliacorinine 
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against the targets PknB and DprE1 (-11.4, -10.9 and -9.8 kcal.mol-1; -12.7, -10.9 and -10.3 
kcal.mol-1, respectively) were further analysed as well as the interactions of the lignan α-
cubebin and Pks13 (-11.0 kcal.mol-1), due to their significantly superior docking scores 
compared to the respective control inhibitors. We suggest that our approach offers a means to 
concentrate research aiming to optimise NP and Hence, this study presents new anti-
mycobacterial candidates and its targets for potential drug optimisation. 
 
§ Cao et al. (2020) 
Cao D, Wang M, Dai J, Li Y, Bhowmick S, Mur LAJ, Wei Y, Sun Z. (2020) Mining the 
secondary metabolites from endotype fungi of Huperzia serrata for medicinal activities (In 
preparation)  
Abstract:  
Huperzia serrata is a genus including ca. 100 species in the Huperziaceae family. In Traditional 
Chinese Medicine (TCM) decoctions that include H serrata. stems have been used as a styptic, 
antispasmodic and analgesic and for the cure of better blood circulation, contusion, strain, 
swelling and schizophrenia. To date, six species in the Huperzia genus have been chemically 
investigated, in order to alleviate the pressure on plant resources, more than 300 endophytic 
fungi have been isolated from Huperzia serrata. 
This review will consider key features of Huperzia Serrata, including its botanical 
characterization, medicinal resources, traditional uses, phytochemistry, pharmacological 
research and secondary metabolites of endophytic fungi. Based on this we will explore its 
future therapeutic and scientific potentials. 
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§ Cao et al. (2020) 
Cao D, Gao J, Yao K, Zhang Y, Bhowmick S, Nash R,Mur LAJ, Wei Y, Sun Z. (2020) 
Phlegmarine alkaloid as an intermediate in biosynthesis pathway of Huperzia serrata- derived 
Huperzine A: a metabolomic analysis using UHPLC and FIE-HRMS (In preparation)  
Abstract:  
Huperzine A (Hup. A) is known as a promising drug candidate for the treatment of Alzheimer’s 
disease (AD). It can be extracted from the natural plant Huperzia serrata (H. serrata), but rarity 
of the source cannot meet the needs of clinical therapy. Therefore, researchers have focused 
their attention on biosynthesis of Hup. A by using phlegmarine alkaloids as the precursors, but 
the pathway of synthesis has not been well established. In this study, we used metabolomics to 
link phlegmarine alkaloids to Hup. A in H. serrata and employed UHPLC-FIE-HRMS to 
explore the profiles of metabolites in H. serrata collected from different geographical regions. 
The identified major sources of variation included Hup. A, Hup. A-derivatives and phlegmarine 
alkaloids. It was found that the contents of Hup. A, Hup. A-derivatives and phlegmarine 
alkaloids were not all the same in samples from different sources. There was a significant 
positive correlation between the content of Hup. A, Hup. A-derivatives, and phlegmarine 
alkaloids Huperzine N/L, Huperzine K and 6-hydroxy-huperzine in particular. These results 
suggest that an association would be expected if these alkaloids were part of the proposed 
biosynthesis pathway of Hup. A. This is the first study reporting the relationship between 
phlegmarine alkaloids and Hup. A in H. serrata and may provide evidence-based clues for the 
development and quality control of H. serrata from different natural resources. 
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§ Cao et al. (2020) 
Cao D, Wang M, Zhang Y, Liu K, Bhowmick S, Mur LAJ, Wei Y, Sun Z. (2020) Efficient 
enrichment of total alkaloid with higher anti-cholinesterase and antioxidant activities from 
Huperzia serrata by microporous adsorption resins (In preparation)  
Abstract:  
For the full development and utilization of lycopodium alkaloids from Huperzia serrata to treat 
Alzheimer's Disease, this work was intended to establish an efficient rapid and cost-effective 
method of separation and purification of these alkaloids through macroporous resin column 
chromatography. The adsorption and desorption characteristics of total alkaloids on ten 
macroporous resins were studied first, AB-8 resin was selected as the best adsorbent and can 
be best described by the Langmuir isotherm model and pseudo-second-order kinetics model. 
The optimum enrichment conditions were as follows: for adsorption, the concentration, flow 
rate and volume of the sample were 4.30 mg/mL, 2 BV/h and 10 BV, respectively. For 
desorption, the alkaloids-loaded AB-8 resin column was desorbed by 7 BV of 80% ethanol at 
a rate of 1.5 BV/h. After one-step purification, the total alkaloids content had 10.14-fold higher 
compared to crude extracts with 82.56% recovery yield. Furthermore, alkaloids-enriched 
extracts exhibited obviously higher antioxidant activity on 2,2-diphenyl-1-picrylhydrazyl 
radical and xanthine oxidase, and anti-cholinesterase activity (with IC50 values of 78.21, 165.43 
and 165.28 µg/mL, respectively) in vitro, which also significantly reduced the NO production 
and iNOS activity in lipopolysaccharide induced N9 cell line. Those results indicated that the 
AB-8 macroporous resin column chromatography established in this work was a promising 
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